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Through South Africa’s first collaborative project between a large scientific 
organisation, the Council for Scientific and Industrial Research (CSIR), and the 
Traditional Healer’s Committee, Dicoma anomala was identified as a plant 
containing potent anticancer and antimalarial compounds. In the process of 
evaluation, extracted plant material with reported or anecdotal use for the 
treatment of respiratory problems was found to have significant anticancer activity 
in vitro in a 3-cell line preliminary screen. The extract was further shown to have 
potent anticancer activity against the 60-cell line panel at the National Cancer 
Institute (NCI) in the USA. Bioassay-guided fractionation, initially utilising an in 
vitro anticancer assay, and structural elucidation resulted in two potent compounds 
with sesquiterpenoid skeletons (C-15 and C-30). The crystal structure of the C-15 
compound, not published previously, was obtained. Both compounds were further 
screened in an antiplasmodial assay during the course of the National Drug 
Development Platform (RSA: CSIR, MRC and UCT) project, and were found to 
have potent activity against Plasmodium falciparum (a malaria protozoon). 
Although the C-15 compound had a selectivity index (SI) of 10, suggesting that it 
was suitable for subsequent development, the dimer was highly toxic (SI index of 
1), limiting opportunities for future development.  A further study of the structure-
activity relationship (SAR), which was initiated for the C-15 compound, showed 
that removal of each unsaturated structural component decreased activity 10–fold 
in both bioassays. Additional investigations were carried out into amino-acid 
Michael adducts with the exocyclic double bond of the C-15 sesquiterpenoids, and 
the products were characterised by NMR spectroscopy and mass spectrometry. A 
similar investigation, involving the conjugate addition of simple amines, was 
undertaken in an attempt to enhance the bioavailability of the parent 
sesquiterpenoid. Three diethylamine derivatives were prepared and characterised. 
A general 10-fold drop in the bioactivity of these “pro-drug” derivatives in both 
assays was observed. Finally, the C-15 compound was tested in vivo in the 
Plasmodium berghei murine malaria model and was found to have some effect on 
the survival rates of the laboratory animals when compared with the control. A 
possible mode of action is suggested based on the experimental and published 
bioactivity data. Further studies to improve the bioactivity and alternative design of 
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Chapter 1: Introduction and Objectives 
South Africa is fortunate in having a plant biodiversity of more than 24000 
indigenous plant species, representing about 10% of all higher plants on Earth.1  A 
large number of South African plants are endemic. The country also boasts a long 
history of traditional medicinal practices, which by and large employ plants as a 
basis for the maintenance of good health. These practices are significant 
throughout the African continent, where up to 80% of the population makes use of 
traditional medicine.2  
 
European botanists began “bioprospecting” to identify economically important 
plants in Africa from as early as the 19th century. With the development of 
biotechnology in the 1950s, many herbal preparations and phytochemicals were 
also tested for efficacy. One of the research highlights of that time, which turned 
the interest of the international scientific community towards Africa, was the 
discovery of the anticancer alkaloids vinblastine and vincristine from the 
Madagascar periwinkle Catharanthus roseus. These systemic chemotherapy 
drugs, which first became available in the 1960s, are still extensively used in 
clinical practice.  
 
In 1996, the first review of bioprospecting in South Africa found that virtually every 
research institution in South Africa was involved in bioprospecting activities, some 
formally and others informally.3 One of the largest bioprospecting projects to date 
began in 1997 at the former Division of Food, Biological and Chemical 
Technologies of the CSIR. The project was based on a collaboration of chemists 
with traditional healers, with the support of ethnobotanists, botanists, 
biotechnologists, pharmacologists and even medical doctors. The traditional 
healers came on board this Bioprospecting Consortium through a formal 
Traditional Healers Committee as stakeholders. The right of the providers of 
indigenous knowledge to any future financial benefits that might be derived from 
                                            
1 Van Wyk B. -E., Gericke N. (2000). People’s Plants. Pretoria: Briza Publications, p. 7. 
2 WHO Traditional Medicine Strategy 2002-2005. Downloaded on 6 December 2008 from World 
Health Organization website: http://whqlibdoc.who.int/hq/2002/WHO_EDM_TRM_2002.1. 
3 Laird S., Wynberg R. (1996). Biodiversity prospecting in South Africa: Towards the development 





commercial exploitation of the indigenous knowledge-based product was protected 
by a Memorandum of Understanding (September 1999) and a Benefit Sharing 
Agreement (February 2003), which were signed between the CSIR and the 
Traditional Healers Committee. To date more 250 claims for cures have been 
provided by traditional healers to the CSIR, which have been captured in the 
“Bioprospecting Database”.  
 
This collaboration soon became one of the fundamental modules of the Drug 
Discovery and Development Consortium at the CSIR. This module employs a so-
called “ethnopharmacological approach” to drug discovery. The idea of this 
approach is that the indigenous use of a plant is taken as a primary indicator of its 
biological activity, and the ultimate objective is to obtain a bioactive plant 
constituent/s, which can be further exploited. The high-throughput screening of 
ethnobotanical extracts (extracts of plants with reported medicinal uses) has a 
much higher hit rate than the screening of randomly collected plant samples.  
 
The initial selection of an ethnobotanical-based research “lead” in this project was 
based on the results of a high-throughput biological screening of the extracts 
prepared from plant samples supplied by traditional healers. The screening of 410 
ethnobotanical extracts using the in vitro anticancer screening technology at the 
CSIR resulted in 171 positive extracts. Plants showing potent (18) and moderate 
(37) activity were selected for further research and development. Following the 
evaluation of the prior art, several plants were regarded as “hits”. One such hit, an 
extract of Dicoma anomala Sond., constitutes the basis of this thesis.  
 
The aims of this study were to: 
 
• Isolate bioactive constituents from the extract of Dicoma anomala 
subsp. gerrardii using bioassay-guided the fractionation  
• Determine the structure(s) of the bioactive ingredients by chemical and 
physicochemical methods (e.g. NMR spectroscopy and mass 
spectrometry) 
• Demonstrate the efficacy of the active compounds in appropriate animal 





• Optimise the extraction methods to achieve the best yields of the active 
compound(s) 
• Investigate the pharmacological properties of bioactive compound(s) 
through some structure-activity studies 
• Prepare several derivatives/analogues with aim to improve selectivity 





Chapter 2: Dicoma anomala: an overview of the 
taxonomy, ethnobotany, phytochemistry and 
biological activities  
2.1 Introduction  
An extract of the roots of Dicoma anomala was found to exhibit strong growth-
inhibitory activity towards a three-cancer cell lines panel. The sample of the roots, 
with anecdotal information on the use of the plant, emerged from the collaboration 
of the CSIR with traditional healer Dr Solomon Mahlaba in 1999. It was introduced 
as Kloenya (Sotho) or Nyongwane (Zulu), and was claimed to be effective in the 
treatment of respiratory disorders and asthma. A botanical specimen was 
identified by SANBI as Dicoma anomala sensu Wild as the genus was under 
revision at the time. A review of the latest taxonomic interpretation of the genus 
was required in order to evaluate prior art of the possible use of the plant or its 
constituents for the treatment of cancer as an initial step in drug discovery 
following the identification of the “hit” through high-throughput biological screening 
of plant extracts.  
 
The genus Dicoma Cass., first described by Cassini in 1817, belongs to the 
subtribe Gochnatiinae, the tribe Mutiseae, and the subfamily Cichorioideae of the 
Asteraceae family. It was previously reported to consist of about 50 to 65 species, 
and it is now recognised to comprise 35 species, 16 of which occur in southern 
Africa.4,5,6,7. Most species are herbs or small shrubs and even trees.  Habitat was 
considered as embodying the taxonomically important and distinguishing 
characteristics in the infrageneric treatment of the genus Dicoma.8 From the highly 
polymorphic species of D. anomala Sond., which has the widest geographical 
distribution within the genus, several subspecies were the subject of 
                                            
4 Cassini M. H. (1818). Bulletin des Sciences de la Société Philomatique de Paris, p. 47. 
5 Bremer K. (1994). Asteraceae. Cladistics and Classification. Portland, Oregon: Timber Press. 
6 Ortiz S. (2001). Annals of the Missouri Botanical Garden, 87, 459–481. 
7 Netnou N. C. MSc Thesis, Rand Afrikaans University, Johannesburg, 2001. 
8 Harvey W. H. (1865). In: Harvey W.H., Sonder O.W. (eds.), Flora Capensis, Hodges, Smith, 





phytochemical studies during the period 1977–1990.9,10,11. The investigation was 
driven by taxonomic considerations with the aim of chemically characterising the 
genus and establishing a correlation of the proposed sectional classification and 
phytochemistry. The formal infrageneric taxonomic division of the species 
recognised three varieties or subspecies of Dicoma anomala: var. α, sonderi 
Harv.; var. β, cirsioides Harv. and var. γ, microcephala Harv. or D. gerrardii.8 
 
Even though several morphologically distinct forms existed, ethnobotanical use 
was reported for the taxa Dicoma anomala without further specification of the 
origin or tradition.  
 
One of the latest taxonomic reviews, which followed the revision by Ortiz (2001), 
was conducted by Ms Netnou in 2001 under the supervision of Prof. Ben-Erik van 
Wyk.7,12 This review was aimed at providing descriptions, keys and distribution 
maps for the ethnomedicinally important species and thus facilitating their correct 
identification. This would naturally result in more accurate documenting and use of 
ethnobotanical information in ethnopharmacological research. An overview of the 
ethnobotany, old and new taxonomy, phytochemistry and pharmacology of 
D. anomala and a few other members of the genus used medicinally are 
presented in this chapter. 
 
2.2 Taxonomy 
Dicoma anomala Cass. comprises erect, suberect or prostrate herbs, with 
underground tubers. It grows in grasslands and stony places on sandy soil. The 
flowering time of D. anomala is from January to May, with peak flowering time in 
February and March. This is a very widespread species, but regional forms can be 
easily distinguished.7 
 
                                            
9 Bohlmann F., Le Van N. (1978). Phytochemistry, 17, 570–571. 
10 Bohlmann F., Singh P., Jakupovic J. (1982). Phytochemistry, 21, 2029–2033.  
11 Zdero C., Bohlmann F. (1990). Phytochemistry, 29, 183–187. 





2.2.1 D. anomala 
D. anomala is widely distributed in sub-Saharan Africa, resulting in pronounced 
morphological variety. In South Africa it is widely distributed in Limpopo, North-
West, Gauteng, Mpumalanga, Free State, Northern Cape and KwaZulu-Natal 
provinces. D. anomala does not occur in the winter rainfall areas of the Western 
Cape. In KwaZulu-Natal it has been mainly recorded in the Tugela Basin on sandy 
soils.13 Following the recent taxonomic revision of Southern African taxa, five 
informal groups of D. anomala subsp. anomala and two of Dicoma anomala 
subsp. gerrardii are now recognised to accommodate intraspecific variation. D. 
anomala subsp. gerrardii also occurs in Namibia and Botswana. Intermediates 
between the above two taxa are known to occur in the North West province. 
 
2.2.2 Distribution of D. anomala subsp. gerrardii 
D. anomala subsp. gerrardii is found throughout South Africa except in the Eastern 
Cape and the winter rainfall areas of the Western Cape (Figure 2.1). Currently, two 
regional forms are recognised for this taxon: the typical form, which occurs 
throughout the RSA region, and the Barberton form, which is found in the 
Barberton area of Mpumalanga Province.  
   
Figure 2.1.  Photo of D. anomala subsp. gerrardii in the Nyala Nature 
Reserve, Brits (left) and the distribution map© in the RSA (right)14,15 
 
                                            
13 www.plantzafrica.com/plantcd/dicomanom.htm. Accessed on 10 October 2008. 
14 The photo of D. anomala subsp. gerrardii was provided by Jean Meyer (SANBI). 





Several intermediate forms occur between D. anomala subsp. gerrardii and its 
close relative D. anomala subsp. anomala. This could be due to cross-pollination 
between the two subspecies in the same habitat. 
 
2.2.3 D. anomala subsp. anomala 
The plants are prostrate and the leaves are linear to lanceolate-oblong. They have 
few heads which are solitary, or rarely one to two, at the ends of branches. They 
are large and wider than they are long, often 30 to 45 mm wide. The involucral 
bracts, which are nearer to 200 mm, are often recurved. This subspecies has 
regional forms that are so characteristic that their geographical origin can easily be 
determined from their appearance. Five forms are recognised at present:4 
1. Common form (Eastern Cape to Limpopo province, Botswana, Lesotho and 
Swaziland). 
2. Lydenburg form (Lydenburg district, Mpumalanga). 
3. Eastern Free State form (north-eastern parts of the Free State and near 
Barberton). 
4. Waterberg form (Waterberg area, Limpopo province). 
5. Pretoria form (Pretoria area in Gauteng). 
 
Synonyms: D. anomala var. cirsioides Harv. and D. anomala. D. anomala subsp. 
cirsioides (Harv.) with four regional variants. D. anomala var. sonderi Harv. is a 
form with narrow leaves.16  
 
2.2.4 D. anomala subsp. gerrardii 
The plants are erect and the leaves are narrow-linear. The heads are numerous, 
or arranged three to five subcorymbosely at the ends of branches. They are 
relatively smaller and longer than they are wide, often 15 − 20 mm in width. The 
involucral bracts are nearer to 50 than 200. In southern Africa, two forms of D. 
anomala subsp. gerrardii are recognised: 
 
                                            





1 Typical form (throughout the RSA region except for the Western and Eastern 
Cape. 
2 Barberton form (Barberton region, Mpumalanga). 
 
Synonyms: D. anomala var. microcephala (Harv)., D. anomala forma. 
microcephala (Harv.) and D. gerrardii Harv. ex F. C. Wilson. 
 
2.3 Ethnobotany 
Common ethnomedicinally important species of Dicoma are the following: D. 
capensis; D. anomala; D. schinzii, D. zeyheri. Species D. anomala is used in the 
primary health care systems of Botswana, Namibia and South Africa.  
 
2.3.1 Vernacular names 
In Africa several vernacular names for D. anomala have been reported: Tihonya in 
Botswana; umwanzuranya (Kirundi/Kinyarwanda) in Burundi and Democratic 
Republic of Congo; umwanzuranya (Kinyarwanda) in Rwanda and weya (Hehe) in 
Tanzania.17 In South Africa, D. anomala is known by the following vernacular 
names: aambeibos, gryshout,18 koorsbossie, korsbossie,19 kalwerbossie,18 
maagwortel, maagbitterwortel,18 maagbossie, swartstorm,19,20,21,22 vyfaartjies, 
wurmbossie (Afrikaans);18 fever bush, stomach bush (English);15 chiparurangomo 
(Manyika);19 chifumuro (Shona); hlwejane,19 hloenya, mohasetse (Southern 
Sotho);15 thlongati, thlonya (Setswana);19 inyongwane, inyongana15 (Swazi, 
Xhosa); and isihlabamakhondlwane, umuna18(Zulu).  
 
                                            
17 Prelude Medicinal Plants Database: http://www.metafro.be/prelude. Accessed on 10 October 
2008. 
18 Hutchins A., Scott A. H., Lewis G., Cunningham A. B. (1996). Zulu Medicinal Plants: An 
Inventory. Pietermaritzburg: University of Natal Press, pp. 334-335. 
19  Roberts M. (1990). Indigenous Healing Plants. Halfway House: Southern Book Publishers, p. 80. 
20 Van Wyk B. -E., van Oudtshoorn B., Gericke N. (1997). Medicinal Plants of South Africa. 
Pretoria: Briza Publications, pp. 104-105. 
21 The vernacular name “swartstorm” normally refers to another plant, Cadaba aphylla (Thunb.) 
Willd. (Capparaceae); (Ref. 17). 






2.3.2 Medicinal uses 
The ethnobotanical uses of D. anomala are summarised in Table 2.1. These uses 
could be linked to several pharmacological properties, such as antibacterial, 
antihelminthic, antiviral, antispasmodic, wound healing, analgesic and 
antiinflammatory. Other medicinally utilised species of Dicoma are used for similar 
conditions. The roots of D. zeyheri are used for coughs and chest ailments, also 
as a blood strengthener for mothers after long and difficult births, and for lumbago, 
back pains and stomach problems.1,23 The leaves and twigs of D. capensis Less. 
are reported to be used for treatment of cancer,23 high blood pressure, febrile 
conditions,24 fever diarrhoea, cough and gastrointestinal complaints.24 The roots of 
D. schinzii are used to treat coughs, sore throats and febrile convulsions in 
infants.23  
 







Source of information 
Circulation  roots RSA; Namibia Roberts, 1990; Von Koenen, 2001* 
Blood disorders roots RSA; Zimbabwe Roberts, 1990; Gelfand, 198525) 
Cardiovascular 
disorders 
roots RSA; Namibia Roberts, 1990; Von Koenen, 2001* 
Cataracts roots Zimbabwe Gelfand, 1985 
Colic roots Namibia Von Koenen, 2001* 




Prelude; Gelfand, 1985 
Coughs and colds roots RSA; Namibia Roberts, 1990; Von Koenen, 2001* 
Cutting pain in the 
stomach 
roots Botswana Prelude 
Dermatosis skin 
eruptions  
roots Burundi; Zimbabwe Gelfand, 1985; Prelude 
Diarrhoea roots RSA; Zimbabwe; Roberts, 1990; Gelfand, 1985; Von 
                                            
23 Watt J. M., Breyer-Brandwijk, M. G. (1962). The Medicinal and Poisonous Plants of Southern 
and Eastern Africa, 2nd edition. Edinburgh & London: Livingstone. 
24 Von Koenen E. (2001). Medicinal, Poisonous and Edible Olants in Namibia. Windhoek: Klaus 
Hess, p. 111. 
25 Gelfand M., Mavi S., Drummond R.B., Ndemera B. (1985). The Traditional Medicinal Practitioner 





Namibia Koenen, 2001* 




Roberts, 1990; Gelfand, 1985; 
Koenen, 2001* 
Fevers roots RSA; Zimbabwe Roberts, 1990; Gelfand, 1985 
Gall sickness (animals) roots Zimbabwe Gelfand, 1985 
Haemorrhoids (as a 
purgative) 
roots Zimbabwe; Namibia Gelfand, 1985; von Koenen, 2001* 
Infertility roots Zimbabwe Gelfand, 1985 
Intestinal parasites roots 
RSA; Zimbabwe; 
Burundi; Namibia 
Roberts, 1990; Gelfand, 1985; 
Prelude; von Koenen, 2001* 
Pneumonia roots RSA Van Wyk & Gericke, 2000 
Psychosis roots Zimbabwe Gelfand, 1985 
Purgative roots RSA Roberts, 1990 
Respiratory complaints roots Zimbabwe Gelfand, 1985 
Sores and scabs roots RSA Roberts, 1990 
Sores and wounds roots Zimbabwe Gelfand, 1985 
Stomach upsets roots RSA Roberts, 1990 
TB cough roots Zimbabwe Gelfand, 1985 
Toothache roots RSA; Zimbabwe Roberts, 1990; Gelfand, 1985 
Colic roots RSA Roberts, 1990 
Uterine sedative roots Zimbabwe Gelfand, 1985 
Varicose veins roots RSA Roberts, 1990 
Venereal diseases roots RSA Roberts, 1990 
Vertigo roots Zimbabwe Gelfand, 1985 
Wounds and ringworm roots RSA Roberts, 1990 
*Use reported for D. anomala subsp. anomala 
 
Recently, two studies concerning the scientific evaluation of D. anomala and D. 
capensis appeared in the literature. One study reports on the evaluation of the root 
extract (MeOH and H2O) of D. anomala collected in the Johannesburg area for its 
potential antibacterial and antiinflammatory properties. Both extracts were found to 
exhibit activity at MIC > 4 mg/mL against all selected bacteria.26 
 
                                            
26 Steenkamp V., Mathivha E., Gouws M. C., van Rensburg C. E. J. (2004). Journal of 





An aqueous extract of D. capensis was evaluated against three cancer cell lines: 
malignant breast MCF-7 and MDA-MB-231; non-malignant breast cell line MCF-
12A; and prostate DU-145.  The extract showed pronounced anticancer activity in 
the range of 30 µg/mL (MCF-7) and 31 µg/mL (MCF-12A) cells.27 However, no 
anticancer bioactivity-guided isolation of the active compound of Dicoma has been 
reported to date. 
 
2.4 Phytochemistry 
All four medicinally used Dicoma species were previously investigated from the 
chemotaxonomic point of view. Several classes of secondary metabolites were 
isolated and characterised. Apart from D. zeyheri, the chemistry of the Dicoma 
species showed much similarity and the compounds commonly occurring in the 
species could be grouped into several classes: acetylenic compounds (cyclic and 
acyclic) (Figure 2.2), phenolic acids, flavonoids (cirsimaritin and scutellarein), 
sesquiterpenes (β-farnesene, α-humulene), triterpenes (lupeol and lupenone), 




























Figure 2.2.  Phytoconstituents of various parts of D. zeyheri 
 
                                            






2.4.1 D. zeyheri 
Unspecified parts of D. zeyheri yielded acetylentic compounds (2.1 and 2.2).9 The 
aerial parts contained allenic acid (2.8) and its ester but no further characteristic 
compounds. The roots were reported to contain β-farnesine (2.7), α-humulene, 
(2.4), cyclysed acetylenes (2.6), allenic acid (2.8), 5E- and 5Z-zeyherin formed via 
the corresponding chlorohydrine (2.10, 2.11 and 2.35).10 Guaianolide β-hydroxy 
dehydrozaluzanin C (2.33) was the only compound in common with the other three 
Dicoma species reviewed later in this section. 
 
2.4.2 D. anomala Sond.  
The aerial parts of D. anomala subsp. cirsioides, collected in KwaZulu-Natal, 
yielded acetylenic compounds, stigmasterol, β-sitosterol, lupeol and some 
sesquiterpene lactones. The latter group included germacranolides (2.12 and 
2.14), with a 7,8-lactone function, albicolide (2.19) and 14-acetoxydicomanolide 
(2.26), with 6,7-lactone closure.9 The roots of D. anomala subsp. cirsoides 
(KwaZulu-Natal) yielded mostly the acetylenic compounds (triynediene).  The 
aerial parts of D. anomala subsp. cirsoides, collected in the former Transvaal 
region, yielded germacrene D (2.5), lupeol, taraxasterol, and sesquiterpene 
lactones (2.23, 2.27, 2.31 and 2.32). The roots of the Transvaal specimen 
contained, in addition to sitosterols and lupenone, some guaianolides (2.33 and 
2.34) and eudesmanolides (2.39, 2.41 and 2.42).10 The constituents of the roots of 
the specimens from the former Natal and Transvaal differed noticeably.10  
 
The aerial parts of D. anomala subsp. anomala collected in the former Transvaal 
yielded phytol, lupeol and its acetate, germacrene D (2.5), germacranolides 2.23, 
2.31 and 2.32, while the roots gave no characteristic compounds.10 Investigation of 
the aerial parts of the same species, collected in Namibia, resulted in the isolation 
of melampolides (2.15 and 2.16), germacranolides (2.20, 2.21 and  2.23) and a 
lactone (2.36), in addition to the lupeol and taraxasterol and their acetates, and 
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Figure 2.3.  Sesquiterpene lactones from Dicoma species 
 
The most recent report is of the phytochemicals isolated through bioassay-guided 





in Lesotho (Morifi and Mohales' Hoek areas), the Free State (Reitz area), and 
Limpopo Province (Sekhukhuni area). Roots that were purchased at the “muthi” 
markets in Durban (KwaZulu-Natal), were also investigated. This investigation 
resulted in the isolation of the novel guaianolide-type sesquiterpene lactone dimer 














Some differences were noticed when comparing the phytochemical profiles of D. 
anomala and its subspecies D. anomala subsp. cirsioides and D. anomala subsp. 
anomala. However, further studies are required to compare five recognised 
regional forms of D. anomala subsp. anomala to make a more 
chemotaxonomically sound conclusion.  
 
2.4.3 D. capensis Less. 
The aerial parts of D. capensis harvested in Namibia yielded several structural 
types of sesquiterpene lactones: melampolides (2.17, 2.18 and 2.37); 
germacranolides (2.19, 2.24, 2.25 and 2.28); and eudesmanolides (2.43 and 
2.44).11  
 
2.4.4 D. schinzii O. Hoffm.  
Roots of D. schinzii collected in the former Transvaal region yielded taraxasterol, 
lupeol and its acetate, their ∆12-isomers and eudesmanolides 2.39, 2.41 and 2.42, 
whilst the aerial parts yielded isobutyrates with a germacrane skeleton (2.45, 2.46 
and 2.47) with a 9β-oxygen function.10 Investigation of the aerial parts of D. 
                                            
28 Matsabisa G. M., Campbell W. E., Folb P. I., Smith P. J. (2006). Treatment of parasitic infections 





schinzii collected in Namibia resulted in several germacranolides (2.24, 2.26 and 
2.28), which lacked the 9β-oxygen function.11 
 
2.5 Summary of reported biological activities of the phytochemicals 
isolated from medicinally used Dicoma species 
2.5.1 Phenolic compounds 
Caffeic acid, which was isolated from unspecified parts of D. anomala, is reported 
to have potent antioxidant properties.29 The flavonoids cirsimaritin and scutellarein 
were isolated from D. anomala subsp. anomala.11 Cirsimaritin is used to treat 
proteinuria (or kidney failure) and was found to have adenosine and 
benzodiazepine receptor antagonist properties in vitro.30 Scutellarein was shown 
to have some effects on the pathologic changes of the heart caused by 
hypertension (uncompetitive protein kinase c inhibitor): it can reverse the 
ventricular remodelling, improve cardiomuscular stiffness and protect cardiac 
muscle.31 The presence of these flavonoids in the aerial parts of D. capensis could 
contribute to its effectiveness in treating high blood pressure, i.e. hypertension. 
 
2.5.2 Phytosterols 
The β-sitosterol, which was found in the roots of D. anomala subsp. cirsoides, is 
best known for its cholesterol-lowering properties.32 In addition, β-sitosterol 
exhibited the following therapeutic properties: anticancer (inhibition of growth and 
metastasis of prostate and skin cancer cells in vitro)33 and antioxidant. It is also 
used for the treatment of prostate enlargement (possibly through inhibition of 5α–
reductase)34 and heart conditions related to high levels of blood cholesterol. It has 
also been shown to increase levels of testosterone and 11-ketotestosterone, and 
                                            
29 Gülçin İ. (2006). Toxicology, 217, 213-220. 
30 Wang J.–P., Chang L.–C., Hsu M.-F., Chen S.–C., Kuo S.–C. (2002). Naunyn-Schmiedeberg's 
Archives of Pharmacology, 366, 307-314. 
31 Zhou J., Lei H. A., Chen Y., Li F., Ma C. (2002). Chinese Medical Journal, 115, 375–377. 
32 Law M. R., (2000). The Western Journal of Medicine, 173, 43-47. 
33 Awad A. B., Fink C. S., Williams H., Kim U. (2001). European Journal of Cancer Prevention, 10, 
507–513. 
34 Cabeza M., Bratoeff E., Heuze I., Ramirez E., Sanchez M., Flores E. (2003). Proceedings of the 





to accelerate spermatogenesis.35 The high concentrations of phytosterols in the 
roots could be responsible for the reported use of D. anomala for the treatment of 
infertility35 and “heart problems”. 
 
2.5.3 Terpenoids 
2.5.3.1 Diterpenes and triterpenes 
Phytol (an acyclic diterpene) is reported to possess potent antimycobacterial 
properties (MIC of 2 µg/mL) in the same concentration range as ethambutol, a 
clinically useful drug with an MIC in the range 0.95 to 3.8 µg/mL.36 Lupeol is 
reported to act as a potent modulator of the NF-kB pathway, which is related to 
inflammation and shows lipoxygenase inhibitory activity (IC50 = 35 µM) and was 
shown to inhibit skin cancer in mice.37,38. 
 
2.5.3.2 Sesquiterpenes 
The compound α-humulene (2.4), which was isolated from the roots of D. zeyheri, 
is known for its antitumour activity.10,39 Costunolide is reported to inhibit various 
biological and immunological actions. It has shown a preventative effect against 
carcinogenesis and is known to induce apoptosis in human promonocytic 
leukaemia U937 cells by depleting intracellular thiols.40 Furthermore, costunolide 
has been reported to inhibit the killing activity of cytotoxic T-lymphocytes, which 
are important in the process of the elimination of virus-infected cells.41 The 
presence of costunolide has not been reported in any of the reviewed Dicoma 
species, but the 14-,15-oxygenated costunolide derivatives appeared 
characteristic and could possess biological properties similar to those of 
                                            
35 Christianson-Heiska I., Smeds P., Granholm N., Bergelin E., Isomaa B. (2007). Comparative 
Biochemistry and Physiology, Part C: Toxicology and Pharmacology, 145, 518–527.  
36 Rajab M. S., Cantrell C. L., Franzblau S. G., Fischer N. H. (1998). Planta Medica, 58, 19-21. 
37 Gutierrez-Lugo M. -T., Deschamps J. D., Holman T. R., Suarez E., Timmermann B. N. (2004). 
Planta Medica, 70, 263–265. 
38 Saleem M., Afaq F., Adhami M. V., Mukhtar H. (2004). Oncogene, 23, 5203-5214. 
39 Pichette A., Legault J., Madelmont J. -C. (2008). Use of Compositions Comprising Sesquiterpene 
Derivatives for the Treatment of Cancer, EP20020708107. 
40 Choi J. -H., Ha J., Park J. -H., Lee Y. S., Park H. -J., Choi J. -W., Masuda Y., Nakaya K., Lee K.-
T. (2002). Japanese Journal of Cancer Research, 93, 1327–1333. 
41 Taniguchi M., Kataoka T., Suzuki H., Uramoto M., Ando M., Arao K., Magae J., Nishimura T., 





costunolide. The dehydrozaluzanin C (2.33) is reported to possess antiprotozoal42 
and antifungal properties (GI50 = 30 µM).
43 For tuberiferin (2.41), an inhibitory 
action has been shown on the respiratory burst of peritoneal inflammatory 
polymorphonuclear leukocytes. This implies some potential of tuberiferin as an 
antiinflammatory agent. It also substantially decreased carrageenan-induced 
mouse paw oedema. The latter bioactivity could contribute to the wound-healing 
property of the Dicoma plants.   
 
2.6 Conclusion 
It is apparent that the original sample of the roots of D. anomala delivered by a 
traditional healer and identified as D. anomala sensu Wild could probably be 
further sub-classified into D. anomala subsp. gerrardii on the basis of the 
description of the plants as “erect and with small leaves”. Previously classified as 
D. anomala var. microcephala and as D. gerrardii, there was no information in the 
literature on the results of the phytochemical investigations of D. anomala subsp. 
gerrardii. A comprehensive literature review of Dicoma ethnobotany did not reveal 
any anecdotal information on the use of D. anomala subsp. gerrardii or any of its 
synonyms. However, many anecdotes described the D. anomala plants as erect or 
prostrate, therefore the information related to the use of the plant is fuzzy and 
should be treated with caution. Furthermore, D. anomala has not been linked 
directly to cancer as such, unlike D. capensis, where the aerial parts are said to be 
used to treat the pathology associated with cancer.  
 
With regard to the bioactivity of phytochemicals isolated from the extracts of D. 
anomala Sond., lupeol and β-sitosterol are reported to have anticancer properties 
by directly inhibiting the growth of skin cancer in mice38 and of prostate cancer cell 
lines in culture.34 Lupeol was isolated from the aerial parts but not the roots of D. 
anomala, and was found in the roots of D. schinzii. The presence of costunolide 
derivatives with oxygen functions at C-14 and C-15 are characteristic for the genus 
and may have bioactivity similar to that of costunolide. Furthermore, 
                                            
42 Fournet A., Munoz V., Roblot F., Hocquemiller R., Cave A., Gantier J.-C. (1993). Phytotherapy 
Research, 7, 111–115. 





sesquiterpenes such as dehydrozaluzanin C (2.33) or tuberiferin (2.41) could have 
contributed to the observed effects.  
 
To date no reports on the phytochemistry of D. anomala subsp. gerrardii could be 
found. In the following chapter the work on bioassay-guided fractionation of 
organic extract of D. anomala subsp. gerrardii and the isolation of compounds 







Chapter 3: Experimental 
3.1 General materials and methods 
3.1.1 Liquid chromatography 
The purification of the compounds from the extracts was performed using the 
following chromatographic techniques: vacuum liquid chromatography (VLC), 
column chromatography (CC), flash chromatography (FC) and semi preparative 
liquid chromatography (LC).  
 
For detection, identification and estimation of yields, two high performance liquid 
chromatography (HPLC) instruments were used (Sections 3.1.1.4 and 3.1.2.3).  
 
3.1.1.1 Column chromatography 
In the purifications by column chromatography (CC), packed with Silica gel 60 
(0.063 - 0.2 mm), the choice of the column sizes was based mainly on the quantity 
and the complexity of the crude sample; columns usually ranged from 10-90 cm in 
length and 1-4 cm in diameter; EtOAc/Hexane/DCM/MeOH – isocratic solvent 
mixtures were employed for all consecutive purifications (the proportions of the 
solvents are specified in relevant sections). Fractions were combined based on the 
similar chemical compositions as determined by thin layer chromatography (TLC). 
The solvent was removed under vacuum on a rotary evaporator. TLC plates, used 
throughout the experiments, were pre-coated glass silica gel plates (F254; 0.2 mm; 
Merck or Sigma Aldrich). 
 
3.1.1.2 Flash chromatography 
This method is based on the same principle as for CC, but flash silica gel with 
particle sizes ranging from 35 – 75 µm, was used as a stationary phase and the 
fractions were collected by applying vacuum. Smaller columns (25 – 90 cm in 
length and 1-2 cm in diameter) were used to achieve a separation of compounds 






3.1.1.3 Vacuum liquid chromatography 
VLC was utilised mostly for the large-scale purifications of the crude extracts and 
fractions in batches of 5 – 10 g of extract on 400 – 500 g of SiO2 60 (0.063 – 
0.2 mm) under reduced pressure, using a range of solvents and stepwise 
gradients. Pooled fractions were combined on the basis of similarity of chemical 
profiles as determined by TLC. Fractions were concentrated under vacuum on a 
rotary evaporator and the extracts further dried in the vacuum desiccator.   
 
3.1.1.4 HPLC-UV/MS 
A HPLC Waters Alliance 2690 system, equipped with a Waters 996 photodiode 
array detector (UV), and coupled to a Quattro micro mass spectrometer (Section 
3.1.3), interfaced with Masslynx software, was utilised to profile, identify and 
estimate the yields of plant metabolites. Stock solutions of test samples were 
prepared on the basis of the complexity to concentrations ranging from 5 000 ppm 
(crude extracts) to 100 ppm (pure compounds). The choice of solvent depended 
on the solubility of a sample. All stock solutions were filtered though a 0.45 µm 
PTFE filter (Microsep) prior to injection. HPLC-grade solvents (Romil, Microsep) 
were used. The calibrations and quantifications were carried out using Waters 
Millennium 2010 Chromatography manager GPC software version 2.0 (Millipore 
Corporation, Waters Chromatography Division). A range of analytical columns and 
two sets of gradient conditions were used for analyses, and are summarised in 
Tables 3.1 and 3.2. These analyses were performed at CSIR Biosciences.  
 
Table 3.1.  Gradient conditions for the Waters Alliance 2690 for methods 
T3.1-1 and T3.1-2 (run time – 90 min) 
Time (min) Flow (mL/min) % A (Water) % B (ACN) Curve 
0.00 1.000 90 10 1 
61.00 1.000 20 80 6 
64.00 1.000 0 100 6 
75.00 1.000 0 100 6 
75.10 1.000 90 10 6 
90.00 1.000 90 10 6 
HPLC Method T3.1-1. Column: Thermo C8 Hypersil Gold (250 x 4.6 mm, 5 µm ), T = 40 °C 
HPLC Method T3.1-2. Column: Agilent Tech Zorbax Rx-C8  (250 x 4.6 mm, 5 µm ), T = 40 °C 






Table 3.2.  Gradient conditions for the Waters Alliance 2690 for methods 
T3.2-1 and T3.2-2 (run time - 60 min) 
Time (min) Flow (mL/min) % A (Water)* % B (ACN) Curve 
0.00 1.000 90 10 1 
10.00 1.000 90 10 5 
35.00 1.000 0 100 6 
45.00 1.000 0 100 4 
50.10 1.000 90 10 5 
60.00 1.000 90 10 5 
HPLC Method T3.2-1. Column: Supelco F5 Discovery® HS F5 (150 x 2.1 mm, 3 µm), T = 50 °C 
HPLC Method T3.2-2. Column: Waters Atlantis® T3 RP-amide (150 x 2.1 mm, 3 µm), T = 50 °C 
HPLC Method T3.2-3. Column: Agilent Tech Zorbax Rx-C8  (250 x 4.6 mm, 5 µm ), T = 40 °C 
*Water containing 0.1% formic acid 
 
3.1.1.5 Preparative-scale liquid chromatography 
The Semi-prep HPLC System: Agilent 1200 series, fitted with Waters Atlantis C18 
T3 (10 x 250 mm, 5 µm) column, was used for purification of water-soluble amino 
acid adduct (5.27). A stock solution of 5 000 ppm was prepared and was injected 
onto a preparative scale column (100 µL). The gradient table presented in Table 
3.3 was utilised. This work was carried out at CSIR Biosciences.  
 
Table 3.3.  Gradient conditions for the Agilent 1200 for method T3.3 (run time 
– 40 min) 
Time (min ) Flow (mL/min) %A (Water)* %B (ACN) 
0.0 5.000 100 0 
3.00 5.000 100 0 
12.50 5.000 80 20 
18.00 5.000 0 100 
22.00 5.000 0 100 
25.00 5.000 100 0 
40.00 5.000 100 0 
HPLC Method T3.3: Column: Waters Atlantis C18 Prep. T3 (250 x 10 mm, 5 µm) 






3.1.2 Mass spectrometry (MS) 
3.1.2.1 Quattro LC Micro mass spectrometer  
The mass spectral data were obtained from a hyphenated HPLC-UV/MS 
instrument (Section 3.1.1.4) equipped with a triple quadrupole Quattro LC Micro 
mass spectrometer, which was set to operate in both the ESI- and ESI+ modes (49 
– 478 amu) with a gain of 10. The cone voltage was varied between 20 and 70 eV, 
the desolvation temperature was 450 °C, and the source block temperature was 
set at 120 °C. Samples were dissolved in ACN/MeOH (2:1 v/v), vortexed until fully 
dissolved, and volumes between 10 and 50 µL were injected onto the analytical 
column. This work was carried out at CSIR Biosciences.  
 
3.1.2.2 HREI-MS  
HREI-MS spectral data were obtained from University of the Witwatersrand. A VG 
70SEQ HRMS instrument, operated mainly in the EI mode, using 8 kV as the 
standard ionisation energy was used to generate the spectra.  
 
3.1.2.3 Waters ThermaBeam (TMD) system  
This type of analysis was done on a Waters ThermaBeam (TMD) system 
comprising a 2695 Solvent Delivery System fitted with analytical column 
(Phenomenex Gemini C18; 250 x 2 mm, 5 µm; T = 40 °C), a 2996 PDA detector, 
column heater and ThermaBeam EI-MS detector (TMD). The gradient table is 
summarised in Table 3.4. The TMD was operated in positive scan mode (50 – 650 
amu) with a gain of 10. The nebuliser temperature set at 70 °C, the expansion 
region temperature at 80 °C and the source temperature at 225 °C. The total 
volume of post-column eluent was sent to the TMD. The TMD was tuned every 
day prior to starting an analysis run and caffeine was injected as a test compound 
to ensure functionality of the total system. The three samples were suspended in 
ACN/MeOH (2:1 v/v), vortexed until fully dissolved, filtered (0.45 µm) and 10 µL 








Table 3.4.  Gradient conditions for the Waters 2695.  Method T3.4 (run time – 
60 min) 
Time (min) Flow (mL/min) % C (H2O) % D (ACN) Curve 
0.0 0.2 90 10 6 
1.0 0.2 90 10 6 
20 0.2 30 70 6 
40.0 0.2 0 100 6 
41.0 0.25 0 100 6 
45.0 0.25 0 100 2 
50.0 0.25 90 10 3 
58.0 0.2 90 10 6 
59.0 0.2 90 10 6 
 
3.1.3 NMR spectroscopy  
NMR analyses were carried out on a Varian 400 MHz Unity spectrometer at the 
CSIR. TMS was used as an internal reference standard. Routine analysis 
generally involved the following 1D and 2D core procedures: 
• 1D 1H analysis (investigation of chemical shifts, signal intensities and 
scalar (J) couplings between nuclei) 
• 1D 13C analysis (to establish the chemical shifts and the number of 
carbons present) 
• DEPT sequence (to determine number of proton baring carbons) 
• 2D 1H↔ 1H COSY/gCOSY sequence (to establish proton connectivity) 
• 2D HMQC/gHMQC and HSQC/gHSQC sequences (to establish 1H↔13C 
correlations) 
• 2D HMBC sequence (to identify fragments through long-range 1H↔13C 
correlations due to spin exchange over 2 or 3 bonds or across 
heteroatoms) 
• 2D NOESY experiments (for stereochemical analysis of space 







A Perkin Elmer 241 polarimeter at 589 nm with a sodium lamp at 589 nm as a light 
source and a cell with path length 1 dm was used in all experiments. These 
experiments were performed with CHCl3 as the solvent. 
3.1.5 Determination of melting points 
Melting points were determined using a Reichert hotstage apparatus and are 
uncorrected. 
 
3.1.6 X-ray crystallography 
Crystallography experiments were conducted by Dr Melanie Rademeyer at the 
University of KwaZulu-Natal on an Oxford Diffraction Excalibur-2 CCD area 
detector diffractometer, using Mo-Kα X-radiation and a graphite-crystal 
monochromator. Data collection, cell refinement and reduction were conducted 
using CrysAlis CCD (version 1.171.29.9) and CrysAlis RED (version 1.171.29.9), 
Oxford Diffraction Ltd., 2006. Structure solution and refinement were performed  
using the SHELXS97 and SHELXL-97 (Sheldrick, 2008) programs respectively.44 
Mercury was used for molecular graphics.45  
 
3.2 Biological assays 
3.2.1 In vitro antimalarial screen 
In this in vitro biological activity assay method, compounds or crude extracts were 
evaluated for their effect on Plasmodium falciparum erythrocytic forms of two 
strains, namely chloroquine-sensitive (CQS) D10 and chloroquine-resistant (CQR) 
strains K1. Asexsual erythrocytic stages of P. falciparum were continuously 
maintained in culture following the method of Trager and Jensen.46 Static cultures 
were incubated in sterile culture flasks at 37 °C in an atmosphere of 93% N2, 4% 
CO2 and 3% O2. The host cells were human red blood cells. The parasites were 
maintained at a 5% haematocrit in RPMI 1640 (Biowhittaker) culture medium 
                                            
44 Sheldrick G. M. (1997). SHELXL97 and SHELXS97. University of Göttingen, Germany. 
45 Bruno I. J., Cole J. C., Edgington P. R., Kessler M., Macrae C. F., McCabe P., Pearson J., Taylor 
R.  (2002). Acta Chrystallografica, B58, 389-397. 





supplemented with 25 g/L of Albumax II (lipid-rich bovine albumin) (GibcoBRL), 
44 mg/L of hypoxanthine, and 50 mg/L HEPES (Sigma Aldrich).  
 
All test substances were stored at –20 oC prior to testing. Stock solutions of test 
substances were prepared in 10% methanol or 10% DMSO, depending on the 
solubility, and diluted in Millipore water to prepare 2 µg/mL solutions, which were 
stored at –20 oC. All solvent systems used for preparation of stock solutions were 
evaluated prior to the use and had no measurable effect on the host cells or the 
parasite. Chloroquine diphosphate (Sigma) was used as a reference drug in all 
experiments. The test substances were evaluated in nine serial two-fold dilutions 
(0.2 – 100 µg/mL) in medium and tested once, for each concentration, in replicate 
of two. Test solutions were plated together with the suspension of infected human 
red blood cells and incubated for 24 h in microtitre plates. The conditions for 
incubation were the same as described for the routine maintenance of the P. 
falciparum cultures.  
 
Quantitative assessment of in vitro antiplasmodial activity was determined via a 
modified parasite pLDH assay of Makler et al.47 This enzyme assay differentiates 
between pLDH and host LDH activity by using APAD. The pLDH uses APAD as a 
coenzyme in the conversion of pyruvate to lactate and reduces it to APADH. The 
formation of APADH can be measured by the subsequent reduction of a yellow 
NBT salt to a blue formazan product, the absorbance of which is measured with a 
7520 microplate reader (Cambridge Technology) at λ 620 nm. 
 
The IC50 values, serving as a measure for antiplasmodial activities, were 
calculated using a non-linear dose-response curve fitting analysis via GraphPad 
Prism v.4.0 software. This work was carried out at the Pharmacology Department 
of UCT. 
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3.2.2 In vitro cytotoxicity assay 
Compounds were tested for in vitro cytotoxicity against a CHO cell line using the 
MTT assay.48 This colorimetric assay is based on the ability of viable cells to 
metabolise a yellow water-soluble tetrazolium salt into a water-insoluble purple 
formazan product. The amount of formazan produced can be measured 
spectrophotometrically and is proportional to the metabolic activity and number of 
cells in the test plate. The CHO cells were cultured in DMEM: Hams F-12 medium 
(1:1) supplemented with 10% heat-inactivated fetal calf serum (FCS) and 
gentamycin (0.04 µg/mL) (Highveld Biological, RSA).  
Samples were dissolved in MeOH/H2O (1:9 v/v). Stock solutions (2 mg/mL) were 
prepared and were stored at –20 °C until use. Emetine was used as the positive 
control. The initial concentration of emetine was 100 µg/mL, which was serially 
diluted in complete medium with ten-fold dilutions to give six concentrations, the 
lowest being 0.001 µg/mL. The same dilution technique was applied to all test 
samples with an initial concentration of 100 µg/mL to give five concentrations, the 
lowest being 0.01 µg/mL.  
In the initial stage of the experiments, the cells were adjusted to a concentration of 
105/mL, and 100 µL of this cell suspension was seeded in all wells except in 
column 1 (“blank”) in a 96-well culture plate (Costar). The plates were incubated at 
37 °C for 24 h in a humidified 5% CO2-air atmosphere. After the incubation period, 
the medium was aspirated out of the wells and 100 µL of the test substances (drug 
stock solutions) was added in quadruplicate to the dedicated wells. A further 
100 µL of culture medium was then added to all the wells containing cells and 
drugs, and 200 µL of medium was added to the “blank” wells and to the “no drug” 
wells containing only cells. The microplate was then incubated at 37 °C for 48 h.   
After the 48 h incubation period, 25 µL of sterile MTT (5 mg/mL in PBS) was 
added to each well and incubation was continued for 4 h at 37 °C. The plates were 
then centrifuged at 2 050 r/min for 10 min, and the supernatant was carefully 
aspirated from the wells to ensure that the formazan crystals were not disturbed. 
The formazan crystals were then dissolved in DMSO (100 µL) and the plate was 
                                            






gently placed on a shaker for 5 min. The plate was blanked on the wells in column 
1 and the absorbance of the crystals was measured at λ 540 nm on a Microtitre 
Plate Reader (Cambridge Technologies). The cell viability was calculated in each 
well using the formula: 
Aλ540 test well (cells + drug) 
% Cell viability = 
A λ540 cell control well (cells + no drug) 
x 100 
The concentration of drug that inhibits 50% of the cells (IC50 values) for these 
samples was obtained from dose-response curves, using a non-linear dose-
response curve fitting analysis via GraphPad Prism v.2.01 software.  This assay 
was conducted by the UCT Pharmacology Department. 
 
3.2.3 In vivo murine malaria model 
The in vivo protocol was set up by Prof. Peter J. Smith (UCT). Ethical approval for 
this study was granted by the UCT Animal Ethics Committee. The strain of mice 
used for the experiment was C57 Black6 (6 – 10 weeks old) with average mass 
20-25 g. There were five mice in each tested substance and four mice in each 
control group. The positive control group was treated with standard drug 
chloroquine. The negative control group received no treatment. The mice were 
infected with chloroquine-sensitive Plasmodium bergei ANKA. They were infected 
interperitoneally with 200 µL of 106 cells/mL parasite stock. After 24 h post-
infection, the mice were treated once a day for four consecutive days. From the 
second day post-infection, slides were made from three animals per group to 
determine the percentage of the parasitaemia in the blood using Giemsa stained 
smears. Test substances were administered orally or subcutaneously using water 
or DMSO/water (1:9 v/v). Pure compounds were tested at 100 mg/kg, and CQ was 
administered at 5 mg/kg to the positive control group. This assay was conducted 
by the UCT Pharmacology Department. 
 
3.2.4 In vitro anticancer pre-screen 
All extracts, fractions and compounds were assayed in the 3-cell line panel 
consisting of TK10 (renal), MCF7 (breast), and UACC62 (melanoma). A primary 





Drug Evaluation Branch of the NCI.49,50,51 Crude extracts were tested at ½ log 
serial dilutions of five concentrations ranging from 6.25 to 100 ppm, or at log serial 
dilutions for molar concentrations ranging from 0.01 to 100 µM. The results were 
obtained for each cell line as dose-response curves. For selection and 
prioritization of test substances the biological activities were separated into four 
categories based on the value of the concentration of the compound needed to 
totally inhibit growth of the cells (TGI): 
Inactive:   TGI > 50 ppm 
Weak:   TGI between 15 and 50 ppm for two or three cell lines 
Moderate :  TGI between 6.25 and 15 ppm for two or three cell lines 
Potent:   TGI < 6.25 ppm for two or three cell lines. 
 
The screening results were reported in terms of the averaged response 
parameters, GI50, TGI, and LC50, calculated for all cell lines. 
 
The cell lines were grown in RPMI 1640 medium (Whitehead Scientific), 
supplemented with 10% heat-inactivated FBS (Adcock Ingram Scientific) and 
2 mM of L-glutamine (Sigma Aldrich). The cells were inoculated into 96-well flat-
bottom polystyrene plates at 100 µL with inoculation densities of 1000 (UACC62), 
5000 (MCF7) to 15 000 (TK10) cells/well. The cell lines were plated as per Figure 
3.1.  
 
After cell inoculation, the microtitre plates were incubated at 36 °C, 5% CO2, 95% 
air and 100% relative humidity for 24 h prior to the addition of the experimental 
drugs. After 24 h, the time zero (T0) plate was fixed in situ with chilled TCA to 
measure the cell population for each cell line at the time of drug addition. 
                                            
49 Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K. D., Vistica D., Hose C., Langley J., 
Cronise P., Vaigro-Wolff A., Gray-Goodrich A., Campbell H., Mayo J., Boyd M. (1991). Journal of 
the National Cancer Institute, 83, 757–766.  
50 Kuo S. -C., Lee H. -Z., Juang J. -P., Lin Y. -T., Wu T. -S., Chang J. -J., Lednicer D., Paull K. D., 
Lin C. M., Hamel E., Lee K. -H. (1993). Journal of Medicinal Chemistry, 36, 1146–1156.  
51 Leteurtre F., Kohlhagen G., Paull K. D., Pommier Y. (1994). Journal of the National Cancer 
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   (no drugs)  
Figure 3.1.  Five-dose assay format 
 
Stock solutions of experimental drugs were prepared in DMSO at a concentration 
of 10 000 ppm (or less, with subsequent adjustment of dilution volumes) and 
stored frozen prior to use. Extracts, fractions or compounds were diluted in 
complete media with 0.1% gentamycin sulfate and dispensed into the first of five 
dilution tube. Serial dilutions were made by transferring a set volume (in mL) from 
one tube to the next. The contents of the dilution tubes consisting of the media 
with a range of drug concentrations were dispensed into shallow basins prior to 
plating with a multi-channel pipettor aid. Following addition of the drugs, the plates 
were incubated for 48 h and then fixed in situ by the addition of 50 µL of chilled 
50% TCA. After addition of the TCA, the plates were refrigerated for 1 – 3 h at 4 
°C. The supernatant was discarded, the plates were washed five times with tap 
water to remove excess TCA and media, and air-dried. SRB (Sigma Aldrich), at 
0.4% in 1.0% acetic acid (v/v), was added to each well, and the plates were left to 
stand for 10-20 min at RT to ensure full staining of the cellular protein in the wells. 
Unbound dye was removed by inversion of the plates. The plates were then rinsed 
five times with 1.0% acetic acid and tap water to remove excess water, after which 
they were air-dried. Bound SRB was solubilised in 100 µL of 10 mM trizma base 
on the shaker for 5 min. The absorbance was measured at λ 540 nm on a 
microtitre plate reader (Labsystems Multiscan RC). The percentage of cells in 
each well was calculated using a spreadsheet based on the standard NCI-formula. 






3.2.5 In vitro anticancer 60-cell line panel 
The cytotoxicity profile of the candidate extracts and compounds was determined 
against the panels of human cancer cell lines at the NCI (Maryland, USA). The 
NCI panel of 60 cell lines included leukaemia (L) lines, non-small cell lung cancer 
(NSCLC) lines, colon cancer (CL) lines, central nervous system cancer (CNSC) 
lines, melanoma (M) lines, ovarian cancer (OC) lines, renal cancer (RC) lines, 
prostate cancer (PC) lines, and breast cancer (BC) lines. The results from the NCI 
were reported as mean log10 functions of the three response parameters, GI50, 
TGI, and LC50, calculated for each cell line. Compounds having overall average 
log10 GI50 values of less than 1.1 for all cell lines were selected for further 
investigation.  
 
3.3 Bioassay-guided isolation of sesquiterpenoids from D. anomala 
subsp. gerrardii (Chapter 4) 
3.3.1 Collection of plant material 
Plant material of D. anomala subsp. gerrardii was collected in February 2006 and 
identified by Jean Meyer, a botanist from SANBI. Specimen vouchers were 
deposited at the SANBI Herbarium. All collections were chosen on the basis of 
plant population to ensure sustainable harvesting.  A total of 6 kg of rhizomes was 
collected from the Brits district in North West province. The plants were sun-dried 
prior to delivery. 
 
3.3.2 General extract preparation 
The preparation of plant extracts from the material delivered by a traditional healer 
depended on the anecdotal information and on the intended route of 
administration described in the anecdote. In general, plant material was first dried 
in an oven at 60 °C and ground to a fine powder with a hammer mill. Two 
extraction methods were used. In method A, the plant material was separated into 
two portions and one portion was immersed in distilled DI H2O and boiled to 
produce a hot infusion or “tea”. The infusion was filtered through a cheese cloth 
followed by filtration through Whatman filter paper, after which the filtrate was 
lyophilised (extract yield = 2.5% w/w of dry plant material). The second portion of 





methanol/dichloromethane (MeOH/DCM 1:1 v/v) sufficient to fully immerse the 
plant material. The extract was filtered and concentrated in a vacuum on the rotary 
vacuum evaporator at 60 °C. The concentrate was further dried in a vacuum 
desiccator to give a finished organic extract (extract yield = 2.7% w/w of dry plant 
material). 
 
In method B, a sequential extraction was performed where firstly, a MeOH/DCM 
(1:1 v/v) extract was prepared, filtered and dried. The plant material was then dried 
overnight in an oven at 60 °C and then immersed in cold distilled water for 4 h and 
then extracted. The water extract was filtered and the filtrate was lyophilised. 
 
3.3.3 Preparation of extracts with various solvents  
Equal parts (5 g) of dried and ground plant material were extracted once with 
50 mL of solvent for 24 h with occasional stirring. The following range of solvents 
was utilised in order of increasing polarity: hexane (A), DCM (B), EtOAc (C), 
MeOH/DCM (1:1 v/v) (D), MeOH (E), DI water (F). The extracts were filtered and 
the solvent was removed under vacuum with a rotary evaporator (60 °C). The 
extracts were further dried in a vacuum desiccator overnight and then stored in the 
coldroom at –24 °C.  
 
3.3.4 Processing and extraction of bulk plant material  
A total of 5.6 kg of plant material was oven dried (30 °C) and ground into small 
particles with hammer mill to give 3.7 kg of processed plant material. Part of the 
plant material (300 g) was used for optimisation of the extraction method. The 
remaining portion of the processed material was consecutively extracted with 
3 volumes of EtOAc (15 L) over 3 days. The extraction solvent was filtered through 
a cheese cloth and then through a filter paper. The extract was concentrated 
under reduced pressure on the rotary evaporator at 60 °C and further dried in a 
vacuum desiccator for 96 h to remove all traces of solvent. The extraction yielded 






3.3.5 Bioassay-guided fractionation and isolation of active compounds from the 
extract of D. anomala 
A primary 3-cell line anticancer assay was employed in the bioactivity-guided 
isolation of compounds from the extract of D. anomala. In the initial step, the crude 
extract was separated by polarity by solvent partitioning (Section 3.3.5.1). 
Fractions showing anticancer activity comparable to that of the crude extract were 
then subjected to further fractionation by VLC, CC and FC. 
 
3.3.5.1 Solvent partitioning  
Solvent partitioning of the crude extract was used to pool fractions of various 
polarity ranges (Figure 3.2). The extract (1 g) was dissolved in 100 mL of aqueous 
methanol (MeOH/H2O 9:1 v/v) and extracted with hexane (3 x 100 mL). Hexane 
aliquots were separated with a separating funnel and combined. It was then dried 
over anhydrous NaSO4, filtered through Whatman filter paper and concentrated 
under vacuum on a rotary evaporator (60 °C) to give a hexane-soluble fraction (A). 
Methanol was removed from the remaining aqueous methanol layer under vacuum 
on a rotary evaporator, and the remaining solution was diluted to 100 mL with DI 
H2O and extracted with DCM (3 x 100 mL). The mixture was separated with a 
separating funnel into organic, aqueous and insoluble phases. The organic layers 
were combined and dried over anhydrous Na2SO4, filtered and concentrated under 
vacuum on a rotary evaporator to give a DCM-soluble fraction (B). Traces of the 
organic solvent were removed from the remaining aqueous phase under vacuum 
on a rotary evaporator, after which it was lyophilised to give an H2O-soluble 
fraction (C). The insoluble phase was dried under vacuum on a rotary evaporator 






























Figure 3.2.  Solvent partitioning method and GI50 values (primary anticancer 
assay) 
 
3.3.5.2 Vacuum liquid chromatography 
Large-scale purification of the DCM-soluble fraction (B) was done using VLC in 
batches of 5 – 10 g of extract on 400 – 500 g of SiO2 60 (0.063 – 0.2 mm) under 
reduced pressure, using EtoAc/Hexane/DCM/MeOH and Acetone/DCM/MeOH 
gradients. Pooled fractions were combined on the basis of similarity of chemical 
profile by TLC. Crude fractions A-L were concentrated in vacuum on the rotary 
evaporator and further dried in the vacuum desiccator for 48 h prior to 
bioassaying. The results are summarised in Table 3.5. 
Crude extract 
Aqueous methanol layer 
Dichloromethane-soluble 





(A), GI50 = 25 ppm 
1) Evaporated, 60 °C, vacuum 
2) Added H2O  
3) Extracted H2O layer with DCM  
(x 3) 
 
1) Dried (NaSO4, unhydr.) 





GI50 = 25 ppm 
1) Dissolved in aq. methanol-water  






Table 3.5.  VLC solvent gradient and fractions collected. Bioassay: LC50 















Fraction A 5 - 47.5 47.5 - 3 000 >100 
Fraction B  -   -  >100 
Fraction C 1 - 4.5 4.5 - 6 000 100 
Fraction D  -   -  6.25 
Fraction E  -   -  <6.25 
Fraction F 2 - 4 4 - 3 000 6.25 
Fraction G 2 - - 8 - 1 000 12.5 
Fraction H - 2 - 8 - 1 000 25 
Fraction I - 3 - 7 - 3 000 100 
Fraction J - 3 - 6.5 5 2 000 >100 
Fraction K - 3 - 5 2 2 000 >100 
Fraction L (wash) - 3 - 3 4 2 000 50 
 
Fractions D-H, which showed LC50 values of less than 25 ppm, were combined on 
the basis of similarity of the TLC profile and subjected to further column 
chromatography and bioassay-guided fractionation. 
 
3.3.5.3 Further bioassay-guided fractionation of semi-crude fractions D-H 
Fractions D-H were subjected to further CC and FC (Figure 3.3). The first, 
fractionation was performed using a 90 cm column packed with SiO260 and eluted 
with an EtOAc/Hexane/DCM/MeOH isocratic solvent mixture (9:45:45:1 v/v) to 
give fractions 3.3.5.4 A-N, which were tested for bioactivity. Final purification of the 
major compounds from the two most active fractions 3.3.5.3 F1 and 3.3.5.3 H2 
was achieved by means of FC, using a 40 cm flash column, packed with flash 
silica gel and eluted with a Hexane/DCM/EtOAc/MeOH isocratic solvent mixture 
(45:45:9:1 v/v). The fractions were combined on the basis of similarity of the 
chemical composition determined by TLC analysis. Fractions 3.3.5.3 F1 and 
3.3.5.3 H2 yielded pure compounds 2.14 and 4.3, which exhibited increased 
biological activity in the primary anticancer bioassay. Detection: TLC plates (SiO2 
F254, Merck) were developed in EtOAc/Hexane/DCM, 15:42.5:42.5 v/v, UV λmax = 





= 15.55 min; UV λmax = 211, 242 nm; m/z 245.2 [M+H]+ and tR (4.3) = 23.2 min; UV 
λmax = 215, 313 nm; m/z 485.2 [M+H]
+. Compound 4.2 was recrystallised from 2-
propanol, to yield 400 mg of white orthorhombic crystals. Compound 4.3 was 











LC50< 25 ppm 
(3.5g) 
Fractions  3.3.5.3 A-
E 
LC50> 12.5 ppm  
(0.4 g) 
Fractions  3.3.5.3 F 
LC50< 6.25 ppm 
(0.4 g) 
Fractions  3.3.5.3 G 
LC50> 25 ppm 
(0.2 g) 
 
Fractions  3.3.5.3 H 
LC50= 6.25 ppm 
(1.2 g) 




Fraction 3.3.5.3 F2 
LC50= 6.25 ppm 
 
Fractions  3.3.5.3 I-N 
LC50> 50 ppm 
(1 g) 
Fraction  3.3.5.3 
H1 




LC50< 6.25 ppm 
 
Fraction  3.3.5.3 
H3 

















































Common name: Dehydrobrachylaenolide 
Yield: 400 mg (0.013% w/w of dry plant material) 
Molecular formula: C15H16O3 
ESI-MS, m/z: 245.2 [M+H]+ 
Melting point: 223-224°C (lit.52 mp 225 °C) 
Optical rotation: [α]24D +68°(c= 0.50, CHCl3); (lit. 
53 [α]24D +67.9°, 
c= 0.16, CHCl3) 
UV, λmax (nm): 209; 244 
1H NMR (400 MHz, CDCl3), δH : 1.02 (3H, s, H-14); 1.67 (2H, m, Ha-8, Ha-9);  
1.81 (1H, m, Hb-9); 2.1 (1H, m, Hb-8); 2.6 (1H, 
ddddd, J = 3.0; 3.0; 3.2; 10.8; 11.0 Hz, H-7); 
2.98 (1H, ddd, J = 2.2; 2.3; 10.9 Hz, H-5); 4.07 
(1H, t, J = 10.7; Hz, H-6); 5.43 (1H, d, J = 3.1 
Hz, Ha-13); 5.68 (1H, ddd, J = 0.9; 1.0; 2.4 Hz, 
Ha-15), 5.99 (1H, d, J = 9.9 Hz, H-2); 6.1 (1H, 
d, J = 3.2 Hz, Hb-13); 6.24 (1H, dd, J = 1.0; 2.2 
Hz, Hb-15); 6.76 (1H, d, J = 10.0 Hz, H-1). 
13C NMR : Refer to Table 4.2 (Section 4.4.1.1) 
Antiplasmodial activity (D10); 
(K1), (µg/mL): 
IC50= 0.38; 0.06 
Anticancer activity (µg/mL): GI50= 0.67 
Cytotoxicity (CHO) (µg/mL):  IC50= 4.2; SI (D10)= 11; SI (K1)= 70. 
 
                                            
52 Bohlmann F., Zdero C. (1982). Phytochemistry, 21, 647-651. 
53 Higuchi Y., Shimota F., Koyanagi R., Suda K., Mitsui T., Kataoka T., Nagai K., Ando M. (2003). 

























Molecular formula: C30H28O6 
ESI-MS, m/z: 485.2 [M+H]+ 
UV, λmax (nm): 218; 312 
Melting point: 170 °C melting followed by charring 
Optical rotation: [α]24D +56° (c= 0.50, CHCl3) 
1H NMR (400 MHz, CDCl3) δH:  1.48 (1H, m, Ha-8); 1.88 (1H, dt, J = 6.0; 10.6 
Hz, Ha-15); 2.21 (1H, m, Ha-9); 2.24 (1H, m, Hb-
15); 2.29 (1H, m, Ha-14’); 2.33 (1H, m, Hb-8); 
2.58 (1H, m, Hb-9); 2.63 (1H, m, Hb-14’); 2.68 
(1H, br d, J = 18.8 Hz, Ha-2); 2.27-2.82 (2H, m, 
H-8’); 3.01 (1H, m, H-7); 3.04 (1H, m, H-7’); 3.2 
(1H, br d, J = 9.2 Hz, H-1); 3.28 (1H, dd, J = 9.2, 
10.0 Hz, H-5); 3.36 (1H, dd, J = 3.1; 18.5 Hz, 
Hb-2); 3.73 (1H, br d, J = 10.9 Hz, H-5’); 4.03 
(1H, dd, J = 9.5; 10.9 Hz, H-6’); 4.18 (1H, dd, J = 
9.0, 10.0 Hz, H-6); 4.68 (1H, br s, Ha-14); 5.03 
(1H, br s, Hb-14); 5.52 (1H, d, J = 3.0 Hz, Ha-
13’); 5.53 (1H, d, J = 3.0 Hz, Ha-13); 5.98 (1H, 
m, H-9’); 6.06 (1H, d, J = 1.0 Hz, Hb-13); 6.11 
(1H, t, J = 1.0, Ha-15’); 6.22 (1H, dd, J = 1.0; 1.7 
Hz, Hb-15’); 6.24 (1H, d, J = 1.0 Hz, Hb-13’). 
13C NMR : Refer to Table 4.3 (Section 4.4.2), 
Antiplasmodial activity (D10);  
(µg/mL): 
IC50= 0.46. 
Anticancer activity (µg/mL): GI50= 0.75. 





3.3.5.6 Targeted isolation of compound 4.2 from the organic extract of 
Brachylaena transvaalensis 
The detannified MeOH:DCM extract of roots of B. transvaalensis was obtained 
from the CSIR’s Bioprospecting extract repository. Presence of the compound 4.2 
in the extract was established by means of HPLC-UV/MS analysis (method T3.1-3; 
tR = 25.4 min; UV λmax = 211, 242 nm; m/z 245.2 [M+H]+). The sequence of solvent 
partitioning and chromatographic purifications (Section 3.3.6) was employed to 
purify DHB (4.2) from 1 g of the MeOH/DCM extract of B. transvaalensis. 
Compound 4.2, isolated from D. anomala subsp. gerrardii, was used for the TLC 
analysis (SiO2 F254 plates, Merck) as a reference to guide the purification (Rf = 
0.38 in EtOAc/Hexane/DCM, 15:42.5:42.5 v/v; detection UV λmax = 352 nm). 
Recrystallisation of the fraction, equivalent to 3.3.5.3 F1 from 2-propanol, 
produced 5 mg of pure compound 4.2 in 0.001% yield (w/w dry plant material). 
The authenticity of the structure was confirmed by 1H NMR analysis and the value 
of the optical rotation ([α]24D +67.9°; c = 0.2, CHCl3). 
 
3.3.5.7 HPLC analysis of root extract of D. anomala subsp. anomala for the 
presence of DHB 
An ethyl acetate extract of D. anomala subsp. anomala collected from 
Mpumalanga was subjected to solvent partitioning. The dichloromethane soluble 
fraction (B) was analysed by LC-UV, using compound 4.2, isolated from D. 
anomala subsp. gerrardii, as a standard (method: T3.1-2; tR (4.2) = 19.65 min; UV 
λmax = 211, 242 nm). The UV λmax chromatogram revealed that 
dehydrobrachylaenolide (4.2) was not present in the extract of D. anomala subsp. 
anomala 
 
3.4 Preparation of sesquiterpene derivatives (Chapter 5) 
3.4.1 Data for (6β)-3-oxoeudesm-1,4,11-trien-6,12-olide (5.17) 
The compound was obtained from the Discovery Chemistry Group. Detection: TLC 
plates (SiO2 F254, Merck) were developed with EtOAc/hexane/DCM (15:42.5:42.5 
v/v) as the mobile phase, then sprayed with 15% vanillin/H2SO4 reagent and 
baked in the oven for 5 min at 120 °C, Rf (5.17) = 0.38; LC-UV (Method: T3.2-2), tR 


















Molecular formula: C15H16O3 
1H NMR (400 MHz, CDCl3), δH: 1.27 (3H, s, H-14); 1.55 (1H, m, Ha-9); 1.72 (1H, 
m, Ha-8); 1.9 (1H, m, Hb-9); 2.12 (3H, d, J = 0.5 
Hz, H-15); 2.65 (1H, m, H-7); 4.72 (1H, dd, J = 
0.5, 12.0 Hz, H-6); 5.5 (1H, d, J = 3.1 Hz, 
Ha-13); 6.19 (1H, d, J = 3.1 Hz, Hb-13); 6.2 (1H, 
d, J = 9.6 Hz, H-1); 6.66 (1H, d, J = 9.6 Hz, H-2). 
13C NMR: Refer to Table 5.1 (Section 5.2) 
Antiplasmodial activity (D10); 
(K1), (µg/mL): 
IC50 = 2.82; 2.21 
Anticancer activity (µg/mL): GI50 = 1.3 
Cytotoxicity (CHO) (µg/mL); 
SI(D10); SI(K1):  
IC50 = 1.71; SI (D10) = 0.6; SI(K1) = 0.78 
 
3.4.2 General procedure for preparation of amino-acid adducts of compound 
5.17 
Previously published methods were used for the preparation of the Michael-type 
adducts of sesquiterpene lactones (STLs) with amino-acids.54,55 The 
corresponding sesquiterpene lactone (15 mg, 0.04 mmol) was dissolved in 5 drops 
of acetone and added to 1 mL of phosphate buffer of pH 7.4 (Sigma-Aldrich). The 
mixture was sonicated for 30 min to degas, and an equimolar amount of amino 
acid was added. The reaction was monitored by TLC for 24 h. The solvent was 
removed by azeotropic evaporation on the rotary evaporator using MeOH, 
alternatively, physical data were acquired on the supernatant of the reaction 
                                            
54 Heilmann J., Wasescha M. R., Schmidt T. J. (2001). Bioorganic & Medicinal Chemistry, 9, 2189–
2194. 





mixture. Detection: TLC (cellulose F254, Fluka); n-BuOH/H2O/acetic acid (5:4:1 v/v) 
as the mobile phase; ninhydrin (0.25% ninhydrin in acetone) or anisaldehyde-
spray reagent (10 mL acetic acid conc., 85% MeOH, 5 mL of H2SO4 conc., 0.5 mL 
anisaldehyde); the plate was sprayed and heated to 100 – 110 °C). 
 
3.4.2.1 Reactivity of compound 5.17 towards L-cysteine at physiological pH  
The general method described in Section 3.4.2 was used to prepare an L-cystein 
adduct of compound 5.17. Compound 5.17 and L-cysteine were used in equimolar 
amounts (0.04 mmol). The solvent was evaporated by letting the reaction mixture 
to stand open to air. Two major products were detected in the reaction mixture 
(NMR 400 MHz, D2O). The structures were assigned on the bases of MS and 
NMR data. Detection: Rf (5.28b) = 0.25; TLC (cellulose F254, Fluka); n-
BuOH/H2O/acetic acid (5:4:1 v/v) as the mobile phase; ninhydrin spray reagent. 
The second product was not detected by the TLC analysis of the reaction mixture, 
as it is probably an artefact.  
 











Molecular formula C18H23NO5S 
UV, λmax (nm): 243.9  
ESI-MS, m/z: 366.3 [M+H]+ 
1H NMR (400 MHz, D2O), δH: 1.33 (1H, m, Ha-9); 1.43 (3H, s, H-14); 1.57 (1H, 
m, Hb-9); 1.97 (1H, m, Ha-8); 2.13 (3H, d, J = 
0.5 Hz, H-15); 2.26 (1H, m, Hb-8); 2.37 (1H, m, 
H-7); 2.8 (1H, m, Ha-13); 3.28-3.46 (2H, m, 





Hb-13); 4.2 (1H, dd, J = 3.9; 8.3 Hz, Cys-αCH); 
5.26 (1H, d, J = 11.2 Hz, H-6); 6.36 (1H, H-2)56; 
7.14 (1H, H-1).56 













O OH  
Molecular formula: C18H25NO6S 
Calculated mass: 368.4247 
1H NMR (400 MHz, D2O), δH: 1.36 (1H, m, Ha-8); 1.43 (3H, s, H-14); 2.13 (3H, 
d, J = 0.5 Hz, H-15); 1.97 (2H, m, Hb-8, Ha-9); 
2.11 (1H, m, Hb-9); 2.26 (3H, d, Hz, H-15); 2.36 
(1H, m, H-7); 2.8-2.82 (2H, m, H-13); 3.1 (1H, m, 
Hb-13); 3.28-3.46 (2H, m, Cys-βCH2); 3.53 (1H, 
m, H-11); 4.2 (1H, dd, J = 3.9; 8.3 Hz, Cys-αC-
H); 4.74 (1H, H-6)56; 6.4 (1H, H-1)56; 7.15 (1H, 
H-1).56 
13C NMR: Refer to Table 5.4 (Section 5.3.2) 
 
3.4.2.4 Addition of N-acetyl-L-cysteine to compound 5.17 at physiological pH 
The general method described in Section 3.4.2 was used to prepare an N-acetyl-L- 
cysteine adduct of compound 5.17.  Compound 5.17 and N-acetyl-L-cysteine were 
used in equimolar amounts (0.04 mmol). The solvent was evaporated by letting 
the reaction mixture to stand open to air. Physical data were acquired on the 
supernatant of the reaction mixture suspended in the deuterium oxide. Two 
products were identified in the reaction mixture (NMR, 400 MHz, D2O). The 
structural assignments were deduced only for the major product (5.29), and a 
structure of the probable minor product was proposed in Section 5.3.3. The 
                                            





structure was deduced from the MS and the NMR data (Table 5.5). Detection: TLC 
plates (cellulose F254, Fluka), developed with n-BuOH/H2O/acetic acid (5:4:1 v/v) 
as the mobile phase, and then sprayed with anisaldehyde reagent and baked in 
the oven for 5 min at 120 °C, Rf (5.32) = 0.30; tR = 20.92 min, LC-UV (Method: 
T3.2-2). The second product was not detected by the TLC analysis of the reaction 
mixture, as it is probably an artefact.  
 















Yield: 56.5% (by HPLC-UV) 
Molecular formula C22H29NO5S 
UV, λmax (nm): 242.9  
EI-MS m/z 408.2 [M+H]+ 
1H NMR (400 MHz, D2O), δH:  1.2 (3H, s, H-14); 1.38 (1H, m, Ha-8); 1.88 (2H, 
m, Ha-9, Hb-8); 1.92 (3H, s, CO-CH3); 1.93 (3H, 
s, H-15); 1.95 (1H, m, Hα-7); 2.1 (1H, m, Ha-9); 
2.58 (1H, td, J = 3.1; 8.2; 10.1 Hz, Hβ-11); 2.75 
(1H, dd, J =8.2; 13.6 Hz, Hb-13); 2.85 (1H, dd, 
J = 9.0; 14.0 Hz, Cys-βC-Hb); 2.95 (1H, dd, J = 
3.1; 13.6 Hz, Ha-13); 3.14 (1H, dd, Cys-βC-Ha), 
4.37 (1H, dd, J = 4.3; 9.0 Hz, Cys-αH); 5.05 (1H, 
dd, J = 1.2; 11.3 Hz, Hβ-6); 6.2 (1H, d, J = 9.7 
Hz, H-2); 6.9 (1H, d, J = 9.7 Hz, H-1). 
13C NMR: Refer to Table 5.5, Section 5.3.3 
 
3.4.2.6 Addition of glutathione to compound 5.17 at physiological pH 
The general method described in Section 3.4.2 was used to prepare a glutathione 
adduct of compound 5.17.  Compound 5.17 and glutathione were used in 





reaction mixture to stand open to air. Physical data were acquired on the 
supernatant of the reaction mixture suspended in the deuterium oxide. Two 
products were identified in the reaction mixture (NMR, 400 MHz, in D2O). The 
structural assignments were deduced only for the major product (5.33), and a 
structure of the probable minor product was proposed in Section 5.3.4. The 
structure was deduced on the basis of the 1H NMR data (Table 5.6). Detection: 
TLC plates (cellulose F254, Fluka) were developed with n-BuOH/H2O/acetic acid 
(5:4:1 v/v) as the mobile phase, then sprayed with ninhydrin reagent and baked in 
the oven for 5 min at 120 °C, Rf (5.33) = 0.49; LC-UV (Method: 3.1.5), tR (5.33) = 
21.07 min. 
 














Yield: 44% (HPLC-UV: Method 3.1.5) 
Molecular formula C25H33N3O9S 
1H NMR (400 MHz, D2O), 
δH: 
1.2 (3H, s, H-14); 1.38 (1H, m, Ha-8); 1.88 (2H, m, Hb-8, 
Ha-9); 1.93 (3H, d, J = 1.2 Hz, H-15); 1.95 (1H, m, H-7); 
2.04 (2H, m, Glu-βCH2); 2.1 (1H, m, Ha-9); 2.42 (2H, m, 
Glu-γCH2); 2.62 (1H, td, J = 3.1; 8.2; 10.1 Hz, Hβ-11); 
2.79 (1H, q, J = 9.0; 14.0 Hz, Cys-βC-Hb); 2.89 (2H, 
ddd, J = 3.1; 8.2; 13.6 Hz, H-13); 3.18 (1H, q, J = 5.1; 
14.0 Hz, Cys-βC-Ha); 3.64 (1H, m, Gly-αC-Hb); 3.76 
(1H, m, Glu-αC-H); 3.88 (1H, m, Hz, Gly-αC-Ha); 4.45 
(1H, dd, J = 5.1; 9.0 Hz, Cys-αC-H); 5.02 (1H, dd, J = 
1.2; 11.3 Hz, Hβ-6); 6.18 (1H, d, J = 10.1 Hz, H-2); 6.95 






3.4.3 Reactivity of compound 4.2 towards L-cysteine using basic conditions 
Compound 4.2 (5 mg, 13 µmol) was suspended in D2O and sonicated for 30 min. 
Cysteine (5 mg, 41 µmol) and EtN3 (0.2 mL) were added, and the reaction was left 
stirring for 48 h at RT. The solvent was reduced by azeotropic evaporation via the 
addition of methanol. The product was purified on the preparative Agilent 1200 
HPLC system, tR = 15.2 min (Method T3.3). The structure was deduced on the 
basis of 1H NMR and 13C NMR data. Detection: LC-UV (Method: 3.1.3), tR (5.27) = 
14.62 min. 
 

















Yield: 6.5 mg (88.5% after prep. HPLC) 
Molecular formula: C18D2H23NO6S 
ESI-MS, m/z: 384.3 [M+H]+ 
UV, λmax (nm): 258.9 
1H NMR (400 Hz, D2O), δH: 0.93 (3H, s, H-14); 1.6 (2H, m, Ha-8, Hb-9); 1.45 
(1H, m, Ha-9); 1.74 (1H, m, H-7); 2.52 (1H, br td, 
J = 1.0; 2.0; 10.3 Hz, H-5); 2.74 (1H, d, J = 12.0 
Hz, Ha-13); 2.86 (1H, d, J = 12.0 Hz, Hb-13); 
2.95 (1H, dd, J = 8.3; 15.2 Hz, Cys-βC-Ha); 3.09 
(1H, dd, J = 3.9; 15.2 Hz, Cys-βC-Hb); 3.8 (1H, 
dd, J = 4.4; 8.3 Hz, Cys-αC-H); 3.84 (1H, dd, J = 
10.3; 10.3 Hz, Hβ-6); 5.5 (1H, d, J = 2.0 Hz, Ha-
15); 5.99 (1H, d, J = 1.0 Hz, Hb-15); 7.0 (1H, s, 
H-1) 






3.4.4 General procedure for reduction of sesquiterpene lactones with NaBH4 
The previously described method for NaBH4 reduction of STLs was employed.
57 
15 mg (0.06 mmol) of a sesquiterpene lactone was dissolved in anhydrous ethanol 
(10 mL). The solution was cooled to 0 ºC, and NaBH4 (78 mg, 2 mmol) was added. 
The mixture was stirred at 0 ºC for 10 min, after which 20% acetic acid (10 mL) 
was added to quench the reaction. The solution was diluted further with water 
(20 mL) and extracted twice with CHCl3 (2 x 50 mL). The organic layers were 
combined, dried over anhydrous Na2SO4 and concentrated under vacuum on a 
rotary evaporator to afford brown gum. 
 
3.4.4.1 Stereoselective reduction of compound 5.17 
The reduction of compound 5.17 was performed by using the general method 
described in Section 3.4.3. The main product was purified by flash silica gel 
chromatography using EtOAc/Hexane (3:7 v/v), to afford 13.5 mg of a pale yellow 
solid (total yield = 90%). The structure was identified as α-santonin, on the basis of 
the EI-MS data (NIST 2005 Mass spectral database search, ThermaBeam TMD 
system, Waters) and NMR data and comparison with the published data.58 
Detection: TLC plates (SiO2 F254, Merck) were developed using 
EtOAc/Hexane/DCM (15:42.5:42.5 v/v) as the mobile phase, then sprayed with 
vanillin reagent and baked in the oven for 5 min at 120 °C, Rf (5.36) = 0.35. 
 












Common name: α-Santonin 
Yield: 13.5 mg (90% after CC) 
Molecular formula: C15H18O3 
ESI-MS, m/z: 246.2; 264.1 
                                            
57 Irwin M. A., Lee K. H., Simpson R. F., Geissman T. A. (1969). Phytochemistry, 8, 2009–2012. 
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UV, λmax (nm): 246.4 
1H NMR (400 Hz, CDCl3), δH: 1.23 (3H, d, J = 6.9 Hz, H-13); 1.28 (3H, s, H-
14); 1.44-2.07 (5H, m, H-7, Hα-8, Hβ-8, Hα-9, 
Hβ-9); 2.1 (3H, d, J = 1.3 Hz, H-15); 2.38 (1H, 
dq, J = 6.9, 11.7 Hz, H-11); 4.77 (1H, dq, J= 1.3, 
10.9 Hz, H-6); 6.21 (1H, d, J = 9.9 Hz, H-2); 6.62 
(1H, d, J = 9.9 Hz, H-1). 
13C NMR: Table 5.7 (Section 5.4.1) 
Antiplasmodial activity (D10); 
(K1), (µg/mL) 
IC50 = 8.34; 42.76 
Cytotoxicity (CHO) (µg/mL);  
SI(D10); SI(K1):  
IC50 = 88.31; SI (D10) = 11; SI (K1) = 2.1 
 
3.4.4.3 Reduction of compound 4.2 
The compound 4.2 was reduced using the general method described in Section 
3.4.3. The reaction mixture was analysed by TLC: purple spot Rf = 0.68 and blue 
spot Rf = 0.75, TLC (SiO2 F254, Merck); EtOAc/Hexane/DCM (15:42.5:42.5 v/v); 
15% vanillin/H2SO4 spray reagent. The mixture of products was further analysed 
by LC-ESEI-MS and 5 peaks were observed in the UV chromatogram [tR = 21.438 
(m/z 246.2); 21.717 (m/z 248.2); 22.017 (m/z 248.3); 22.296 (m/z 250.30); 23.020 
min (m/z 244.2, 264.2)]. No additional physical data were obtained due to the 
difficulty of separating the components.  
 
3.5 Preparation of pro-drugs (Chapter 6) 
3.5.1 The OSIRIS Property Explorer 
The OSIRIS Property Explorer was used to calculate “on-the-fly” drug-relevant 
properties for chemical structures. The results allow prediction of properties with 
high risks of undesired effects such as mutagenicity or poor intestinal absorption. 
Lipinski's Rule of Five is a “rule of thumb” to evaluate drug-likeness, or to 
determine whether a chemical compound with a certain pharmacological or 





humans. The rule is based on the calculated parameters, which contribute to the 
overall score of drug-likeness.59,60 
 
3.5.2 General procedure for preparation of Michael adducts of STLs with 
Et2NH.
61  
A mixture of sesquiterpene lactone (15 mg, 60 µM) and diethylamine (30 mg) in 
anhydrous EtOH (9 mL) was treated with Et3N and refluxed at 150 °C overnight. 
The ethanol and volatile di- and triethyl amines were then evaporated under 
vacuum on a rotary evaporator. The resulting residue was chromatographed over 
silica gel, using a DCM/MeOH (97:3 v/v) solvent mixture as the mobile phase. The 
structures were determined on the basis of MS and NMR data. Detection: TLC 
plates (SiO2 F254, Merck) were developed with DCM/MeOH (24:1 v/v) as the 
mobile phase, then sprayed with vanillin spray-reagent and heated in the oven at 
120 °C; LC-MS (Method T3.2-1). Retention factors and retention times for 
products 6.6, 6.7, 6.8, 6.9 and 6.10 are discussed in Chapter 6. 
 









Yield: 10.9 mg (55% after CC) 
Molecular formula: C19H31NO3 
1H NMR (400 MHz, acetone-
d6), δH: 
1.01 (6H, t, J =7.0 Hz, H-17); 1.16 (1H, m, Ha-3); 
1.25 (3H, s, H-15); 1.75 (3H, s, H-14); 2.04 (1H, 
m, Hb-3); 2.12 (1H, m, Ha-2); 2.0-2.18 (2H, m, 
H-8); 2.19 (2H, m, H-9); 2.3-2.4 (1H, m, H-7); 
2.42 (1H, m, Hb-2); 2.49 (1H, td, H-11); 2.42-
2.52 (2H, m, CH3-CH2-N-); 2.73 (1H, dd, J = 5.5; 
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Reviews, 23, 3–25. 
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14.0 Hz, Ha-13); 2.74 (1H, d, J = 8.6 Hz, H-5); 
2.78 (1H, dd, J = 4.7; 14.0, H-b-13); 3.89 (1H, t, 
J = 8.6; 9.2 Hz, H-6); 5.26 (1H, dd, J = 2.3; 12.1 
Hz, H-1) 
13C NMR: Refer to Table 6.2 (Section 6.3.1) 
Antiplasmodial activity (D10), 
(K1), (µg/mL): 
IC50 = 4.27; 6.95 
Anticancer activity (µg/mL): GI50 = 1.11 
Cytotoxicity (CHO) (µg/mL):  IC50 = 0.75, SI (D10) = 0.2 
 

















Yield: 5.2 mg (27% after CC) 
EI-MS: 318.0 [M+H]+ 
UV, λmax (nm): 241.6  
Molecular formula C19H27NO3 
ESI-MS, m/z  318.0 [M+H]+ 
1H-NMR (400 MHz, acetone-
d6), δH: 
1.04 (6H, t, J =7.0 Hz, CH3-CH2-N-); 1.05 (3H, s, 
H-14), 1.75-1.85 (2H, m, H-9); 1.98 (1H, m, H-7); 
2.05-2.25 (2H, m, Ha,b-8); 2.48 (1H, dd, J = 8.2; 
12.9 Hz, Ha-13); 2.4-2.67 (2H, m, J = 7.0; 14.0 
Hz, -N-CH2-CH3); 2.68 (1H, ddd, J = 3.9; 8.2; 
10.3 Hz, H-11); 2.83 (1H, dd, J = 3.9; 12.9 Hz, 
Hb-13); 2.96 (1H, dt, J = 2.4; 10.9 Hz, H-5); 4.40 
(1H, t, J = 10.9 Hz, H-6); 5.51 (1H, ddd, J = 0.8; 
1.6; 2.4 Hz, Ha-15); 5.95 (1H, dd, J = 0.8; 9.8 
Hz, H-2); 6.04 (1H, dd, J = 1.5; 1.6 Hz, Hb-15); 
6.97 (1H, d, J = 9.8 Hz, H-1). 





Antiplasmodial activity (D10); 
(K1), (µg/mL): 
IC50 = 1.29; 2.88 
Anticancer activity (µg/mL): GI50 = 1.3 
Cytotoxicity (CHO) (µg/mL):  IC50 = 4.66, SI (D10)= 3.6 
 









Yield: 3 mg (18% after CC) 
Molecular formula: C17H22O4 
Calculated MW, (g/mol): 290.3541 
1H NMR (400 MHz, CDCl3), δH: 1.06 (3H, s, H-14); 1.29 (3H, t, J = 7.4 Hz, CH3-
CH2-O-); 1.59-1.90 (4H, m, 2H-8, 2H-9); 2.53 
(1H, m, H-7); 4.07 (1H, dd, J = 1.2, 10.1 Hz, H-
6); 4.21 (2H, q, J = 7.4 Hz, CH3-CH2-O-); 5.6 
(1H, d, J = 1.2 Hz, Ha-15); 5.77 (1H, s, Hb-13); 
5.96 (1H, d, J = 9.9 Hz, H-2); 6.1 (1H, d, J = 1.2 
Hz, Hb-15); 6.29 (1H, d, J = 0.8 Hz, Hb-13); 6.73 
(1H, d, J = 9.9 Hz, H-1). 
 















Yield: 5.6 mg (29% after CC) 
ESI-MS, m/z: 318.2 [M+H]+ 





Molecular formula: C19H27NO3 
1H NMR (400 MHz, acetone-
d6), δH: 
0.96 (6H, t, J =7.0 Hz, CH3-CH2-N-); 1.25 (3H, s, 
H-14); 1.48 (1H, m, Ha-9); 1.66 (1H, m, Ha-8); 
1.82 (1H, m, Hb-9); 1.95 (1H, m, H-7); 2.09 (3H, 
d, J =1.2 Hz, 3H-15); 2.4-2.54 (2H, m, J = 7.0; 
13.7 Hz, CH3-CH2-N-); 2.53 (1H, ddd, J = 4.3; 
8.6; J = 12.9 Hz, H-11); 2.59 (1H, dd, J = 4.3; 
13.26 Hz, Ha-13); 2.89 (1H, dd, J = 8.6; 10.1 Hz, 
Hb-13); 4.73 (1H, dd, J = 1.2; 11.3 Hz, H-6); 
6.21 (1H, d, J = 10.0 Hz, H-2); 6.64 (1H, d, J = 
10.0 Hz, H-1) 
13C NMR: Refer to Table 6.4a (Section 6.3.3.1) 
Antiplasmodial activity (D10); 
(K1), (µg/mL): 
IC50 = 8.93; 19.91 
Anticancer activity (µg/mL): GI50 = 22.2 
Cytotoxicity (CHO) (µg/mL):  IC50 = 28.31, SI (D10)= 3.2 
 








Yield: 2.0 mg (12% after CC) 
Molecular formula: C17H22O4 
Calculated MW, (g/mol): 290.3541 
1H NMR (400 MHz, acetone-
d6), δH: 
1.29 (3H, s, H-14); 1.3 (3H, t, J = 7.0 Hz, CH3-
CH2-O-); 1.78 (1H, m, Ha-8); 2.05 (1H, m, Hb-8); 
2.12 (1H, m, Hb-9); 2.21 (3H, d, J = 1.2 Hz, H-
15); 2.68 (1H, td, J = 3.9, 11.0, 12.9 Hz, H-); 4.21 
(2H, q, J = 7.0 Hz, CH3-CH2-O-); 4.77 (1H, dd, J = 





d, J = 10.0 Hz, H-2); 6.25 (1H, d, J = 0.8 Hz, Hb-
13); 6.63 (1H, d, J = 10.0 Hz, H-1). 
13C NMR: Refer to Table 6.4b (Section 6.3.3.2) 
  
 
3.5.3 Preparation of Michael adducts of STLs in an aprotic solvent 
General procedure for preparation of Michael adducts with Et2NH was used. A 
mixture of sesquiterpene lactone 5.17 (15 mg, 60 µM) and an excess of Et2NH 
(100 µM) in dioxane (9 mL) was treated with Et3N, refluxed at 150 °C overnight 







Chapter 4: Isolation, structural elucidation, bioactivity 
and biosynthesis of bioactive 
sesquiterpenoids from an extract of Dicoma 
anomala subsp. gerrardii. 
4.1 Introduction 
Plants have a long history of use in the treatment of cancer, and plant-derived 
anticancer agents constitute a significant part of the current arsenal of 
chemotherapeutic agents.62 However, cancer as a specific disease entity is poorly 
recognised in terms of traditional medicine. Even though more than 3 000 plants 
species have been reported for this use, in many instances the “cancer” is 
undefined, and reference is made to conditions such as hard swellings, 
abscesses, calluses, corns, warts or tumours. Such symptoms would generally 
apply to the skin, and be tangible or visible conditions.63 It is also reported, that 
from the high throughput screening programme of National Cancer Institute (NCI, 
USA), a large percentage of the actives, from randomly selected extracts, were 
those of plants with reported medicinal use. Furthermore, the discovery of the 
Vinca alkaloids, discussed in Chapter 1, was indirectly attributed to the 
observation of an unrelated medicinal use of the source plant.64 
In the search for novel chemotherapeutics from plants, the CSIR began 
high-throughput screening of plant extracts in 1999 using in vitro screening 
technology transferred from the NCI. Two approaches were used to select the 
extracts from the 25 000-extract repository: random and ethnobotanical. The 
results of random screening are reported elsewhere.65 From a total of 410 extracts 
tested through the ethnobotanical selection process, an extract of Dicoma 
                                            
62 Hartwell J. L. (1982). Plants Used Against Cancer. A survey. Lawrence, MA. Quarterman 
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64 Cragg G. M., Boyd M. R., Cardellina J. H., Newman D. J., Snader K. M., Mc. Cloud T. G. (1994). 
In: Ethnobotany and the Search for New Drugs. Ciba Foundation Symposium, Wiley: Chichester, 
UK, 185, 178–196. 
65 Fouche G., Khorombi E., Kolesnikova N., Maharaj V. J., Nthambeleni R., van der Merwe M.  





anomala Sond. exhibited activity at micromolar concentrations, and was selected 
for further evaluation.  
Previous phytochemical investigations of the Dicoma genus, which were 
discussed in detail in Section 2.4 (Chapter 2), revealed that the presence of 
costunolide (4.1) derivatives (Figure 2.2) with oxygen functions at C-14 and C-15 
is characteristic of the genus.9,10 The roots of various Dicoma species yielded 
several common compounds such as β-sitoterol, lupeol, phytol and α-humulene 
(2.4).  












(+)-Costunolide   (4.1) Albicolide   (2.19)  
Extracts of various parts of D. anomala yielded several eudesmanolides (2.39-
2.44), germacranolides (albicolide (2.19) and urospermal A (2.15)) and 
guaianolide 2.33. 
However, D. anomala subsp. gerrardii has not been previously investigated. This 
chapter covers the bioactivity-guided isolation and structure elucidation of active 
compounds, and further biological screening of these compounds against 
Plasmodium falciparum (in vitro and in vivo). 
 
4.2 Plant recollection and processing 
4.2.1 D. anomala subsp. gerrardii 
The original specimen delivered to the CSIR in December of 1999 was identified 
as D. anomala Sensu (SANBI Batch No 99111). However, the latest taxonomic 
interpretation of D. anomala in Southern Africa (Chapter 2) enabled us to revise 
the original classification of the herbarium specimen. Based on the distinct 
morphological features (erect habit; ~12-mm-long involucra comprising few 
bracts), the specimen could be sub-classified as D. anomala Sond. subsp. 





4.2.2 Bulk recollection and processing 
Bulk recollection of rhizomes was carried out in the Brits region of North West 
Province in February of 2006. On average, the fresh rhizomes varied in size from 
3 to 12 cm (Figure 4.2). The plants were air dried to remove excess moisture and 
stored prior to processing for 48 h. The rhizomes were oven dried and ground to a 
coarse powder (~40% mass loss on drying). 
 
Figure 4.2.  Size distribution of the rhizomes in a batch 
 
4.2.3 Optimisation of the extraction method using anticancer 3-cell lines 
bioassay  
The optimisation strategy was based on the initial anticancer screening results of 
the ethnobotanical extracts, using 5 g quantities of dried and ground plant 
material, and a range of organic solvents (Table 4.1). All extracts were screened 
against the preliminary 3-lines panel of cancer cells.  
 
Whilst all the prepared extracts showed a considerable degree of activity, an ethyl 
acetate extract exhibited superior activity to that of the other extracts. The 





Table 4.1.  Cytotoxicity of crude extracts against CHO and cancer cell line 
panels 
3-cell line pre-screen 
(CSIR), potency, value 
(ppm) 




CSIR/NCI ID number 
CHO: IC50 
(ppm) 
GI50 TGI LC50 GI50 
Hexane extract, SM01084A - Inactive Inactive Inactive - 
Crude MeOH:DCM extract 
(SM01084B) 
- 12.5 25 40 
12.8 (weak 
leukaemia) 
Hot infusion (SM01084C) - Inactive Inactive Inactive - 
EtOAc extract   7.8 <<6.25 <<6.25 <<6.25 
1.86 (strong 
leukaemia) 
DCM extract  - 6.25 <<6.25 <<6.25 - 
 
4.3 Bioassay-guided fractionation and isolation of active compounds 
from extract of D. anomala 
The crude dry ethyl acetate extract was subjected to solvent partitioning 
(described in detail in Section 3.3.5.1 of Chapter 3) to produce four fractions: 
hexane-soluble fraction (A); dichloromethane fraction (B), the aqueous fraction (C) 
and the insoluble residue fraction (D). Fraction (B) showed increased activity (GI50 
<<6.25 ppm), the insoluble fraction (D) yielded activity much lower than that of the 
crude extract (GI50 = 25 ppm), whilst the hexane and aqueous fractions were 
completely devoid of activity. Further bioassay-directed fractionation of the 
dichloromethane fraction by vacuum liquid chromatography (VLC) on silica gel, 
followed by successive flash silica gel purifications, resulted in the isolation of two 
bioactive compounds 4.2 and 4.3, with GI50 values of 0.67 ppm and 1.0 ppm 
respectively against the 3-cancer cell lines panel.  
 
4.4 Structure elucidation of compounds 4.2 and 4.3 
The structural assignments of compounds 4.2 and 4.3 were based on detailed 





techniques and comparison of the spectral data with that of compounds previously 
isolated from Dicoma sp.66,67 
 
4.4.1 Structure of compound 4.2 
4.4.1.1 Structure elucidation of compound 4.2 using spectroscopic techniques 
Compound 4.2 was isolated as a colourless powder with a total yield (w/w) from 
dry plant material of 0.013%. LC-ESI-MS analysis of compound 4.2 revealed a 
















The 1H NMR spectrum exhibited 13 signals which integrated as approximately 
16 protons. The 13C NMR data gave a total count of 15 non-equivalent carbon 
atoms. From the 1H and 13C NMR analyses, hydrogen and carbon counts allowed 
an estimation of a probable molecular composition of C15H16O3 with eight sites of 
unsaturation. The 1H, 13C, gHSQC, gHMBC, COSY and NOESY data of compound 
4.2 are summarised in Table 4.2. 
 
The 1H NMR spectral data clearly showed the presence of one tertiary methyl 
group at δH 1.02. Furthermore, it revealed the presence of a pair of olefinic 
hydrogens (δH 5.99 and δH 6.76) which had vicinal coupling of 10.0 Hz indicative of 
Z-geometry. The 1H NMR spectrum also showed a pair of sharp doublets (J = 3.1 
Hz) at δH 5.43 (J = 3.2 Hz) and at δH 6.10, which were assigned to geminal 
exomethylene protons. A further set of signals in the low-field region which 
corresponded to a doublet of doublet of doublets at δH 5.68 (J = 2.4; 1.0; 0.9 Hz) 
                                            
66 Croasmun W. R., Carlson R. M. K. (1987). Two-dimensional NMR Spectroscopy: Applications for 
Chemists and Biochemists. New York: VCH Publishers. 
67 Saunders J. M., Hunter B. K. (1987). Modern NMR Spectroscopy. A Guide for Chemists. Oxford: 





was caused by the geminal and allylic coupling, and was assigned to a second 
exomethylene group. Another distinct proton signal, which appeared at δH 4.07 as 
a triplet (J = 10.7 Hz), corresponded to one oxymethine proton. The chemical shift 
values for a multiplet, resonating at δH 2.6, and a doublet of doublet of doublets (J 
= 2.2; 2.3; 10.9 Hz) at δH 2.98, suggested that both protons were deshielded by 
the neighbouring group/s. In addition, three aliphatic protons (by integration) were 
observed in the region δH 1.28 – 1.84.  
 
The 13C NMR spectra showed 15 signals, with 5 quaternary and 10 proton-bearing 
carbons, as was evident from the DEPT spectra. Of the five methine groups, there 
were two aliphatic CH groups. One was a deshielded oxymethine signal at δC 79.2, 
assignable to C-6 (δH 4.07), and the remaining two were assigned to the olefinic 
carbons C-1 (δC 158.4) and C-2 (δC 127.5), corresponding to proton signals as δH 
5.99 and δH 6.76. Of the four CH2 groups, two corresponded to the two sets of 
exomethylene protons (δH 5.43 and δH 6.1) and the remaining two to the aliphatic 
groups. Of the five quaternary carbons, two were carbonyl signals at δC 187.6 and 
δC 170.0, two were olefinic and one was an aliphatic carbon atoms. Two carbonyl 
groups and three double bonds (eight sp2 carbons) accounted for five of the eight 
degrees of unsaturation. The three remaining degrees of unsaturation were 
assumed to ring structures. Based on this evidence, it was strongly suspected that 
the unknown compound may be a sesquiterpene lactone (STL), similar to those 
previously isolated from the Dicoma species. Structural assignments were 
deduced as follows. 
 
Unambiguous 13C↔1H correlations were obtained from the gHSQC spectrum via 
one-bond 13C↔1H coupling. Examination of the COSY spectrum revealed a strong 
vicinal coupling (J = 10.8 Hz) between the H-6 and H-7 protons, while the H-7 
proton showed strong coupling to C-8 (δH 1.67 and δH 2.1) and H-13 protons (δH 
5.43 and δH 6.1). Further couplings of the Hb-8 proton to C-9 protons (δH 1.67 and 
δH 1.81) were also observed. HMBC correlations between C-1 with a proton signal 
at δH 1.67 of C-9 proton along with the long-range coupling between carbon C-9 at 
δC 36.1 and the H-14 protons, allowed the methyl group to be placed at C-10 (δC 





between C-13 (δC 117.6) protons and the carbon C-7 (δC 49.5), the tertiary carbon 
C-11 (δC 138.2) and the carbonyl carbon C-12 (δC 170.0). HMBC correlation of the 
C-11 carbon to the oxymethine C-6 (δC 79.2) proton at δH 4.07 allowed a fragment 












The location of the doubly conjugated keto-group, subsequently identified as C-3 
(δC 187.6), followed from the HMBC correlations of the carbon signal C-3 to the 
geminal protons H-15, and a long-range correlation of carbon C-2 to proton signals 
for H-15. Further HMBC correlation between the C-6 proton and carbon C-5 (δC 
138.2) and carbon C-10, and the correlation of the methyl proton H-5 to the tertiary 
carbon C-10 pointed to the existence of two fused cyclohexane rings forming a 
skeleton of the eudesmanolide-type sesquiterpenoid molecule. The last site of 
unsaturation was attributed to a lactone ring, and together with the above 
substantiation data, the structure of compound 4.2 was deduced.  
 
The structure was further confirmed by comparison of its 1H NMR data, 13C NMR 
data and physical constants with published values.52,68 Thus compound 4.2 was 
identified as 3-oxoeudesma-1,4(15),11(13)-triene-12,6α-lide, which was identical 
to the structure of dehydrobrachylaenolide (2.42), previously isolated from various 
Dicoma species (Chapter 2).10  
 
                                            





















1 CH 158.4 6.76 (d); J = 10.0 H-2, H-15 H-2 H-2, Hb-9 
2 CH 127.5 5.99 (dd); J = 10.0; 
1.0 
H-1 H-1 H-1 
3 C 187.6 - H-1, Ha-15, Hb-15 - - 
4 C 140.5 - H-2, H-5, Hb-15  - - 
5 CH 52.6 2.98 (ddd); J = 2.2; 
2.3; 10.9 





6 CH 79.2 4.07 (t); J = 10.7 H-1,H-5, Hb-8 H-5, H-7 H-14, Ha-15 
7 CH 49.5 2.6 (ddddd); J =  
3.0; 3.0; 3.2; 10.8; 
11.0  




3, Hb -13 
H-5 
8 CH2 21.1 Ha 1.67 (m) 
Hb 2.1 (m) 




9 CH2 36.1 Ha 1.67 (m)  
Hb 1.81 (m)  





10 C 39.6 - H-1, H-2, H-5, Hb-8, 
Ha-9, Hb-9, H-14 
- - 
11 C 138.2 - H-6, H-13 - - 
12 C 170.0 - Hb-13 - - 
13 CH2 117.6 Ha 5.43 (d); 
J13b = 3.1 
Hb 6.10 (d);  




14 CH3  19.6 1.02 (s) 
H-1, H-5, Ha-9, Hb-9 H-9 
H-6, Ha-8, 
Hb-9 
15 CH2 122.2 Ha 5.68 (ddd) 
J15b = 0.9; 1.0; 2.4  
Hb 6.24 (dd); 
J15a = 1.0; 2.2  
H-5 H-5 Ha-15↔H-6, 
Hb-15 
 
Assuming that H-7 is α-oriented, as in all sesquiterpene lactones from higher 





C-5, C-6, C-7 of compound 4.2 could be derived from the size of the observed 1H 
NMR couplings (J5,6~J6,7~10.8 Hz) and NOE correlations to be anti-periplanar, 
suggesting Hα-5, Hβ-6 and Hα-7 have a relative spatial orientation.69  
 
This was in good agreement with previously reported stereochemistry for 
dehydrobrachylaenolide and irazunolide, and was subsequently confirmed by 
X-ray data (Section 4.4.1.2).10,70 
 
4.4.1.2 X-ray crystallographic study of compound 4.2 
Compound 4.2 was recrystallised from 2-propanol to yield white orthorhombic 
crystals (mp 223-224 °C). The crystal system and space group for compound 4.2 
were identified from diffraction symmetry and systematic absences as 
orthorhombic, P 212121, with four equivalent molecules in the asymmetric unit 
(Figures 4.3 and 4.4).  The X-ray crystal structure of compound 4.2 revealed the 
presence of the three-ring eudesmanolide system with endo-exo cross-conjugated 
methylenecyclohexenone moiety trans-fused with cyclohexane C-1 - C-5 and 
trans-annelated with the α-methylene-γ-lactone (at C-6 - C-7), and therefore 
confirmed the proposed structure for the compound 4.2. 
 
Figure 4.3.  X-ray structure of compound 4.2 
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Figure 4.4.  Packing of the molecules in the crystal of compound 4.2 
 
The relative stereochemistry, initially deduced from the size of the coupling 
constants, whereby the anti-periplanar arrangements of the protons at C-5 to C-9 
suggested H-5α, H-6β and H-7α spatial orientations, was also confirmed. While 
ring B exists in a classic chair conformation, the presence of four sp2-hybidrised 
carbon atoms in ring A of compound 4.2 leads to a flattening of the chair due to 
their planar geometry with the four carbons lying in one plane (Figure 4.5).  
 







The structure shows that C-15 is placed in the pseudo-equatorial position while C-
14 is in the axial position above the plane of the ring. Detailed crystallographic 
data for compound 4.2 are presented in Appendix 2.  
 
The unambiguous assignment of absolute stereochemistry of compound 4.2 was 
made on the basis of the value of the optical rotation ([α]24D+68° (c 0.50, CHCl3)) 
which is identical to that of the synthetic compound ([α]24D+67.9° (c 0.16, CHCl3)),  
in which the stereochemistry followed from the precursors,53 and is very close to 
the value for the natural isolate ([α]24D+67° (c 0.16, CHCl3)) with postulated 
absolute stereochemistry.52 
 
4.4.2 Structure elucidation of compound 4.3 
The second active compound 4.3 was purified by flash silica gel chromatography 
and further re-crystallisation from cold MeOH to yield yellow needles with a total 
yield of 0.004% (w/w) of dry plant material. The optical rotation was measured to 
give [α]24D +56° (c = 0.5, CHCl3). The structure of compound 4.3 was determined 



























The melting point was not determined as the C30 compound started melting at 
170 °C and as soon as any liquid was generated, a lot of charring was observed. 
No further melting was observed below 270 °C (limit of apparatus).  The low-
resolution FAB of compound 4.3 showed a molecular peak at m/z 485.2 [M + H]+ 
and UV λmax 218 and 312 nm. The monoisotopic exact mass of m/z 484.18511 
was established by positive high-resolution EI-MS, which was consistent with the 
molecular formula C30H28O6 and calculated mass of 484.1885. Seventeen sites of 





HSQC, HMBC, COSY and NOESY data for compound 4.3 are summarised in 
Table 4.3. 
 
In the 13C NMR spectra 30 intense signals were observed. There were 6 aliphatic 
and 4 olefinic methylenes, 7 methines, with 2 methines bearing an oxygen function 
(δC 83.1 and 84.1), as followed from the DEPT analysis. All proton-carbon 
relationships were determined from the HSQC analysis, and 11 carbon signals 
were assigned to quaternary carbons, 4 of which were carbonyl groups (δC 169.2, 
169.6, 193.2 and 220.2). Detailed examination of HSQC also revealed the 
presence of a minor impurity.  
 
Connectivity between the atoms was derived from COSY and HMBC experiments. 
The sub-structure of a 7-membered ring in fragment 4.3i was derived from COSY 
cross-peaks between H-1 and H-5 and H-9, and the HMBC correlations of carbons 
C-9 and C-1 to H-14a,b. Further HMBC correlations of the carbon signal of C-10 















The carbonyl keto-group C-3 (δC 220.2) was placed following positive cross-peaks 
between C-3 and protons H-1 and H-2, and between protons H-1 and H-5, and 
carbon C-4. Further long-range correlations in the HMBC spectrum were observed 
between C-13 geminal protons (δH 5.53 and δH 6.06) and the carbons C-7 (δC 
43.52), C-11 (δC 138.2) and the carbonyl carbon C-12 (δC 169.6). HMBC 
correlation of the C-11 carbon to the oxymethine C-6 (δC 84.1) proton at H-6 (δH  
4.18), and between carbon C-15 and protons H-5 (δH 3.28), H-6 and another 
proton resonating at δH 2.29 ppm, allowed a fragment 4.3i to be established   





between geminal protons Ha,b-14 of 0.5-3.0 Hz was not observed and the two 
proton signals (δH 4.68 and δH 5.03) appeared as broad singlets. In total, 6 sites of 
unsaturation were accounted for from the total of 17 sites. 
 
Table 4.3.  1H and 13C NMR data for compound 4.3 in CDCl3 
Atom 
number 










1 CH 40.0 
3.2 (br ddd); 
J1,5,-cis = 9.2 
H-5, H-9, H-
14 
H-11 H-7, Ha-9 
2 CH2 45.1 
Ha 2.68 (ddd); 
J1 =3.1 
Hb 3.36 (dd); 




3 C 220.2 - H-1, H-2 - - 




5 CH 50.0 
3.28 (dd); J1,5 = 




6 CH 84.1 
4.18 (dd); 
J5 = 10.0,  
J7 = 9.0 
Ha-8 H-5,H-7  Hb-15 
7 CH 43.5 3.01 (m) H-8, Hb-13 H-6, H-13a H-1, H-5 
8 CH2 32.2 
Ha 1.48 (m) 







9 CH2 39.5 
Ha 2.21 (m) 













11 C 138.2 - H-7 - - 
12 C 169.6 - H-13 - - 
13 CH2 121.6 
Ha 5.53 (d); 
J7 = 3.0 
Hb 6.06 (d); 








14 CH2 114.1 
Ha 4.68 (br s) 




1, H-9’  
Ha-14↔Ha-
2, Hb-14  
Hb-14↔Hb-
9, Ha-14 
15 CH2 31.7 
Ha 1.88 (m) 







1’ C 158.5 - H-5’, H-9’ - - 
2’ C 144.6 - H-5’, H-9 - - 
3’ C 193.2 - Ha,b-15’ - - 
4’ C 141.2 - H-5’ - - 
5’ CH 49.1 
3.73 (br d); 
J6’= 10.9 
H-15’ H-6’, H-15’  H-7’ 
6’ CH 83.1 
4.03 (dd); J5’ 
= 10.9, J7’ = 9.5 
H-5’  H-5’, H-7’  
7’ CH 46.8 3.04 (m) 
H-8’, H-9’, 
Ha,b-13’ 
H-1’, H-6’ H-5’ 
8’ CH2 28.9 
Ha 2.28 (m)  
Hb 2.82 (m) 








10’ C 134.2 - H-8’ - - 
11’ C 138.6 - H-7’ - - 
12’ C 169.2 - H-5’, H-13’ - - 
13’ CH2 120.2 
Ha 5.52 (d); 
J7’ = 3.0 






14’ CH2 33.0 
Ha 2.29 (m)  






15’ CH2 121.7 
Ha 6.11 (t); J15’b 
= 1.0 
Hb 6.22 (dd); 











The substructure (4.3i) appeared similar to a structure of sesquiterpene 
guaianolide dehydrozalluzanin C (2.33), which is characteristic of this genus.Error! 
Bookmark not defined.,71  
Following the above argument, protons H-13’ (δH 5.52 and δH 6.64) showed cross 
peaks to C-7’ (δC 46.8); Ha,b-13’ ↔C-11’ (δC 138.2), Ha,b-13 ↔C-12’ (δC 169.6) 
and C-11’↔H-6 (δH 4.18)], another structural element, containing α,β-unsaturated 
ester or a lactone moiety, was deduced (part of fragment 4.3ii). Further 
examination of the COSY spectrum allowed to establish the sequence from C-5’ to 
C-9’ in the fragment 4.3ii. HMBC correlations of carbon C-1’ to the olefinic proton 
H-9 (δH 5.97) and between carbon C-14’ and the H-9’ proton, and of carbon C-2’ to 
the H-5’ proton were also observed. The conjugated carbonyl C-3’ (δC 193.2) was 
placed on the basis of cross-peaks between carbon C-3’ and the C-15’ protons (δH 
6.11 and δH 6.22), the H-5’ proton with carbon C-4’ (δC 141.2), and the COSY 
correlation between the Ha,b -15’ protons and the H-5’ (δH 3.73) proton. The 
HMBC correlation of carbon C-1’ to H-5’, together with the above arguments, 















Along with the fragment 4.3i, 13 of the 17 degrees of unsaturation were assigned. 
Of the remaining four, three degrees of unsaturation could be assigned to further 
ring elements, such as two lactone moieties (C-6-O-C-12 and C-6’ -O- C-12’) and 
a cyclopentanone ring through C-3’ - C-2’ closure (4.3ii ring A’).  
 
                                            






The last unaccounted site of unsaturation could be that of the cyclohexene ring 
fused between rings A’ and B’ of substructure 4.3ii thus connecting the two 
substructures 4.3i and 4.3ii via a spiro centre. The spatial orientation of the carbon 
C-14 at position C-4 is likely to be derived from steric approach control during the 
dimerisation process, the least hindered isomer being generated with C-15 above 











































































Analysis of the literature shows that dimeric guaiane lactones are, in the main, 
formed from A/B-cis, B/C-trans linked monomers. In monoguaianolides, the five-





they adopt planar forms.72 In compound 4.3 ring A was deduced to assume 1α-H 
and 5α-H envelope conformation, and the ring A’ should be planar due to the 
presence of 4 sp2 carbons. The size of the coupling constant (J = 9.2 Hz) further 
substantiated the cis relationship between the protons at the C-1 - C-5 ring 
junction. In case of 1β,5α–trans-guaianolide, a value of 10.0 Hz or greater is 
expected according to the literature.73,74 Both lactone ring junctions were proposed 
to assume trans-(6β,7α)-H configuration from the size of the couplings (J6,7 = 10.8 
Hz and J6’7’ = 9.4 Hz), and also from the observed long-range coupling (J = 3.0 Hz) 
between pairs of the Ha-13 methylene proton and the proton H-7, and the Ha-13’ 
proton with the H-7’ proton.71  
 
From the previous X-ray structural results, and by means of empirical calculation 
by the methods of molecular mechanics, in the monomeric cis-, trans-guaianolides 
the 7-membered ring B exists mainly in the twist-chair conformations with 
approximate two-fold axis passing through C-5 and the midpoint of the C-8 - C-9 
bond (TC5 form) or TC8 form, and rarely, in the chair conformation. The TC5 form 
was found in 3-oxograndolide (4.4),75 while the TC8 conformation was present in 
dehydrocostus lactone (4.5a),76 which is considered the most elementary 
exomethylenecycloheptane trans-fused guaian-6,12-olide. For an isolated 
methylenecycloheptane TC5 and TC8 are indistinguishable and represent one of 
the calculated minima for this species.77  





3-Oxograndolide   (4.4)
O
O




Mokko lactone   (4.5b)  
 
                                            
72 Tashkhodzhaev B., Karimov Z. (1994). Chemistry of Natural Compounds, 30, 186–192. 
73 Merfort I., Willuhn G., Wendisch D., Gondol D. (1996). Phytochemistry, 42, 1093-1095. 
74 Zdero C., Bohlmann F., King R. M., Robinson H. (1987). Phytochemistry, 26, 1207-1209. 
75 Rychlewska U. (1985). Acta Crystallographica, 41, 540–542. 
76 Fronczek F. R., Vargas D., Parodi F. J., Fisher N. H. (1989). Acta Crystallographica, 45, 1829-
1831. 
77 Rychlewska U., Szczepanska B., Daniewski M., Nowak G. (1992). Journal of Crystallographic 





The conformation of a 7-membered ring in dimeric guaianolides would be 
determined by the degree of the steric stress arising as the result of dimerisation 
and may differ from the traditional forms existing for the monoguaianolides. The 
chemical shift overlap precluded a detailed study of the conformations of the 
7-membered ring of compound 4.3 via deduction of geminal coupling constants 
(J7,8 and J8,9). Due to the similarity of the chemical shifts of exomethylene protons 
in fragment 4.3i to that of dehydrocostus lactone (4.5a), it was assumed that the 
twist-chair conformation of the 7-membered ring should be the most probable 
conformation.76,78  
 
The conclusion about the geometry at carbon C-4 (structure 4.3iv) was based on 
the NOE correlation observed between H-6 (δH 4.18) and H-15b (δH  2.24), which 
would not be likely with carbon C-14 lying below the plane. This was in good 
agreement with the recently published relative stereochemistry of this dimer.28  
 
4.5 Summary of the literature study of compounds 4.2 and 4.3 
In summary, the literature review revealed that compound 4.2 was originally 
isolated from the roots of Brachylaena transvaalensis and that is where its name 
dehydrobrachylaenolide was derived from.52 However, the compound was not 
detected in the roots of D. anomala subsp. anomala in two previous 
investigations.9,10 Several biological activities were reported for 
dehydrobrachylaenolide (4.2). These included the inhibitory activity toward 
induction of intracellular adhesion molecule–1 (ICAM-1) with IC50 value of 3.0 µM 
and antibacterial properties.79 Compound 4.3 was reported only once in a recent 
patent application on its activity against P. falciparum.28 However, the NMR 
structural data for this compound has not been published.  
 
                                            
78 Milosavljević S., Juranić I., Bulatović V., Macura S., Juranić N., Limbach H. H., Weisz K., Vajs V., 
Todorović N. (2004). Structural Chemistry, 15, 237–245.  





4.6 Targeted isolation of compound 4.2 from the organic extract of B. 
transvaalensis 
B. transvaalensis E. Phillips & Schweick was investigated as potential source of 
dehydrobrachylaenolide (4.2). The wood of this invasive tree, also known as 
Forest Silver Oak, is used for kraal construction.80 The root system is large, and is 
widely spread around the stem. The presence of dehydrobrachylaenolide (4.2) in 
the extract of roots of B. transvaalensis was confirmed by LC-ESI-MS analysis 
(Method T3.1-3; tR = 25.4 min; UV λmax = 211, 242 nm; m/z 245.2 [M+H]
+). 
Subsequently, dehydrobrachylaenolide (4.2) was isolated from the extract of the 
roots of B. transvaalensis following the same sequence of solvent partitioning and 
chromatographic conditions as for the extract of D. anomala subsp. gerrardii 
(Section 3.3.5). Compound 4.2 isolated from D. anomala subsp. gerrardii was 
used as a TLC standard to guide the purification (Rf = 0.38 in 
EtOAc/DCM/Hexane; 15:42.5:42.5 v/v). The compound was isolated as a white 
powder (0.001% yield w/w of dry plant material). The structure was confirmed by 
the 1H NMR analysis and the value of optical rotation. 
 
4.7 HPLC analysis of root extract of D. anomala subsp. anomala for the 
presence of dehydrobrachylaenolide (4.2) 
An ethyl acetate extract of D. anomala subsp. anomala collected in Gauteng was 
subjected to solvent partitioning (described in the experimental section) to produce 
a dichloromethane soluble fraction (B), which was analysed by HPLC, using 
compound 4.2, isolated from D. anomala subsp. gerrardii as a standard (Method: 
T3.1-2; tR = 19.65 min; UV λmax = 211, 242 nm). The UV λmax chromatogram 
revealed that dehydrobrachylaenolide (4.2) was not present in the extract. This 
finding was in good agreement with the results of previous investigations of this 
subspecies of Dicoma.9,10 
 
                                            
80 Loffler L., Loffler P. (2005). Swaziland Tree Atlas: SABONET Report No. 38. Pretoria: Capture 





4.8 In vitro evaluation of compounds 4.2 and 4.3 in the cancer and 
malaria models 
4.8.1 In vitro anticancer activity 
Compounds 4.2 and 4.3 were tested for their cytotoxicity towards cancer cell lines 
in the 3-cell line pre-screen to confirm their activity, and towards the Chinese 
hamster ovarian cell line (CHO) for general indication of their cytotoxicity.  
 
Compound 4.2 was further evaluated against the 60-cell line panel at the NCI. 
Parthenolide was used as a positive standard. The results are summarised in 
Table 4.4. 
 
Table 4.4.  Evaluation of the in vitro activity against cancer cell line panels 
and CHO 
3-cell line pre-screen 
(CSIR), (µg/mL) 
60-cell line panel, average 







GI50 TGI LC50 GI50 TGI LC50 
EtOAc extract of D. 
anomala subsp. 
gerrardii   
























0.68 0.75 4.89  12.23 - - - 
Parthenolide 
(NSC157035) 
0.75 1.11 2.35 3.58 17.9 a 46.6 a 153 a 
 
                                            





4.8.2 In vitro antimalarial activity  
The pure compounds 4.2 and 4.3, isolated from the roots of D. anomala subsp. 
gerrardii, and the crude ethyl acetate extract were tested for potential activity 
against P. falciparum in the high-throughput assay.  
 
The relative IC50 values were determined as a mean value for the two replicates 
and are not statistically significant. Chloroquine was used as positive control in 
each run. The results are summarised in Table 4.5 and some selected dose 
response curves are presented in Appendix 3. The selectivity index was also 
determined and used as an indicator of the toxicity of the test compound towards 
mammalian cells (CHO) when compared to the activity against the parasite. 
 












(µg/ml); n = 2 
SI for 
D10 
SI for K1 
EtOAc extract of D. 
anomala subsp. 
gerrardii   




















0.46 NT 0.68 1.5 - 
Crude (DCM:MeOH) 
extract of B. 
transvaalensis 
2.1 - - - - 
Chloroquine  0.02 0.103  ~906 ~179 
SI (selectivity index) = cytotoxicity CHO IC50/antiplasmodial  IC50 
D10 =  P. falciparum – chloroquine-sensitive strain 
K1 = P. falciparum – chloroquine-resistant strain 
CHO = Cytotoxicity against Chinese hamster ovarian cells 






Both pure compounds were regarded as potent against the two strains of the 
parasite, when compared to the standard compound chloroquine (CQ). Compound 
4.2 showed significant activity towards the CQ-sensitive strain and superior activity 
against the CQ-resistant strain when compared to CQ with SI of 11 and 70, 
respectively. Compound 4.3 was found to exhibit a similar degree of cytotoxicity 
towards CHO cells as for P. falciparum infected erythrocytes, resulting in a 
selectivity index (SI) of 1.5.  The crude extract of D. anomala subsp. gerrardii 
exhibited a 50% inhibitory concentration of 1.4 µg/mL. 
 
4.9 In vivo evaluation of compound 4.2 in the rodent malaria model 
Advancement of a potential antimalarial candidate from discovery to pre-clinical 
development requires a demonstration of in vivo efficacy in one or more animal 
models of malaria.82 The in vivo antiplasmodial activity of compound 4.2 was 
evaluated using the murine in vivo model, where C57 Black6 mice were infected 
with chloroquine-sensitive P. bergei ANKA parasite strain. The compound and 
controls were all administered by subcutaneous injection. The results for the pure 
compound, tested at a once-off dose of 100 mg/kg in the in vivo assay (Figure 4.6) 
showed that 60% of the treated mice survived 9 days longer than the control 
group, indicating some beneficial properties.  
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Figure 4.6.  Survival rates of mice following infection with P. bergei 
                                            
82 FDA Draft Guidance for Industry. Malaria: Developing drug and non-vaccine biological products 
for treatment and prophylaxis. (2007). CDER: http://www.fda.gov/Cder/guidance/7631dft.pdf. 





The level of parasitaemia in the P. berghei infected mice treated with compound 
4.2 was exceptionally high, yet survival continued up to day 9 with 60% 
parasitaemia. All controls with parasitaemia levels of 28% died after day 6. These 
data have provided the first evidence of the in vivo efficacy of compound 4.2, at 
least regarding short-term survival of parasitic infection – although evidence of 
parasitic clearance was not obvious.  One can only assume that there may be 
some suppression of immune response associated with this effect. In the control 
group, two of the four mice died on day 6 and the remaining animals all perished 
on day 7. 
 
4.10 Discussion 
4.10.1 Isolation of bioactive compounds and their anticancer activity 
Bioassay-guided fractionation of the ethyl acetate extract of D. anomala subsp. 
gerrardii using in vitro anticancer bioassay (3-cell line panel) resulted in the 
isolation of two potent sesquiterpenoids 4.2 and 4.3, which showed approximately 
3-fold higher activity than the crude extract. Compound 4.2 also showed the same 
selectivity trend towards the leukaemia sub-panel in the 60-cell line panel 
anticancer assay as the crude extract. The in vitro activity of compound 
(dehydrobrachylaenolide) 4.2 in the 60-cell line panel compares well with that of 
sesquiterpene lactone parthenolide (GI50 = 17.9 µM) – a compound currently in 
clinical development in the form of an amino derivative. The lack of significant in 
vivo activity, revealed through extensive screening of this class of compounds by 
the NCI, precluded compounds 4.2 and 4.3 from being evaluated further. The poor 
in vivo activity trend of sesquiterpene lactones was attributed mostly to solubility 
problems.83  
 
The solubility of a drug is often found by octanol-water partitioning and 
determination of the Log P value. For any given drug, for uptake to occur through 
a membrane, it should possess some lipophilic character, but should also possess 
limited aqueous solubility to allow distribution of the molecule (Log P < 5).59 The 
octanol-water partition coefficient (measured Log P) could not be determined due 
to the insufficient quantity of the dehydrobrachylaenolide. The calculated Log P 
                                            





value for compound 4.2 (Log P = 1.5) could be used to direct preliminary solubility 
optimisation studies aimed at improving its drug-like properties. 84 
 
4.10.2 Evaluation of compounds 4.2 and 4.3 for antimalarial activity 
Due to the nature of the active compounds isolated from D. anomala, the 
compounds 4.2, 4.3 and the crude ethyl acetate extract were evaluated for a 
possible antiplasmodial activity in vitro. The crude extract, compounds 4.2 and 4.3 
were found to exhibit potent activity against the QC-sensitive strain of the 
parasites (D10) with an SI of 3.7, 11 and 1.5 respectively [SI (chloroquine) > 
1 500].85,86  Based on the yields of the isolated active compounds 4.2 and 4.3 
(0.8% and 0.25% w/w crude extract, respectively), the antimalarial activity of the 
crude extract (IC50 = 1.4 ppm) could probably be attributed to these constituents 
[IC50(4.2) = 0.38 ppm and IC50(4.3) = 0.46 ppm]. It is possible that there are other 
bioactive constituents present in the extract, which may contribute to the overall 
activity. Furthermore, the activity of the compounds against the QC-sensitive strain 
(0.38 ppm and 0.46 ppm) is within an order of magnitude of that of the standard 
agents [IC50(chloroquine) = 0.020 ppm; IC50(quinine) = 0.063 ppm and 
IC50(artemisinin) = 0.039 ppm].87  The compound 4.2 was also potent against the 
K1 (CQ-resistant) strain, showing superior activity against the QC-resistant strain 
(K1) with an SI of 70, therefore falling well above the acceptable value of 10 for 
potential development.86 Compound 4.3 is excluded from further consideration 
because of the high toxicity, irrespective of a provisional patent on its use, as a 
very poor selectivity index (SI = 1.5) makes it hardly an attractive candidate as an 
antimalarial drug. For dehydrobrachylaenolide (4.2), this is a first report of its in 
vitro antiplasmodial activity. The in vitro data were sufficient to advance this 
compound into the in vivo model.  
 
                                            
84 XLogP: A partition coefficient or distribution coefficient that is a measure of differential solubility 
of a compound in two solvents. PubChem uses version 2 of the algorithm of the reference 
[Wang R., Gao Y., Lai L. (2000). Perspectives in Drug Discovery and Design. 19, 47–66.] to 
generate the XlogP value. 
85 Rasoanaivo P, Ratsimamanga-Urverg S., Amanitrahasimbola D., Rafrato H., Rakoto R. -A. 
(1999). Journal of Ethnopharmacology, 64, 117–126.  
86 Pink R., Hudson A., Mouries M., Bendig M. (2005). Natural Reviews in Drug Discovery, 4, 727–
740. 





The efficacy of dehydrobrachylaenolide (4.2) was further demonstrated in the in 
vivo murine malaria model. The level of parasitaemia in the P. berghei infected 
mice treated with dehydrobrachylaenolide (4.2) was exceptionally high, yet the 
survival continued up to day 9 with 60% parasitaemia. All controls with 
parasitaemia levels of 28% died after day 6. This is, however, the first report of the 
in vivo efficacy of dehydrobrachylaenolide. 
 
The clinical efficacy of artemisinin (5.1) and derivatives are characterised by an 
almost immediate effect and a rapid reduction of parasitaemia.88 This suggests 
that the mode of action of dehydrobrachylaenolide (4.2) is rather different to that of 
artemisinins. Even though its antiparasitic activity was evident from the in vitro 
studies, the survival of animals with such high parasitaemea levels could be due to 
the suppression of immune response of a host, which normaly leads to septic 
shock and death.  
 
Sesquiterpene lactones are well known for their ability to inhibit NF-κB DNA 
binding, and there is also the published activity of dehydrobrachylaenolide (4.2) to 
inhibit interlukin-1b induced expression of ICAM-1 in the A549 cell line in vitro.53 It 
was also established that there is an increased expression of ICAM-1 on the 
endothelial surface of the brain at the ring and trophozoite blood stages of the 
parasite cycle in the host. Since ICAM-1 is one of the major receptors for 
sequestration of P. falciparum-infected erythrocytes in the brain endothelium, it 
may be reasonable to hypothesise that dehydrobrachylaenolide (4.2) could 
prevent adhesion of infected erythrocytes to the brain endothelium by inhibiting 
expression of ICAM-1.89 Furthermore, in light of the specific mechanism involved, 
several models for studying malaria in vivo were reviewed, and it was found that in 
the current model with P. bergei infected C57BL/b mice, the sequestration of 
parasitised red blood cells could not be observed.90 This suggests that the P. 
bergei model, used for evaluation of in vivo activity of compound 4.2, may not be 
suitable. The fact that parasitaemia at day 9 reached 60% at 100% survival could 
imply a higher affinity of the drug towards the inhibition of induction of ICAM-1 than 
                                            
88 Kayser O., Kiderlen A. F., Croft S. L. (2003). Parasitology Research, 90, 55–62. 
89 Tripathi A. K., Sullivan D. J., Stins M. F. (2006). Infection and Immunity, 74, 3262–3270. 





towards a parasite-related target. The importance of this possibility warrants 
seeking a model in which the effect of a drug on the adhesion and sequestration of 
P. falciparum-infected erythrocytes can be observed. 
 
4.10.3 Structure-activity relationship considerations for dehydrobrachylaenolide 
(4.2) and other eudesmanolides 
Until recently, there was a common perception that STLs are poor drug 
candidates. One of the early publications by Schmidt stated that STLs as a class, 
although structurally diverse and with many associated therapeutic uses, do 
possess unspecific toxicity as alkylating agents, and presumably this precludes 
any useful application.40,91 The reactivity of STLs towards sulfhydryl groups is 
mediated chemically by an α,β-unsaturated carbonyl moiety (e.g. α-methylene-γ-
lactone). These functional groups react with biological nucleophiles, such as 
sulfhydryl groups of cysteine and GSH, by Michael-type addition, thereby inhibiting 
a variety of cellular functions which directs the cells into apoptosis.55,91,92,93,94 In the 
series of eudesmanolides, the principle active centre (against cancer 3-cell lines) 
was attributed to an α,β-unsaturated ketone with an exocyclic methylene grouping, 
since this can act in the same way as α-methylene-γ-lactone.97 This identifies the 
O=C-C=CH2 system as being the necessary component of the structure. This was 
further supported by the findings of the qualitative structure-activity relationship 
(QSAR) studies, which indicated that the α,β-unsaturated carbonyl groups and an 
acyl moiety near an exocyclic methylene group correlate with the SAR 
requirements for cytotoxicity, and therefore it is unlikely to separate the desired 
therapeutic effect from undesired side effects such as cytotoxicity and 
allergenicity.95 
 
In contrast, a recent study of the dehydrocostus – mokko lactones pair (4.5a - 
4.5b) showed that α-methylene-γ-butyrolactone moiety in dehydrocostus lactone is 
                                            
91 Schmidt T. J. (1999). Current Organic Chemistry, 3, 577–608. 
92 Picman A. (1986). Biochemical Systematic Ecology, 14, 255–281. 
93 Kupchan S. M., Fessler D. C., Eakin M. A., Giacobbe T. J. (1970). Science, 168, 376–378. 
94 Dirsch V. M., Stuppner H., Ellmerer-Muller E. P., Vollmar A. M. (2000). Bioorganic & Medicinal 
Chemistry, 8, 2747–2753. 
95 Siedle B., Garcia-Pineres A. J., Murillo R., Schulte-Monting J., Castro V., Rungeler P., Klaas C. 





responsible for the cytoprotective effect in HepG2 cells.96 There are other 
examples of STLs exhibiting high selectivity towards cancer cell lines in vitro, such 
as ludovicins (A, B, C) and parthenolide.97,98 The above arguments suggested that 
each compound within the sesquiterpene lactone structural class should be 
treated individually since compounds with similar structural elements may exhibit 
vastly different activity profiles. 
 
Enzyme alkylation is the most accepted mode of action reported in the antitumour, 
antiplasmodial and cytotoxic activities of STLs. It is postulated that for an effective 
alkylating agent should contain two or more functional groups.99,100 Some studies 
showed a correlation between the number of alkylating structural elements and 
bioactivity.101 The determination of the structural requirements for malaria/cancer 
activity was therefore guided by initial studies of the reactivity of 
dehydrobrachylaenolide (4.2) containing three potential alkylating sites (Figure 

















Figure 4.7.  Potential alkylation sites of compound 4.2 
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The established reactivity pattern towards amino acids was used to further 
determine the strategy for our SAR evaluation. Work related to the preparation of 
amino acid adducts of model STLs and the SAR of some α-santonin derivatives is 
presented in Chapter 5.  
 
4.10.4 Drug-likeness and the pro-drugs of STLs 
In their natural form, sesquiterpene lactones may be regarded as having low 
therapeutic potential, especially when applied systemically.102 This is due to their 
broad spectrum of biological effects and the lack of predictive selectivity, as well 
as the multitude of undesired side effects. However, some recent examples of so-
called pro-drugs of STLs, namely ambrosin, arglabin, parthenin and parthenolide, 
reinforce the view of several authors that sesquiterpene lactones could serve as 
lead compounds for the development of pharmaceuticals.103,104,105,106,107 
Remarkably, the same strategy was involved in the pro-drug preparation for all 
three drugs and proved effective in the application of anticancer (arglabin and 
parthenolide) and antimalarial drug-development. 
 
Other than the reactivity and kinetics of binding to biological nucleophiles, some 
physico-chemical and steric factors also proved important for their biological 
activity. The lipophilicity, molecular geometry and the chemical environment of the 
drug and/or a target sulfhydryl may also affect the end result.108,109 However, the 
reports relating to the effect of aqueous solubility of STLs on toxicity are 
inconclusive. For instance, an increase in neurotoxicity accompanies increased 
lipophilicity in artemisinin derivatives with solubility of less than 50 mg/L (Log P > 
3), whilst several compounds with a cyclopentanone ring, which varied significantly 
                                            
102 Willuhn G. (1998). In: L. D. Lawson, R. Bauer (eds), Phytomedicines of Europe. American 
Chemical Society: Washington, DC, ACS Symposium Series, 691, pp. 118–132. 
103 Hejchman E., Haugwitz R. D., Cushman M. (1995). Journal of Medicinal Chemistry, 38, 3407–
3410. 
104 Shaikenov T. E., Adekenov S. M., Williams R. M., Prashad N., Baker F. L., Madden T. L., 
Newman R. (2001). Oncology Reports, 8, 173–179 
105 Bhonsle J. B., Kamath H. V., Nagasampagi B. A., Ravindrananthan T. (1994). Indian Journal of 
Chemistry, 33, 391–392. 
106 Hwang D. R., Wu Y. S., Chang C. W., Lien T. W., Chen W. C., Tan U. K., Hsu J. T. A., Hsieh H. 
P. (2006). Bioorganic & Medicinal Chemistry, 14, 83–91. 
107 Willuhn, G. (1981). Pharmazie in unserer Zeit, 10, 1–7. 
108 Gören N., Woerdenbag H. J., Bozok-Johansson C. (1996). Planta Medica, 62, 419–422. 





in lipophilicity, elicited the same cytotoxicity.92 Therefore an optimum lipophilicity 
range (Log P) should be established for the best systemic activity.  
 
Dehydrobrachylaenolide (4.2) could be used as a model to generate more water-
soluble pro-drug candidates with possible enhanced bioavailability, which could 
favourably affect the toxicity-to-bioactivity ratio. This could be achieved by using a 
known approach similar to the one used in the preparation of water-soluble 
derivatives of parthenolide. The aim would be to investigate the effect of the 
addition of secondary amines to the C-11 - C-13 exocyclic double bond of some 
model STLs on biological activity and toxicity.106 The solubility will also allow a 
more accurate assessment of the potency of the compound. Work related to the 
preparation of water-soluble pro-drug derivatives is presented in Chapter 6. 
 
4.10.5 Biosynthesis  
Sesquiterpene lactones are plant secondary metabolites that are mainly found in 
the Asteraceae but also occur infrequently in other higher plant families and lower 
plants.110 Sesquiterpene lactones isolated from Dicoma species belong to the 
germacrane framework, and are further divided into to the guaianolide, 
eudesmanolide, or germacranolide types. It is generally accepted that most known 
lactones of these three types of sesquiterpene lactones have a common origin in 
synthesis in the plants, particularly those that co-occur or that are found in plants 
of close botanical affinity. It is considered plausible to derive some insight into the 
nature of the reactions involved in the transformation of biosynthetic precursors to 
complex compounds via established pathways, and subsequently by known 
secondary metabolic alterations. As previously proposed, all STLs from plants are 
derived from a single acyclic precursor, an activated form of farnesol-farnesyl 
diphosphate FPP (4.6a) via the mevalonate-FPP-germacradiene pathway.111,112,113 
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The results of a more recent study by Cane suggest that FPP undergoes ionisation 
followed by electrophilic attack of the resultant allylic cation on the distal double 
bond to form a 10-membered ring intermediate 4.7a (Scheme 4.1).112 The derived 
cationic intermediate can itself undergo further cyclisations and rearrangements 
with the reaction being terminated by quenching of the positive charge, either by 
removal of a proton or capture of an external nucleophile, usually water. 
Recognising that there is a geometric barrier to direct cyclisation of trans, trans-
FPP to 10-membered rings containing a cis double bond, it was subsequently 
proposed that FPP would in such cases undergo an initial isomerisation to the 
corresponding geometric form.114 
 
With regard to further transformations, it was postulated that the majority of STLs 
are derived from a single germacranolide precursor, (+)-costunolide (4.1),113,115 the 
simplest of the sesquiterpene lactones in its relationship to farnesol. The reported 
biochemical pathway for (+)-costunolide in chicory roots involving various enzymes 
is shown in Scheme (4.1).116 Cyclisation of farnesyl diphosphate (FPP) to (+)-
germacrene A (4.8)  is followed by hydroxylation of the isopropenyl side chain, and 
the oxidation of germacra-1(10),4,11(13)-trien-12-ol (4.9) via germacra-
1(10),4,11(13)-trien-12-al (4.10) to form germacra-1(10),4,11(13)-trien-12-oic acid 
(4.11). The postulated hydroxylation at the C-6 position of germacratrien-12-oic 
acid (4.12) and subsequent lactonisation yield (+)-costunolide (4.1). The primarily 
formed cation 4.7a could also be deprotonated to yield germacrene D (2.5), 
previously isolated from D. anomala, after hydride migration to cation (4.14) and 
subsequent conformational change from cisoid structure (4.15) to transoid 
(2.5).9,117 According to currently accepted hypotheses, in addition to trans-FPP 
(4.6a) and cis-FPP, nerolidyl diphosphate (NDP) may also be a precursor in the 
enzymatically catalysed formation of sesquiterpenes in order to allow adequate 
alignment of p-orbitals for the formation of products with cis-double bonds.118 
However, there is not enough evidence to imply a mevalonate  pathway to the 
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formation of germacrene D (2.5) in D. anomala as it is also known to be formed via 
the methylerythritol phosphate pathway (mevalonate-independent pathway).119 
 
Based on the previous study of a large number of stereospecific biomimetic 
transformations of germacranolides and their derivatives into eudesmanolides and 
guaianolides, it has been postulated that this second cyclisation, leading to 
eudesmanolides and guaianolides, is directed by C-1 - C-10 and C-3 - C-4 
epoxidations respectively.115  
 
4.10.5.1 Biosynthesis of dehydrobrachylaenolide (4.2) 
Eudesmanolides may be derived from germacranolides containing C(1)-C(10)-
epoxide moiety.115 Epoxidation, followed by acid-catalysed opening of the oxirane, 
allows either an E1 elimination generating the allylic alcohol artemorin (4.18a) or its 
epimer (4.18b). Alternatively, the intermediate cation (4.17a) and (4.17b) may be 
trapped resulting in the formation of a fused 6,6-ring system characteristic of the 
eudesmanolides. The resultant tertiary cation loses a proton to generate a tri-
substituted double bond leading to douglanin (4.19a) or santamarine (4.19b) with 
the biosynthetic difference between the two considered to be in the initial 
epoxidation.  The douglanin (4.19a) could be derived directly from artemorin 
(4.18a) via an acid-catalysed process.111 The regiochemistry of double bond 
formation avoids the ring strain of introducing a sp2 centre at a ring junction and 
the thermodynamically less stable exocyclic double bond. These species can then 
undergo epoxidation generating ludovicin A (4.20a) and its epimer (4.20b). 
Reynosin (4.19c) and ridentin B (4.20c) are thought to be derived from known 
allylic alcohol species 4.18b. The introduction of a 3-hydroxy group as in 3α- 
hydroxyreynosin (4.21b), or the 3-keto group of ludovicin C (4.22a) can be 
accomplished by ring opening of a 3,4-epoxide.111  
 
                                            




















































Scheme 4.1.  Reported pathway for biosynthesis of STLs in chicory120 
 
Rearrangement of the epoxides can also generate ludovicin B (4.21a) or 3α-
hydroxyreynosin (4.21b) if we implicate the more spatially available methyl group 
(kinetic process). These can undergo dehydration, generating brachylaenolide 
(2.43) and tuberiferin (2.41) respectively, or oxidation resulting in ludovicin C 
(4.22a), with the β-hydroxyketone functional group, which is susceptible to acid-
catalysed elimination, generating the sesquiterpene lactone 
dehydrobrachylaenolide (4.2), the subject of the current body of work. Dehydration 
of ludovicin A (4.20a) before rearrangement of the epoxide cannot be excluded in 
the generation of brachylaenolide (2.43). Introduction of the 3β-hydroxy group in 
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ridentin (4.20c) via an alternative process followed by oxidation to 
β-hydroxyketone resulting in artecalin (4.22b) could also lead to 
dehydrobrachylaenolide (4.2).  
 
Taking into account that costunolide was never isolated from Dicoma sp., and that 
the 14,15-hydroxy compounds are characteristic of the genus, it is possible that 
enzymatic hydroxylation occurs prior to any further transformation of costunolide. 
An alternative biosynthetic path is proposed in Scheme 4.3. The hydroxylation at 
C-1 occurs through 1,3-allylic rearrangement of the primary alcohol at C-14, 
yielding compounds 4.24a or 4.24b, followed by the protonation of the exocyclic 
double bond, which in turn leads to 6,6-cyclisation via proton transfer (most likely 
the C-3 proton) to yield 15-hydroxydouglanin (4.26a) or 15-hydroxysantamarine 
(4.26b), which can undergo a second 1,3-allylic rearrangement to yield dihydroxy-
dienes (4.21a-c). 
 
Even though any of these routes is chemically possible, only albicolide (2.19) of 
the most likely intermediates has been previously isolated from the Dicoma 
species. Since several compound pairs in Scheme 4.2 were isolated from a single 
plant species Tanacetum praeteritum subsp. praeteritum108 (e.g. douglanin – 
santamarin; reynosin - 3α-hydroxyreynosin), it is possible that all the proposed 
synthetic routes co-exist in the same plant. Further phytochemical studies are 
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Scheme 4.3.  Proposed biosynthetic pathways to the eudesmanolides from 
costunolide via albicolide 
 
4.10.5.2 Biosynthesis of the guaianolide dimer 4.3 
The structure of the bissesquiterpenoids, the carbon skeleton of which consists of 
30 atoms, was considered as the product of the Diels-Alder [4+2] cyclo-addition of 
two sesquiterpenoid molecules with subsequent dehydration (Scheme 4.3). It may 
be assumed that in the plant it is formed as the result of the diene synthesis 
between dehydrozaluzanin C (2.33) corresponding to fragment 1, and another 
guaianolide (4.38) corresponding to fragment 2. This hypothesis is partially 
confirmed by the reported isolation of dehydrozaluzanin C from another 
subspecies of D. anomala, but it has not yet been possible to isolate the 




































Scheme 4.4.  Proposed precursors of guaianolide dimer 4.3 
 
Following the argument as for biosynthesis of eudesmanolides, the C-4 - C-5 
epoxide of the germacradienolide 4.16c would be cyclised into the guaianolide 
skeleton (Scheme 4.4). After several biosynthetic steps following the second 
cyclisation, cumambrin B (4.28) or 8-desoxycumambrin B (4.29) could probably 
serve as a precursor of this group of guaianolides.111,121 The cumambrin B (4.28) 
appears to have arisen by stereospecific oxidative closure of the costunolide-like 
ring, or it could also be derived directly from the dehydrocostus lactone. Its 
presence in D. anomala subsp. gerrardii is yet to be established to support this 
hypothesis. 
                                            

































































4,5-epoxide (4.16c)Cumambrin B  (4.28)
              
Scheme 4.5.  Proposed biosynthetic pathways to the guaianolide fragments 
from (+)-costunolide 
 
Consequently, it appears likely that the required biosynthetic machinery to produce 
the required precursors for the C-30 compound 4.3 is present in the Dicoma spp. 
of interest. The postulated Diels-Alder type cycloaddition could then proceed either 
in the presence or absence of a controlling enzyme – the electron densities of the 
coupling partners being favourably matched. It is possible that the plant may utilise 
this dimerisation process to detoxify the compounds by removal of some 





Chapter 5: Reactivity of sesquiterpene lactones 
towards biological nucleophiles – structure-
activity relationships of some natural and 
synthetic eudesmanolides 
5.1 Literature overview of the biological activities of eudesmanolides 
The dehydrobrachylaenolide (4.2), isolated from the extract of roots of D. anomala 
subsp. gerrardii, has shown potent in vitro activity against cancer cell lines and 
against P. falciparum. The compound has also shown an unusual activity profile in 
the in vivo murine malaria model.  
 
There is a common perception that the structural requirements of sesquiterpene 
lactones (STLs), necessary for bioactivity, are the same as for cytotoxicity, tagging 
the entire class with limited pharmacological applicability. Even though a large 
number of STLs lack selectivity in vitro, recently several STLs have made it to the 
market. The best examples, as seen from the literature review, are the registered 
drugs artemisinin (5.1) for treatment of malaria and arglabin (5.2) for treatment of 
cancer. Another plant-derived STL, parthenolide (5.3), has been recently 
advanced into the Rapid Development Programme (RADP) by the NCI as an 



















Generally, most of the observed biological effects of STLs have been attributed to 
their capability to deactivate enzymes and other essential proteins by the 
formation of covalent bonds with free sulfhydryl groups, such as cysteine (CYS) 
residues in such polypeptides, resulting in alkylation of these groups. In general, 
                                            





STLs have been demonstrated to inhibit a variety of important sulfhydryl-bearing 
enzymes (phosphofructokinase, glycogen synthase, inosine monophosphate 
dehydrogenase and others), leading to cellular dysfunction or death.55 The 
mechanism is believed to be based on Michael-type addition of the free thiol 
groups of proteins to α,β-unsaturated carbonyl structures of STLs.91 The 
dehydrobrachylaenolide (4.2) possesses an endo-exo cross-conjugated 
cyclohexadienone structure in the A ring, in addition to the α-methylene-γ-lactone, 
thus altogether containing three electrophilic sites which qualify as Michael 
reaction acceptors (MRAs).53 
 
MRAs can undergo nucleophyllic addition to thiol groups of biomolecules such as 
glutathione (gly-cys-γ-glu or GSH). The bioactivities of STLs are known to be 
neutralised by cellular GSH, which is able to bind to α-methylene-γ-lactones and 
thereby inactivate their biological activity.123,124 However, substantial depletion of 
intracellular GSH by STLs did not lead to loss of cell viability and to a significant 
deactivation of such drugs, as reported in another study.95 It was also shown that 
cellular GSH depletion by STLs can chemosensitise tumour cells to oxidative 
damage. This sensitisation was shown to correlate to the rate of GSH resynthesis 
in the cells.125 Furthermore, GSH-STL conjugates were found to be capable of 
deactivating vital cellular proteins, as it appears, by an entirely different 
mechanism to that of free STL.126  
 
Michael receptor acceptors are also able to act as inducers of phase II enzymes, 
thus having a potential for cytoprotection. In turn, the potency of Michael reaction 
acceptors as inducers of phase II enzymes depends on their reactivity towards 
sulfhydryl groups.127 Several studies have clearly demonstrated that reaction of 
STLs with sulfhydryl reagents such as cysteine and GSH can be reversible, and 
that the reaction kinetics depends on the number and type of the α,β-unsaturated 
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carbonyl sites, the pH of the medium, the concentration of thiol and the character 
of sulfhydril target structures.128 For instance, at physiological pH, the rate of GSH 
and CYS addition to the exocyclic methylene group of helenalin is much higher 
than addition to the endocyclic cyclopentanone double bond, with the latter 
reaction being completely reversible at physiological pH.  
 
It was also noticed that another antioxidant sulfhydryl-containing amino acid, which 
increases intracellular GSH levels, N-acetyl-L-cystein (NAC) can neutralise the 
bioactivity of STLs. NAC is a generically available nutritional supplement which 
has been demonstrated to increase intracellular-reduced and total glutathione by 
92% and 58% respectively.129 For instance, costunolide-induced apoptosis in 
human leukaemia U937 cells was almost completely blocked by the addition of 
NAC.130 Furthermore, parthenolide-mediated apoptosis, correlated with reactive 
oxygen species (ROS) generation, was completely inhibited by NAC.131  
 
Multiple studies into structure-activity relationships (SAR) of STLs are reported. 
Some are significant to the present discussion. As it was realised that the effect of 
a given STL on the cell may vary from cytoprotection to induction of apoptosis and 
that this variation is determined by actual STL, the cell type and the environment, 
the SAR was reviewed within a narrow group of structurally related STLs of 
eudesmanolide skeleton in the selected bioassays. In vitro growth inhibition of 
cancer cells and of P. falciparum was examined. The inhibition of induction of 
ICAM-1 was also considered because of its relevance to dehydrobrachylaenolide 
4.2, and because of its implication in pathologies associated with cancer and 
malaria.  
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5.1.1 Anticancer activity of eudesmane STLs 
Although various modes of action have been suggested to account for some 
biological activities of STLs, the exact mechanism of their anticancer activity has 
not been sufficiently explained.132 Several eudesmane compounds isolated from 
Tanaceum praeterium subsp. praeterium were tested against the human lung 































Armexin (5.4a) Armefolin (5.4b) Armexifolin (5.5)3-a-hydroxyreynosin (4.32b)
 
Figure 5.1.  STLs evaluated for activity against GLC4 and COLO320 cell lines 
 
The SAR for this series of compounds can be summarised as follows: in the 
mono-hydroxy eudesmanolides (4.30a, 4.30b, 4.30c and 5.5) the spatial 
orientation of the C-1-OH group does not effect the activity [IC50 (5.4a) = 7.8 µM 
(GLC4), 8.1 µM (COLO 320); IC50 (4.30b) = 8.1 µM (GLc4), 7.4 µM (COLO320); 
IC50 (4.30c) = 10.7 µM (GLC4); 8.9 µM (COLO320)], but the presence of a 
conjugated enone element in compound 5.5 causes a 2 - 4 times increase in 
growth inhibitory concentration [IC50 (5.5) = 2.5 µM (GLC4); 4.3 µM (COLO 320)]. 
The difference in spatial orientation of the C-1-OH group in the dihydroxy 
compounds caused some activity variation (50%), with αH-1 and αH-3 showing 
superior activity. The shift of a double bond [exo-endo: C-4 - C-15 to C-4 - C-5], 
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however, had no significant effect on activity in pairs of isomers 4.30b – 4.30c and 
5.4b – 4.32b [IC50 (5.4) = 15.2 µM (GLc4), 8.1 µM (COLO320); IC50 (4.32b) 16 µM 
(GLc4), 18.2 µM (COLO320)]. It is noteworthy that a vastly different bioactivity 
relationship exists for the santamarin (4.30b) - douglanin (4.30a) pair evaluated in 
the NF-κB DNA binding assay, with santamarin showing 3-fold stronger activity 
[IC100 (4.30b) = 100 µM; IC50 (4.30a) = 300 µM].95 
 
The results of in vitro evaluation of a range of synthetic eudesmane compounds 















































Figure 5.2.  STLs evaluated for activity against P388 lymphocytic leukaemia 
 
Overall, the α-methylene-γ-lactones showed stronger activity than the 
corresponding saturated α-methyl-γ-lactones. The C-3 acetal (5.7) exhibited a 4-
fold stronger activity [GI50(5.7) ~ 0.5 ppm] than its keto precursor [GI50(5.8) ~ 2 
ppm]. The α-bromo ketone (5.9) was the most active compound in the series, 
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followed by tuberiferine (2.41), and a 20-fold decrease in activity was observed in 
compound (5.11) due to the saturation of α-methylene of the lactone [IC50(5.11) < 
0.1 ppm; IC50(2.41) ~ 0.3 ppm]. Interestingly, the α-bromo ketone 5.10, possessing 
a saturated α-methyl-γ-lactones moiety, showed significant growth inhibitory 
activity when compared to compounds 5.9 and 5.11 [IC50(5.10) ~ 0.5 ppm]. The 
spatial orientation of the C-3-hydroxy group in compounds 5.12 and 5.13 had a 10-
fold activity difference, with the α-hydroxy compound being more active than its 
epimer [GI50(5.12) ~ 0.1 ppm;  GI50(5.13) ~ 1 ppm]. However, the acetate of the β-
hydroxy compound showed activity of the same order of magnitude as the α-
hydroxy compound 5.12. 
 
In addition, several synthetic eudesmane compounds were tested for activity 
































Figure 5.3.  STLs evaluated for activity against KB tumour cells 
 
In the 2-bromo-3-hydroxy-compounds 5.15 - 5.16 with saturated C-11 - C-13 bond, 
the orientation of the hydroxy group markedly influenced the bioactivity. For 2α-
bromo-3α-hydroxy-α-methyl-γ-lactone (5.16) the activity was almost as high [GI50 = 
0.56 ppm] as that of a doubly conjugated C-3-keto compound 5.17 with an 
α-methylene-γ-lactone moiety [GI50 = 0.48 ppm], whilst its 3-βOH epimer was 
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found to be completely inactive.133,135 In the unsaturated 2-bromo-3-hydroxy-α-
methylene-γ-lactones 5.18 - 5.19, the orientation of the 1-OH group was to a less 
significant extent (10-fold). In 2α-bromo-3α-hydroxy-α-methyl and 2α-bromo-3α-
hydroxy-α-methylene-γ-lactones, the bromine and hydroxy groups are located on 
the same face of the molecule. Thus the hydroxy group assumes an axial position 
while the bromine remains equatorial. Such an antiperiplanar arrangement 
between βH-2 and the hydroxy group makes the structure highly susceptible to 
elimination. In the 2-bromo-α-methyl-γ-lactone range of eudesmanolides, α-bromo 
and -βOH are on opposite faces and both assume equatorial positions. This 
conformation is considered more stable, which may adequately account for the 
drop in bioactivity.  
 
5.1.2 SAR against P. falciparum  
In the series of STLs isolated from Eupatorium semialatum Benth. (Figure 5.4) the 
configuration of the cyclohexane ring system was found to have an effect on their 
antiplasmodial activity against a chloroquine-sensitive strain (CQS) of the parasite 
(pLDH-assay).47,136 All the active compounds within the series contained structural 
elements that assumed a full chair conformation. The activity of the compounds 
with different geometry of the A ring fell into a much lower range. A shift of the C-4 
- C-5 endocyclic methylene group to a C-4 - C-15 exocyclic position led to 
decreased activity [IC50(5.20) = 27 µM; IC50(5.21) = 16.3 µM; IC50(5.22) = 13.3 µM; 






















Figure 5.4.  Eudesmanolides evaluated for activity against P. falciparum 
                                            
136 Lang G., Passreiter C. M., Wright C. W., Filipowicz N. H., Addae-Kyereme J., Medinilla B. E., 





The overall activity of these compounds was by two orders of magnitude less 
potent than CQ itself. 
 
5.1.3 SAR of eudesmane STLs as inhibitors of induction of the intracellular 
adhesion molecule-1  
The eudesmane STLs were screened for their inhibitory activity on the induction of 
intracellular adhesion molecule-1 (ICAM-1) through an in vitro model of human 






























Figure 5.5.  Structures evaluated for inhibitory activity of ICAM-1 induction 
 
The activity within the series ranged from IC50 = 3-1000 µM, with DHB (4.2) being 
the most active, and tetrahydrosantonin (5.23) the least active compound [IC50 > 
1000 µM]. In another study by Dirsch, a compound coded “SRC2” (5.10) [IC50 = 
5.6 µM], with toxic concentration to normal A459 cells [IC50 > 100 µM], was almost 
as active as DHB (4.2), whilst α-santonin (5.24) showed no activity [IC50> 100 
µM].94,123 The toxicity of DHB (4.2) was more than double that of “SRC2” [IC50 
(A459) = 55 µM], but their selectivity index (SI) was very similar [SI~20]. 
Compounds which lacked an α-methylene-γ-lactone moiety, appeared to inhibit 
the signalling pathway that triggered nuclear translocation of NF-κB. However, 
STLs containing an α-methylene-γ-lactone moiety, seemed to control the same 







5.1.4 SAR summary 
Although the structural requirements for the antitumour and antiplasmodial activity 
of some STLs have been postulated, the overall impression from the literature 
studies is that these compounds cannot be generalised even within their class 
(e.g. eudesmanolides). Different bioactivities have different structural 
requirements.94 The SAR is highly dependent on the spatial and physicochemical 
characteristics of a candidate compound in relation to the target/targets. Different 
alkylating sites within a given molecule may have entirely different effects on 
targets, thus certain selectivity can be assumed. The number of potential alkylating 
centres, however, is well correlated with the activity trend in non-halogen 
containing compounds. Structures containing an α-methylene-γ-lactone moiety 
should be treated separately from their α-methyl-γ-lactone containing counter-
structures when the SAR is reviewed. 
 
Briefly it can be said that bioactivities of STLs depend on a specific mechanism 
and often show considerable selectivity towards the target, thus leaving a 
“therapeutic window” between activity and toxicity. Even though some direction of 
the SAR can be derived from the literature studies in Chapter 3 and the present 
background study, further work is required to derive the SAR for compound 4.2 
and its congeners.  
 
5.2 Objectives 
The reactivity and selectivity of the three potential alkylating structural elements in 
DHB towards biological thiols was not previously studied. One of the main 
objectives of the work presented in the following sections was to establish a 
correlation of alkylatable functionality of compound (4.2) and its biological 
activities. Preparation of amino acid adducts of some STLs, and the detection and 
characterisation of the reaction products constitutes the first part of this chapter. 
Due to the limited quantity of compound (4.2), only preparation of L-cysteine 
adduct was attempted. Further reactivity towards amino acids was studied using 





review revealed that compound 5.17 is patented for its use as an antileukaemic 
agent,137 but no reports related to P. falciparum have been found to date.  
 
A second objective was to establish structure-reactivity relationships of the two 
sesquiterpene lactones 4.2 and 5.17. Several target structures were identified 
(Figure 5.6) for the study of the SAR. Due to the low yields and limited quantity of 

















(5.25) (2.41) (5.26) (5.8)     
 
Figure 5.6.  STLs selected for SAR 
 
Furthermore, reduction of compounds 4.2 and 5.17 was attempted in order to 
obtain some of the targeted compounds for the SAR study. The final selection of 
STLs used in the SAR study was based mainly on the availability of the 
compounds.  
 
5.3 NMR assignments for (6β)- 3-oxoeudesm-1,4,11-trien-6,12-olide 
(5.17) 
The Discovery Chemistry group of the CSIR provided compound 5.17 in ample 
quantities. The compound resulted from an attempted synthesis of 











                                            
137 Adenkov S. M. (2000). Arglabin compounds and therapeutic uses thereof. US Patent 6,020,365. 













J (Hz) δC 
δH 
(multiplicity)
, J (Hz) 
1 CH 154.6 6.2 (d), J = 9.6 154.0 6.20 (d), J = 9.6 
2 CH 126.2 6.66 (d), J = 9.6 124.6 6.67 (d), J = 9.6 
3 C 186.4 - 184.9 - 
4 C 129.2 - 127.3 - 
5 C 150.9 - 150.0 - 
6 CH 
81.6 
4.72 (dd), J = 12.0; 
0.5 
80.3 
4.70 (dd), J 
=12.0; J = 0.5 
7 CH 50.5 2.65 49.1 Not reported 
8 CH2 
21.9 
Ha 1.72 (m); Hb 
2.18 (m) 
20.4 Not reported 
9 CH2 
37.9 
Ha 1.55 (m); Hb 1.9 
(m) 
36.5 Not reported 
10 C 41.5 - 40.3 - 
11 C 137.9 - 136.4 - 
12 C 169.2 - 169.4 - 
13 CH2 
119.8 
Ha 5.5 (d); Hb 6.19 
(d), J =3.12  
118.4 
5.52 (d), J = 3.0 
6.15 (d), J = 3.0 
14 CH3 11.0 1.27 (s) 9.6 1.30 
15 CH3 25.4 2.12 (d), J =0.5 24.0 2.13 (d), J = 0.5 
* Varian EM-390 (90 MHz); CDCl3 solution, using TMS as an internal standard. 
 
The 1H NMR and 13C NMR signals (Table 5.1) were assigned based on previously 
published data.135  
 
5.4 Reactivity towards amino acids  
As determined in previous studies by Schmidt (1999), the reaction of STLs with 
free amino acids is pH dependant (Scheme 5.1).55 At higher pH values (in the 
physiological range), the course of the reaction is determined by the ratio of acidity 
of the thiol group of amino acid (forward reaction) to the adduct’s enol tautomer 
(reverse reaction). At low pH values the speed of addition of amino acids is said to 





thioether-sulfur (initiating a reverse reaction) is less favourable compared with 





























































Scheme 5.1.  Mechanism of Michael addition of amino acids to STLs under 
basic and acidic conditions (adopted from Schmidt, 1999)55 
 
The addition of amino acids to STLs was studied in the basic environment as well 
at the physiological pH, using available methods. Progress of the reactions with 
amino acids was monitored by TLC using cellulose plates and specific spraying 
agents: anisaldehyde/sulfuric acid reagent (detection of STLs) and ninhydrin 
reagent (detection of amino acids). The appearance of a coloured band upon 
detection with ninhydrin requires a direct reaction of this compound’s α-amino and 
the carboxyl groups of the amino acids. If reaction takes place through an α-amino 
group of amino acids, anisaldehyde can be used for detection of the product. 
 
5.4.1 Reactivity of dehydrobrachylaenolide (4.2) towards L-cysteine using 
basic conditions 
The adduct of dehydrobrachylaenolide (4.2) and cysteine was prepared under 
basic conditions in deuterated water (24 h, RT). Two coloured spots were 
observed on the TLC plate upon detection with ninhydrin, of which the lower one 
corresponded to the free amino acid. The reaction mixture was separated using 
the preparative HPLC reversed phase column (UV λmax = 258.9; tR = 10.335 min), 
employing an isocratic method described in Section 3.4.2.8 (Chapter 3). This 
yielded pure DHB-CYS adduct 5.27 in 37% yield. The structure was determined by 






















Examination of the 1H NMR and 13C NMR spectra revealed the presence of an 
amino acid moiety with characteristic carbon chemical shifts at Cys-Cβ δC 33.5 (δH 
2.95 and δH 3.09 ) and Cys-αC δC 53.9 (δH 3.8 ).
97,139 The disappearance of the 
olefinic signals corresponding to C-13 protons in the 1H NMR spectrum, and the 
signals corresponding to C-11 and C-13 in the 13C NMR spectrum, were 
suggestive of addition of cysteine to C-13 rather than to C-1 or C-15. The lactone 
ring and the exocyclic double bond between C-4 and C-15 remained intact. The 
deuterium was incorporated at C-11, but the expected triplet was not observed in 
the 13C NMR spectrum probably due to the low intensity. This was further 
supported by the observed COSY correlation of the Cys-βC protons with Ha,b-13 
and the splitting pattern of the Ha,b-13, which appeared as doublets and not as a 
double doublet as would be expected in the case of hydrogen incorporation at C-
11. Furthermore, an additional deuterium was incorporated at C-2 which gave no 
resonance in the 13C NMR spectrum.  
 
The distinct doublet for H-1 in the parent structure resonating at δH 6.76 collapsed 
into a sharp singlet at δH 7.0 due to deuteration of C-2. This could be a result of the 
addition reaction of the second cysteine to C-1 which was reversible, and the rapid 
elimination of cysteine from C-1 resulted in the product 5.26.93 
 
                                            
139Yoshikawa M., Hatakeyama S., Inoue Y., Yamahara J. (1993). Chemical Pharmaceutical. 





















2 CD Not observed  - - - 
3 C 194.8 - H-1, H-15 - 
4 C 143.2 - H-1, H-5 - 
5 CH 54.4 2.52 (dt); J = 10.3 H(14) 
H-6, 
Ha,b-15 
6 CH 67.1 3.84 (dd); J = 10.3 - H-5 
7 CH 47.6 1.74 (m) H-13 H-8 
8 CH2 21.0 Ha 1.48 (m); Hb 1.49.(m) H-7 H-7 
9 CH2 35.3 Ha 1.48 (m); Hb 1.6 (m) H-14 H-8 
10 C 39.7 - H-14 - 
11 CD Not observed  - - - 
12 C 170.4 -  - 
13 CH2 29.5 
Ha 2.74 (d); J = 12.0 





14 CH3 17.2 0.93 (s) H-1 - 
15 CH3 121.8 
Ha 5.5 (d); J = 2.0 
Hb 5.99 (d); J = 1.0 
H-3 H-5 
Cys-βC βCH2 33.5 
Ha ~2.95 (dd); J = 8.3; 
15.2 









-  Cys-βCHa,b - 
 
The stereochemistry at C-11 could not be deduced due to the incorporation of 
deuterium at C-11. However, the expected absence of Nuclear Overhauser effects 
between H-6 and Ha,b -13 in the NOESY spectrum, which would occur if the side 





position.139,140 Strong resonances of formic acid, originating from the HPLC 
buffered solvent used for purification, were present in the spectra (δc 170.4 and δH 
8.2). 
 
5.4.2 Reactivity of compound 5.17 towards L-cysteine at physiological pH  
The addition of cysteine was carried out in a phosphate buffer (pH 7.4) to mimic 
intracellular pH conditions using a published method.141 Progress of the reaction 
was monitored by TLC over 24 h (Figure 5.7 (left): cellulose F254; n-Bu-
OH/H2O/AcOH 5:4:1 v/v; ninhydrin spray reagent, 120 °C).  
 
The solvent from the reaction mixture was evaporated by adding MeOH for 
azeotropic effect, resuspended in a MeOH/H2O (1:1 v/v) solvent mixture, and then 
analysed by LC-ESI-MS/UV. A mixture of products was obtained as indicated by 
the UV analysis. The positive ESI-MS showed two major molecular peaks (tR = 
12.22 and 12.39 min). Structures of C-13 - cysteinyl adducts 5.28a and 5.28b 
were identified by using 1H, 13C, gHSQC and gCOSY NMR analysis. The NMR 
data are summarised in Tables 5.3 and 5.4 respectively. 
 
Two sets of intense signals corresponding to STL-cysteinyl adducts 5.28a and 
5.28b were distinguished using gHMQC (Figure 5.8) and gCOSY (Figure 5.9) 

















O OH  
 
(5.28a)         (5.28b) 
 
                                            
140Yoshikawa M., Shimoda H., Uemura T., Morikawa T., Kawahara Y., Matsuda H. (2000). 
Bioorganic & Medicinal Chemistry, 8, 2071–2077. 
141Lastra A. L., Ramirez T. O., Salazar L., Martinez M., Trujillo-Ferrara J. (2004). Journal of 





     
Figure 5.7.  TLC of the addition of cysteine (left) and glutathione (right) 
 
The carbon proton assignments were deduced from the gHMQC spectrum. 
Characteristic disappearance of proton resonances corresponding to the olefinic 
H-13 protons indicated that the products present in the supernatant of the reaction 
mixture lacked C-11 - C-13 double bond, and that the nucleophyllic addition took 
place at position C-13 of the STL. The C-1 - C-2 and C-4 - C-5 double bonds 
remained in place and their proton chemical shifts were extracted from the gHSQC 
cross peaks, and were almost indistinguishable in the two products (5.28 a/b; δC 
158.8, C-1; δC 124.3, C-2; δC 154.8/154.9, C-4; δC 128.9/127.3, C-5). 
 
The presence of olefinic signals corresponding to H-1 and H-2 in the proton and 
carbon spectra indicated that the C-1 - C-2 double bond was unaffected in both 
major reaction products. The proton chemical shifts could not be differentiated due 
to the overlapping of the resonances and were approximated to the value of the 
centre of the COSY cross-peaks corresponding to H-1 and H-2. 
   |     |    |   |    |     |   | 
  SM 1min1h  2h 3h 24h 
 
     |    |     |      |     |    | 
  1min 1h   2h    3h   24h 






Figure 5.8.  gHSQC spectrum of the supernatant of the reaction mixture of 
compound 5.17 and L-cysteine 
 
Similarities in the values of the chemical shifts and the sizes of the proton 
couplings, and the equal ratio of the two major products also precluded a definite 
assignment of the proton sets of C-13 and C-11 to the corresponding structures. 
Therefore some of the assignments are interchangeable, since it was not possible 
to obtain a quality HMBC spectrum and to establish long-range proton carbon 
correlations.  
 
The two cross-peaks of the same size and intensity at δH 5.26 and δH 4.74 and the 
chemical shifts of the corresponding carbons C-6 and C-6’ and in the 13C spectrum 
indicated that the lactone ring was intact in the one product 5.28a (δC 82.0) but 
was opened in the other 5.28b (δC 72.9). Further examination of the 
13C spectrum 
revealed that there were three sets of signals assignable to the cysteine moieties, 
which were differentiated by analysis of HSQC and COSY positive cross-peaks. 
The first set was at δC 33.7 (δH 4.2) and δC 53.9 (δH 3.28 and δH 3.46) and was 
assigned to the product 5.28a on the basis of the similarity of coupling constants J 






Figure 5.9.  gCOSY spectrum of the supernatant of the reaction mixture of 
compound 5.17 and cysteine 
 
The second set also followed from the gCOSY spectrum, δH 4.02 , δH 3.16 and δH  
3.07, with the corresponding carbons resonating at δC 53.9 and δC 34.0, which was 
deduced from the HMQC spectrum, and was assigned to Cys-αH of the second 
product 5.28b (Table 5.3). The size of the integration was equivalent to that of the 
proton resonating at δH 4.2, thus the earlier estimated ratio of the major products 
could be confirmed as 1:1.  
 
The peak at 12.22 min, m/z 382.2 [M – H]- and m/z 384.3 [M + H]+, UV λmax = 
243.9 nm is consistent with the molecular formula C18H25NO6S with a calculated 
mass of 383.4518. This corresponded to a second product 5.28b, which was not 
observed on the TLC of the reaction mixture, but was present in the supernatant of 
the reaction mixture at a slightly lower concentration. The structure was also 
determined to be a mono-adduct of cysteine at position C-13 but with the lactone 
ring being opened as a result of hydrolysis. As a result of the ring opening, the 















1 CH 158.8 ~7.1* H-2 
2 CH 124.3 ~6.4* H-1 
3 C 189.7 - - 
4 C 154.8 - - 
5 C 128.9 - - 
6 CH 82.0 5.26 (br d); J = 2.0; 11.2 H-7 
7 CH 49.0 2.37 (m)  
8 CH2 24.0 Ha 1.36 (m); Hb 1.97 (m)  
9 CH2 37.7 Ha 1.97 (m); Hb 2.11 (m)  
10 C 40.8 - - 
11 CH 46.0  3.53 (m)  H-13 
12 C 163.3 - - 
13 CH2 29.97 3.05* ; 3.17*  
14 CH3 22.64 1.43 (s)  
15 CH3 10.73 2.13 (d); J6 = 1.2  
Cys-αCH CH 53.9 4.2 (dd); J = 3.9; 8.3  Cys-βH2 
Cys-βCH2 CH2 36.98 
Ha 3.27 (dd); J =  8.3; 14.7 
Hb 3.46 (dd); J = 3.9; 14.7 
Cys-αH 
COO- C 180.87 - - 
      *Multiplicity and coupling constants were not determined due to the overlap with other signals 
 
This resonance was not observed in the 1H NMR spectrum due to suppression by 
the solvent, and was deduced from the gHSQC and COSY positive cross-peaks of 
the H-6 and H-7 (δH 2.36) protons. The typical resonance up-field shift by 0.5 ppm 
from the closed lactone ring is characteristic for these compounds. The 
stereochemistry at the newly formed stereogenic centre C-11 could not be 
determined. The signal of lower intensity at δH 3.9 was assigned to another 
cysteinyl derivative (from gHSQC correlations), which is probably a less favourable 
stereoisomer of compound 5.28a at C-11. However, a full structure could not be 
proposed due to the low concentration of the compound in the mixture and the 










δC  δH (multiplicity); J (Hz) 
COSY 
1H↔1H 
1’ CH 160.0 ~7.1  
2’ CH 124.4 ~6.4  
3’ C 188.5 -  
4’ C 154.9 -  
5’ C 127.3 -  
6’ CH 72.91 4.74** H-7  
7’ CH 50.93 2.36 (m) H-6 
8’ CH2 22.64 Ha 1.97(m); Hb 2.26 (m)  
9’ CH2 37.61 Ha 1.33 (m); Hb 1.57 (m)  
10’ C 42.08 -  
11’ CH 46.0 3.39 (m)  
12’  COO 178.2 - - 
13’ CH2 28.5 Ha 3.05 (m)*  
Hb 3.16 (m)* 
 
14’ CH3 24.0 1.43 (s)  
15’ CH3 10.1 2.26 (d); J = 2.0  
Cys- αCH CH 53.9 4.02 (dd); J = 4.4; 7.3  
Cys-βCH2 CH2 34.0  Ha 3.2 (m)*; Hb 3.29 (m)* Cys-Ha 
COO- COO- 180.9 - - 
* Multiplicity and coupling constants were not determined due to the overlap with other signals  
**Chemical shift was determined from COSY positive cross peaks 
 
5.4.3 Addition of N-acetyl-L-cysteine to compound 5.17 at physiological pH  
Reaction at physiological pH, using the same method as in Section 5.4.2, resulted 
in one major product (LCMS-UV). Since the α-amino group of NAC is acylated, no 
reaction with ninhydrin was observed. The positive ESI-MS of the reaction mixture 
showed a molecular peak at m/z 408.2 [M + H]+ and the negative ESI-MS showed 
a peak at m/z 406.1 [M - H]-, UV λmax 242.9 nm, which is consistent with the 
molecular formula C22H29NO5S with a calculated mass of 407.4806. The total yield 
of 56% was estimated on the basis of the total area of the UV λmax peaks resolved 
by HPLC.  The major reaction product 5.29 was identified as an N-acetyl-L-
cysteinyl adduct to C-13 of the sesquiterpene lactone by means of 1H NMR 





avoid interference from the sesquiterpene starting material. The coupling 

















The structural assignment of the 1H NMR signals of the 13(11)-N-acetyl-cysteinyl 
adduct was possible by detailed examination of the proton spectrum, coupling 
constants and comparison to the 1H NMR data of the cumanin-13(11β)-N-acetyl-
cysteinyl adduct.141 Complete disappearance of the proton peaks corresponding to 
germinal protons of the C-11 – C-13 exocyclic double bond at δH 5.5 and δH 6.19 
indicated that unreacted starting material was not present in the supernatant. The 
addition reaction took place between C-13 of the exocyclic double bond of the 
starting material and the sulfhydryl group of NAC. This is a first report of the 
structure of compound 5.29.  
 
One equivalent of unreacted NAC was present as a disulfide in the 1H NMR 
spectrum at δH 4.2 (Cys-αH); δH 3.3 and δH 3.1; and δH 1.9.  The assignment of 
stereochemistry at C-11 was based on the detailed comparisions of 1H NMR 
chemical shifts and coupling constants to that of the eudesmanolides 
saussureamine D and E (5.30 and 5.31), where the thermodynamically favoured 
addition product with βH-11 was formed.139,140 The coupling constant J7,11 of 10.1 
Hz is characteristic of the pseudo-axial position of βH-11 in trans-lactones. In the 
case of αH-11 the size of coupling constant H-11 - H-7 would be in the region of 
6.4 – 8.0 Hz.142  
 
                                            











δH, (multiplicity) J (Hz) 
1 CH 6.90 (d) J1,2 = 9.7 
2 CH 6.20 (d)  J2,1 = 9.7  
3 C - - 
4 C - - 
5 C - - 
6 CH 5.05 (dd) J6,7 = 11.3; J6,15 = 1.2 
7 CH 1.95 (m)  
8 CH2 Ha 1.38 (m); Hb 1.88 (m)  
9 CH2 Ha 1.88 (m); Hb 2.1 (m)  
10 C - - 
11 CH 2.58 (td); J = 3.1; J = 8.2; J= 10.1 
J7α = 10.1; J13b = 8.2; J13a 
= 3.1  
12 C - - 
13 CH2 
Ha 2.95 (dd)  
Hb 2.75 (dd)  
J13b = 13.6; J11β = 3.1  
J13a = 13.6; J11β = 8.2  
14 CH3 1.20 (s)  - 
15 CH3 1.93 (s)  - 
Cys-βCH2 CH2 
Ha 3.14 (dd) J = 8.2; J = 13.6 
Hb 2.85 (dd) J = 3.1; J = 13.6 
JHb-Cys-β = 14.0; JH-Cys-α = 
4.3 
JHa-Cys-β = 14.0; JH-Cys-α = 
9.0 
Cys-αCH CH 4.37 (dd) 
JHb-Cys-β = 4.3; JHa-Cys-β = 
9.0 
CO-N C - - 
COO- C - - 
CO-CH3 CH3 1.92 (s)  - 
 
The second set of signals, next to resonances of H-1 and H-2, with much lower 
absolute intensity at δH 6.15 (J = 9.7 Hz) and δH 6.93 (J = 9.7 Hz) was attributed to 
























Saussureamine D (5.30)  
 
The upfield signal at δH 1.93 of the shielded methyl group of C-15 was present, 
thus indicating that both internal conjugated double bonds on the A ring of the 
sesquiterpene lactone remained intact. Integration of the 1H NMR spectrum 
indicated that the products were in the ratio of 2.5:1. The minor compound was of 
too low a concentration to enable full structure assignment. However, close 
examination of the lower intensity signals allowed a structure to be proposed for 
the minor product 5.32 as the αH-11- stereoisomer of the major product 5.29 at 














The unassigned set of signals at δH 4.0, which appeared of equal value of the 
integral to that of the assigned resonance at δH 4.2, was subsequently assigned to 
the two protons of the Cys-αH of the NAC disulfide as a by-product of the reaction. 
This followed from the size of the integration and the splitting pattern of this 
resonance, which appeared as a set of overlapping triplets indicating a small 
difference in the chemical environment of the two protons, but the equivalence of 
the neighbouring Cys-βH2 protons, as opposed to the NAC moiety of the STL 
























           (5.33)  
 
The reaction at physiological pH, using the same method as in Section 5.4.2 
resulted in the formation of one major product (Rf = 0.49; TLC: cellulose F254; 
n-BuOH/H2O/AcOH, 5:4:1 v/v; ninhydrin spray reagent, 100 °C). This was further 
supported by the LC-UV/MS analysis of the reaction mixture. The addition product 
eluted at tR 21.07 min (UV λmax = 241.9 nm) and was followed by the starting STL 
at tR 23.65 min (UV λmax = 243 nm). The yield of the glutathionyl adduct was 
estimated to be 42% on the basis of the total area of the UV λmax peaks resolved 
by HPLC. The negative ESI-MS showed a molecular ion peak at m/z 550.2 [M - 
H], and the m/z 552.4 [M + H]+ was observed in the positive ESI-MS. These data 
were consistent with the molecular formula C25H33N3O9S and the calculated 
molecular weight of 551.6092 corresponding to STL glutathionyl adduct. The 
structural assignments were based on the 1H NMR analysis of the D2O soluble 
components of the dried reaction mixture. The chemical shifts and coupling 
constants are summarised in Table 5.6. 
 
Complete disappearance of the proton peaks corresponding to germinal protons of 
the C-11 - C-13 exocyclic double bond was indicative of the absence of the 
starting material in the supernatant. The addition reaction took place at the 
expected position C-13. In addition, the appearance of the double sets of signals 
with different absolute intensity at δH 6.18 and δH 6.15 (J = 10.1 Hz); and δH 6.95 
and δH 6.93 (J = 10.1 Hz) revealed the presence of a second minor product in the 
reaction mixture. Integration of the 1H NMR spectrum indicated that the products 










δH (multiplicity) J (Hz) 
1 CH 6.95 (d) J = 10.1 
2 CH 6.18 (d)  J = 10.1 
3 C - - 
4 C - - 
5 C - - 
6 CH 5.02 (dd) J7 = 11.3; J15 = 1.2 
7 CH 1.95 (m)  
8 CH2 Ha 1.38(m); Hb 1.88 (m)  
9 CH2 Ha 1.88 (m); Hb 2.1 (m)  
10 C - - 
11 CH 2.62 (td)  
J7 = 10.1; J13b = 8.2; 
JH13a = 3.1 
12 C - - 
13 CH2 
Ha 2.89 (dd) 
Hb 2.89 (dd)  
J13b = 13.6; J11 = 3.1 
J13a = 13.6; J11 = 8.2 
14 CH3 1.2 (s)  - 
15 CH3 1.93 (d)  J6 = 1.2 
Cys-αCH CH 4.45 (dd)  
JHb-Cys-β = 5.1; JHa-
Cys-β = 9.0 
Cys-βCH2 βCH2 
Ha-Cys-β 3.18 (dd)  
Hb-Cys-β 2.79 (dd)  
JHb-Cys-β = 14.0; JH-
Cys-α = 5.1 
JHa-Cys-β = 14.0; JH-
Cys-α = 9.0 
Cys-αCONH C - - 
Gly-αCH2 CH2 Ha 3.88 (dd); Hb 3.64 (dd)  - 
Gly-αCOOH C - - 
Glu- αCH CH ~3.76   
Glu- βCH2 CH2 2.04  - 
Glu-γCH2 CH2 2.42
b   
Glu-αCOOH C - - 
Glu-γCONH C - - 
 
a  The chemical shifts for Gly-αCH2-Ha and Hb were taken as the centre of the multiplet as the ABX splitting 
pattern could not be analysed directly from the spectrum due to overlapping of several frequencies. 
b  The chemical shifts for Glu-γCH2-Ha and Hb were taken as the centre of the multiplet as the ABM2X splitting 






In the 1H spectrum of the reaction mixture, a number of GSH peaks were 
identifiable.143 An ABX splitting pattern was observed for the methylene protons of 
the cysteine residue (Cys-βCH2). These protons are diastereotopic and have 
different chemical shifts (δH 3.18 and δH 2.79). The two protons of Gly-CH2 are also 
not equivalent. Two ABX quartets overlap with Glu-αCH with a chemical shift of δH 
3.76. All the chemical shifts and coupling constants were in good agreement with 
the literature values for GSH.144,145 Based on these deductions, the major reaction 
product was identified as STL-13(11)-glutathionyl adduct 5.33. The 
stereochemistry at C-11 was deduced from the size of coupling constant J7,11 of 
10.1 Hz, which is identical to that of the NAC adduct (5.29) and is characteristic of 
the pseudo-axial position of βH-11 in trans-lactones.142 This is a first report of this 
structure. 
 
The unaccounted high absolute intensity of the resonances at δH 3.76 and δH 2.04 
was explained by following the same argument as was used to deduce the 
presence of NAC-disulfide.  Based on the values of the corresponding integrals 
and the yield of the product determined from the HPLC, it was plausible to assume 



















The minor compound was present in a too low concentration to enable full 
assignment of the structure. However, the positions of the minor peaks suggested 
                                            
143 Brown F. F., Campbell I. D., Kuchel P. W., Rabenstein D. C. (1977). FEBS Letters, 82, 12–16. 
144 Keire D. A., Rabenstein D. L. (1989). Bioorganic Chemistry, 17, 256–267. 
145 Kennett E. C. (2005). University of Sydney. PhD thesis, 217 p. http://hdl.handle.net/2123/620. 





that possibly the by-product is an αH-11-stereoisomer of the major product at C-
11. The following structure is proposed as 5.35. Instances of the formation of both 
isomers in various ratios during the addition reaction of the cysteine and 
glutathione to STLs have been previously reported.54,93 
 
5.5 Reduction of compounds 4.2 and 5.17 with NaBH4 
Since the biological activity of most sesquiterpene lactones often depends on the 
α-methylene-γ-lactone moiety, an attempt was made to determine what effect the 
reduction of the C-11 - C-13 exocyclic double bond would have on the 
antiplasmodial activity and cytotoxicity of compounds 5.17 and 4.2. The STLs were 
reduced with NaBH4 in ethanol using a previously published method.
57 
        
Figure 5.11.  TLC plates: reduction of compounds 5.17 (left) and 4.2 (right) 
 
5.5.1 Stereoselective reduction of compound 5.17 
The reduction of compound 5.17 led to a single product, obtained in 90% yield. 
The positive ESI-MS of the product showed a molecular ion peak at m/z 246. 2 [M 
+ H]+, UV λmax 241.6 nm, which is consistent with the molecular formula C15H18O3.  
     |           |        |          
  SM         5.36 
              
         |        |             |          
  SM      reaction mixture 










The reaction product was isolated as a yellow gum. The TLC analysis (Figure 5.9, 
left) revealed that the Rf value of the reaction product was identical to that of α-
santonin (5.24) standard (EtOAc/Hexane 30:70 v/v). The presence of a single 
product (UV λmax = 246.4 nm; TIC EI m/z = 246.2) was confirmed by LC-ESEI-MS 
analysis of the reaction mixture (Section 3.1.3.3, Chapter 3). The molecular ion at 
264.0 was assigned to M+H2O. The structure was fully assigned on the basis of 1H 
and 13C NMR data, which was almost identical to that of the synthetic α-santonin, 
with the exception of a small solvent impurity resonating at δH 0.15 and δC 29.9. 
The 1H and 13C NMR data are summarised in Table 5.7. The 1H NMR data clearly 
indicated that the α-methylene function was reduced to give the 11,13-dihydro 
derivative. The pair of doublets corresponding to the C-13 methylene group in the 
starting material were absent from the 1H NMR spectrum of the product due to 
replacement by a methyl group signal resonating at δH 1.23 (d, J = 6.9 Hz). An 
additional proton signal resonating at δH 2.38 was subsequently assigned to H-11. 
This was further supported by the observed multiplicity of this resonance which 
appeared as a dq due to vicinal coupling with H-7 (J = 11.7 Hz) and to both of the 

















(5.17) (5.24)  
 





Table 5.7.  1H and 13C NMR data for compound 5.36 in CDCl3 
Experimental data Lit. 58 NMR data for α-santonin (5.24) Atom 
number 
δC
  δH (multiplicity); J (Hz) δC
  δH (multiplicity); J (Hz) 
1 154.9 6.62 (d); J = 9.9 155.0 6.7 (d); J = 9.9 
2 126.1 6.21 (d); J = 9.9 125.5 6.25 (d); J = 9.9 
3 186.5 - 186.1 - 
4 129.1 - 128.2 - 
5 151.1 - 151.1 - 
6 81.6 4.77 (dq); J = 1.3; J = 10.9 81.1 4.81 (dq); J = 1.3; J = 10.9 
7 53.7 53.3 
8 23.3 22.7 
9 38.1 
1.44-2.07 (m, 5H) 
37.6 
1.44-2.07 (m, 5H) 
10 41.5 - 41.2 - 
11 41.2 2.38 (dq); J = 6.9, J = 11.7 40.7 2.43 (dq); J = 6.9, J = 11.7 
12 177.7 - 177.5 - 
13  12.67 1.23 (d); J = 6.9 12.3 1.28 (d); J = 6.9 
14  25.4 1.28 (s) 25.3 1.34 (s) 
15  11.1 2.1 (d); J = 1.3 10.7 2.14 (d); J = 1.3 
 
The stereochemistry at C-11 followed from the magnitude of the coupling constant 
between H-7 and H-11 (J = 11.7 Hz), which suggested an antiperiplanar 
relationship. The anion is protonated from the less-hindered side of the enolate 
double bond to form the thermodynamically more stable stereoisomer, where the 
new methyl group is less hindered. These results thus confirmed the previously 
described stereoselectivity of reduction of STLs with NaBH4.57 The orientation of 
the methyl group was confirmed by measuring the specific optical rotation of the 
product in chloroform (α25D = -100 °, c = 4%) and for the synthetic 95% pure (-)-α-





5.5.2 NaBH4 reduction of dehydrobrachylaenolide (4.2) 
The dehydrobrachylaenolide (4.2) was reduced with NaBH4 using a published 
method.57 The reaction resulted in a mixture of starting material and two products 
by TLC (Figure 5.9, right). The reaction mixture was further analysed using LC-EI-
MS. The Maxplot chromatogram produced a cluster of five peaks with retention 
times between 21.23 and 23.37 minutes. The TIC EI chromatogram displayed six 
peaks with common mass ions observed between m/z 230 and 250 (230, 233, 
246, 248 and 250). Based on the published data of NaBH4 reduction of 
dehydrocostus lactone 4.5a and the general mechanism of NaBH4 reduction, two 
conceivable reduction products 5.39 and 5.23 were assigned to the major peaks 
with masses of m/z 248.3 (tR = 21.816 min) and m/z 250.3 (tR = 22.100 min).
140 
One of the minor peaks at tR 21.816 min with a mass of m/z 246.3 could be 














































Figure 5.13.  Conceivable mechanism of reduction of 
dehydrobrachylaenolide (4.2)  
 
The formation of the proposed C-4 - C-15 over the C-1 – C-2 reduction product 
















The possibility of the presence of trapped intermediates 5.37 with MW 248.3 and 
MW 250.3 - 5.38 cannot be ruled out. No additional physical data could be 
obtained for these products due to low yield and difficulty of separation. 
 
5.6 SAR 
To study the SAR, five structurally modified STLs were generated as intermediates 
in an attempted synthesis of dehydrobrachylaenolide (4.2) by the Discovery 
Chemistry Programme of the CSIR, and were tested for growth inhibitory 
properties in vitro.  
 
5.6.1 In vitro anticancer activity 
The SAR study was carried out in the 3-cell line anticancer assay at the CSIR. All 
the compounds were tested across a concentration range of 6.25-100 ppm. The 
effect of the test compounds on growth inhibition of CHO cells was also evaluated. 
The results are summarised in Table 5.8.  
 
Although α-santonin (5.24) was completely devoid of activity, 
dehydrobrachylaenolide (4.2) was found to exhibit the highest activity within the 
series. Furthermore, its activity was found to be at least 10-fold stronger than the 
activity of its isomer compound (5.17) and of parthenolide (5.2). A mixture of 
compounds (5.42) showed a 50-fold drop in activity and a 3-fold decrease in 
cytotoxicity towards CHO cells. A similar activity drop was observed for compound 
(5.43) which contains a saturated α-methyl-γ-lactone moiety, whilst its cytotoxicity 
towards CHO cells decreased by 50-fold. Finally, the growth inhibitory 





and CHO cells was almost identical, suggesting that CHO cells are of limited use 
for measuring the selectivity of this type of compound as an anti-cancer lead. 
 
Table 5.8.  In vitro cytotoxicity of STLs towards CHO and cancer cell lines  
3-cell line pre-screen (CSIR), 
µM Structure Code 
CHO: IC50 
(µg/mL) 
GI50 TGI LC50 
O
O
O   


























(5.8)  91.7 54.2 81 >100 
Parthenolide (5.2) 7.6 5.32 18.1 46.1 
 
5.6.2 In vitro antimalarial activity 
The test compounds were assayed in duplicate against chloroquine-sensitive 
(CQS) and chloroquine-resistant (CQR) strains of P. falciparum (D10 and K1). The 
quantitative assessment of antiplasmodial activity in vitro was determined via the 
LDH assay described in detail in the experimental section (Chapter 3). The results 
























































(5.17) 2.82 2.21 1.71 0.6 






It could be clearly seen that the presence of the α-exomethylene double bond C-
11 - C-13 is not sufficient for the antimalarial activity observed in our parent 
compound. With removal of the endocyclic and exocyclic double bonds in the A 





The mixture of isomers 5.42 showed only a 10-fold drop in activity compared to 
DHB (4.2), and a 3-fold decrease in toxicity followed by the drop in the SI. The 
activity of compound 5.17 was inferior when compared to DHB (4.2) with the 
poorest cytotoxicity index of the samples examined. This is likely to be attributable 
to the effect of the migration of the C-4 - C-15 double bond to carbons C-4 - C-5 
and the the resultant change in the geometry of the A ring. Interestingly, 
commercial α-santonin (5.24) was considered completely inactive, whilst its toxicity 
was reduced only 3-fold.  
 
The activity of α-santonin (5.36), obtained by the reduction of compound 5.17, 
showed an almost 10-fold higher activity than commercial α-santonin (5.24) with 
very low cytotoxicity towards CHO cells. This activity could possibly be due to the 
hydrocarbon solvent impurity present in the reduction product. The possibility of an 
experimental error in the bioassay cannot be ruled out. The 
dehydrobrachylaenolide (4.2) showed superior antimalarial activity against both 
strains of the parasite and is discussed in detail in Chapter 4.  
 
5.7 Discussion  
5.7.1 Reactivity towards amino acids and product characterisation 
The monocysteine adduct at C-13 of dehydrobrachylaenolide (4.2) was obtained 
via a reaction of equimolar quantities of sesquiterpene lactone and free amino acid 
in the basic environment. The reaction proceeded regioselectively. Incorporation of 
deuterium at C-2 suggested transient addition of the second molecule of cysteine 
to C-1 of STL followed by a rapid elimination reaction. This finding led to the 
conclusion that in addition to the α-methylene-γ-lactone moiety, the α,β-
unsaturated endocyclic methylene also has a strong alkylating potential. From the 
stereochemical considerations, the preferred site for the addition of the second 
cysteine would be C-15 carbon of the exocyclic double bond due to its cis-
orientation in relation to the carbonyl oxygen. With such geometry, a simultaneous 
interaction of the carbonyl oxygen of the STL with the protonated amino group of 
the amino acid and its thiol group with exocyclic methylene carbon could take 
place. This would likely lead to electron withdrawal from the conjugated system 





coordination of the solvent. This could partly explain the selectivity towards the C-1 
site. It is also highly probable that in a situation where there is close proximity of a 
number of donor species, e.g. surface or pocket of polypeptides,102 all three 
potential binding sites in dehydrobrachylaenolide (4.2) could form covalent bonds 
with protein residues.  
 
The reaction of compound 5.17 with equimolar amounts of GSH and NAC at 
physiological pH resulted in the formation of C-13 amino-acid mono-adduct in both 
cases. Low yields of the products could equally be due to the formation of a by-
product and possibly to slow rates or reversibility of the reaction. The reaction 
proceeded stereospecifically to yield the expected product with S-configuration of 
the newly formed stereogenic centre, as was deduced from the size of the 
coupling constants H-7 – H-11. The Michael-type addition of STLs to amino acids 
and amines is said to occur from the exo-face of the convex-shaped molecule. 
This is in good agreement with the data published for the STLs of other structural 
types.146,147 The additional potentially alkylating structural element of compound 
5.17 did not show reactivity towards amino acids in the physiological buffer. 
Formation of a by-product 5.29 in the addition reaction with GSH and NAC 
implicated potential reactivity of compound 5.17 towards the OH-nucleophiles. It is 
evident from previous studies that reactivity with the OH-nucleophiles does not 
correlate with the bioactivity of STLs.148  
 
5.7.2 Reduction with NaBH4 
The reduction of compound 5.17 proceeded as expected, regioselectively and 
stereospecifically, to yield α-santonin as a single product. Such selectivity and 
specificity is in good agreement with the previously reported data for other 
structural types of STLs.57 Reduction of compound 4.2 afforded a mixture of 
products. No further work to deduce the exact structures of the reductants was 
completed due to the limited quantities of dehydrobrachylaenolide (4.2). 
                                            
146 Matsuda H., Kagerura T., Toguchida I., Ueda H., Morikawa T. (2000). Life Sciences, 66, 2151–
2157. 
147 Lawrence N., McGown A. T., Nduka J., Hadfield J. A., Pritchard R. G. (2001). Bioorganic 
Medicinal Chemistry Letters, 11, 429–431. 







As became apparent from the literature review, there is an overall inclination to 
reinforce a relationship between the presence of alkylating elements in STLs and 
bioactivity. This was confirmed to hold for the series of compounds evaluated in 
the present study. DHB, with three potential alkylating sites, exhibited the 
strongest activity profile in the in vitro cancer and malaria models within the series 
of tested compounds. It inhibited the growth of cancer cell lines at 0.68 (µg/mL) 
and showed potent activity against P. falciparum at IC50 equal to 0.38 (µg/mL) for 
the D10 strain and equal to 0.06 (µg/mL) for the K1 strain, which fall within the 
activity range of the standard drug chloroquine [IC50(K1) = 0.122 (K1); IC50(Dd2) = 
0.152 µg/mL]. It was also found to inhibit growth of a CHO cell line at a 10 to 70-
fold higher concentration (IC50 = 4.2 µg/mL). Although it showed some selectivity 
towards the targets in vitro (cancer cells and P. falciparum infected cells), there is 
a potential threat of generic toxicity, which can manifest in vivo. As it appeared in 
this SAR study, the presence of 1,2-cis and 4,15-trans double bonds cross-
conjugated with the keto group as well as the presence of the α-methylene-γ-
lactone moiety is essential for bioactivity. Removal of any of the potentially 
alkylating elements from the eudesmane skeleton resulted in a dramatic loss of 
activity (10 to 50-fold), whilst the cytotoxicity was reduced by a single digit number 
at the most. The α,β-unsaturated ketone, with the exocyclic methylene group, was 
reported to act just as α-methylene-γ-lactone.149 In contrast, the most drastic 
activity drop was found to be due to the saturation of α-methylene of the lactone 
and not due to saturation of the ketone-conjugated olefinic elements.  
 
Furthermore, in another SAR study of the series of eudesmanolides, the 
importance of the conformation of the A-ring was emphasised, where a full chair 
arrangement was required for activity against P. falciparum.136 This requirement, 
however, did not hold for DHB (4.2), as its A-ring is completely flattened by the 
four sp2 carbon atoms, as was evident from the X-ray structure of DHB (4.2) 
(Section 4.4.1.2).  In the same study it was observed that stronger activity against 
P. falciparum occurred in eudesmanolides containing endocyclic C-4 - C-5 or C-3 - 
C-4 rather than exocyclic C-4 - C-5 double bond. This requirement did not hold 
                                            





either for the compounds in which the double bond was conjugated with the α,β-
unsaturated ketone function. The compound (4.2) was found to be at least 10-fold 
more active than its isomer 5.17 with the C-4 - C-5 unsaturation in both in vitro 
models. It showed a similar activity advantage over parthenolide (5.2). 
 
From the SAR work presented in this chapter, it can be concluded that DHB could 
play a valuable role as a drug candidate. Further mechanistic studies and an in 
vivo dose response toxicity study would be necessary to gain in-depth knowledge 
of the structural requirements for selectivity with respect to the desired biological 






Chapter 6: Preparation, structures and bioactivity of 
pro-drugs of sesquiterpene lactones 
6.1 Background and objectives 
Further development of many STL-based drugs with antitumour and antimalarial 
properties has been limited by their aqueous insolubility and lack of selectivity, 
especially for oral intake.103’
150 STLs are highly reactive compounds and can 
hypothetically alkylate any thiol, amino and hydroxy group containing molecules of 
suitable geometry. Such reactivity profile can lead to non-beneficial and toxic 
effects. Detailed investigations of the sesquiterpene lactones helenalin, parthenin 
and ambrosin provided evidence of the formation of mono- and bis- Michael-type 
adducts with secondary amines (6.1-6.3), which were later proposed to act as pro-
drugs of these potent STLs.103,105,151 The reversibility rate is said to be controlled 
by the physicochemical factors of the environment and half-life of a pro-drug, and 
it is a function of time. Just by a variation of the added amine, the end result 
induced by a pro-drug, can vary not only in potency towards a specific target, but 
by the target protein, or may even affect an entirely different pathway. 
 
These secondary and tertiary amino Michael-adduct products of STLs are further 
converted to water-soluble hydrochlorides and quaternary ammonium salts which 
are considered to serve as pro-drugs, and are converted back to parent STLs after 
administration by a retro-Michael mechanism. The conversion of tertiary amino 
Michael adducts back to STL could possibly be activated through metabolic 
N-oxidation of the amines to the N-oxides followed by Cope elimination.103,152 
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151 Lee K. -H., Furukawa H., Huang E. -S. (1972). Journal of Medicinal Chemistry, 15, 609–611. 
152 Low L. L., Castagnoli N., (1980). In: M. E. Wolff (ed); Burger’s Medicinal Chemistry. John Wiley 
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At least two reassuring examples of the success of this approach are known. The 
first is the registered drug, arglabin, for treatment of leukaemia, which is used in 
the form of dimethylamino hydrochloride (6.4).153 Another good example is the 
hydrochloride of the dimethylamino adduct of parthenolide (DMAP; (6.5)), which at 
present is in the Rapid Development Program of the NCI, having shown up to a 















      (6.4)                           (6.5) 
 
This approach was selected as a starting point in an attempt to improve the in vivo 
activity of dehydrobrachylaenolide (DHB) through preparation of secondary amino 
derivatives that might retain bioactivity via a pro-drug mechanism. The present 
chapter deals with the preparation and in vitro bioactivity evaluation of Michael-
type secondary amino adducts of dehydrobrachylaenolide (4.2), 6β-3-
oxoeudesma-1(2),4(5),11(13)-trien-6,12-olide (5.17), and parthenolide (5.3) as a 
reference compound. 
 
                                            
153 Adenkov S. M. (2004). Therapeutic uses of Arglabin in combination with other chemotherapy 





6.2 Selection of the amino side chain based on prediction of OSIRIS 
molecular properties 
Molecular properties were calculated with the OSIRIS Property Explorer.154 The 
following calculated properties contributing to the overall drug-likeness score are 
included in the computing (the explanation below is cited directly from the 
website): 
• Molecular weight 
• Log S calculation  
• Log P value  
 
“Optimizing compounds for high activity towards a biological target often goes 
along with increased molecular weights. However, compounds with higher weights 
are less likely to be absorbed. More than 80% of all traded drugs have a molecular 
weight below 450. The aqueous solubility of a compound significantly affects its 
absorption and distribution characteristics. Typically, a low solubility goes along 
with a bad absorption and therefore the general aim is to avoid poorly soluble 
compounds. The estimated log S values are given as a unit stripped logarithm 
(base 10) of the solubility measured in mol/L. It is said that more than 80% of 
drugs on the market have an estimated log S value greater than -4. The value of 
Log P of a compound, which is the logarithm of its partition coefficient between n-
octanol and water log (coctanol/cwater), is a well established measure of the 
compound's hydrophilicity. Low hydrophilicities and therefore high Log P values 
cause poor absorption or permeation. It has been shown that for compounds to 
have a reasonable probability of being well absorbed, their Log P value must not 
be greater than 5.0. The distribution of calculated Log P values of more than 3 000 
drugs on the market underlines this fact”.154 
 
Parthenolide and DMAP were used as examples. The following set of molecular 
properties was shown for parthenolide and DMAP, respectively: cLog P of 2.77 
and 1.99; solubility of (-2.97) and (-2.19); drug-likeness 0.33 and 1.98 and drug 
scores of 0.16 and 0.55 respectively.  
 
                                            





For parthenolide (5.1), some undesired effects were predicted, such as high risk of 
mutagenicity and high risk of irritatant effects, with a very low drug score. In 
contrast, the calculated properties for PDMA were suggestive of drug-
conformance behaviour. The results of the calculations for DHB side chain 
compounds are summarised in Table 6.1. 
 















2.16 -2.99 -6.55 0.21 
Medium risk of 
mutagenicity and high 
risk of irritant effects 
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1.97 -2.63 1.26 0.38 
Drug-conformance 
behaviour; with 
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1.02 -2.1 -1.07 0.27 






0.47 -2.23 -3.21 0.22 






0.06 -1.62 -2.43 0.24 




Based on the empirical calculations of molecular properties, a diethylamino side 






6.3 Preparation of Michael adducts with diethylamine 
The general synthetic method shown in Scheme 6.1 was employed for the 






















Scheme 6.1.  Synthesis of the diethylamino adduct of parthenolide  
 
6.3.1 Preparation of diethylamino-parthenolide (6.6) 
The diethylamino-parthenolide (6.6) was prepared on the 60 µM scale. Following a 
single purification by column chromatography on silica gel (EtOAc/n-Hexane 1:1 
v/v) of the pure diethylamino-parthenolide adduct 6.6 was recovered (55% yield). 
The structure of the product 6.6 was confirmed by analysis of the 1H NMR and 13C 
NMR data, which was compared to the published data of DEA-parthenolide. The 
1H and 13C NMR values for diethylamino-parthenolide (6.6) are summarised in 
Table 6.2.  
 
The 13C NMR spectrum exhibited the 17 resonance signals. The presence of the 
two oversized N-ethyl resonances at δC 47.3 and δC 11.54, and the disappearance 
of the signal for the exocyclic methylene C-13 at δC 121.3 ppm were observed. 
These findings were further substantiated by 1H NMR data, where signals 
corresponding to the pair of exomethylene geminal protons have disappeared, 
indicating that addition took place across the C-11 - C-13 exomethylene double 
bond.  
 
Further examination of the 1H NMR spectrum revealed a typical triplet 












δC  δH (multiplicity); J (Hz) Lit.
(106) 1H NMR 
δH (mult.); J 
(Hz)  
1 CH 124.7 5.26 (dd); J = 2.3; J = 12.1 5.15 (dd); J = 
2.4; J = 12.0 
2 CH2 24.0 Ha 2.12 (m); Hb 2.42 (m)  
3 CH2 36.7 Ha 1.16 (m); Hb 2.04 (m)  
4 C 60.9 - - 
5 CH 66.6 2.74 (d); J = 9.0  2.72 (d); J = 9.0 
6 CH 82.1 3.89 (t); J = 9.0; J = 9.2 3.81 (t); J = 9.0 
7 CH 48.4 2.3 - 2.4 (m)  
8 CH2 29.8 Ha 2.0 (m); Hb 2.18 (m)  
9 CH2 41.1 2.19 (m)  
10 C 135.0 - - 
11 CH 46.5 2.49 (m)  
12 C 176.7 - - 
13 CH2 52.8 Ha 2.73 (dd); J11 = 5.5; J13b = 14.0 
Hb 2.78 (dd); J11 = 4.7; J13a = 14.0 
2.8 (ddd); J = 
4.9; J = 14.1; J = 
29.8 
14 CH3 16.5 1.75 (s)  
15 CH3 16.8 1.25 (s)  
NCH2CH3 CH2 47.3 Ha 2.42 (m); Hb 2.52 (m)  
NCH2CH3 CH3 11.6 1.01 (t); J = 7.0 1.01 (t) 
 
However, instead of the expected quartet for the four –CH2 protons of the ethyl 
group of amino side chain, two multiplets were observed, which were assigned to 
two sets of geminal diastereotopic protons (δH 2.42 and δH 2.52). The resonance at 
δH 2.49 was assigned to H-11. The protons of C-13 appeared to be diastereotopic 
(δH 2.73 and δH 2.78) as the rotation around the C-11 - C-13 was restricted for 
steric hindrance. 
 
An upfield shift of 0.4 in the 1H NMR spectrum was observed for H-7 which was no 





correlations between C-13 (δC 52.8) to the –CH2 protons of the ethyl group of 
amino side chain (δH 2.42 and δH 2.52) and from the strong COSY cross-peaks 
between the H-13 and –CH2 protons of the ethyl group of amino side chain The 
stereochemistry of the newly formed stereogenic centre C-11 has previously been 
determined by means of X-ray crystallography as an S-configuration.106 
 
6.3.2 Preparation of diethylamino-dehydrobrachylaenolide (6.7) 
The DEA-dehydrobrachylaenolide was prepared using the general method 
depicted in Scheme 6.1. The reaction on the micromolar scale of compound 4.2 
resulted in a mixture of the two major products (Figure 6.1) and some unreacted 
starting material (Rf = 0.92; MeOH/DCM 1:24 v/v). The reaction products were 
purified using column chromatography (MeOH/DCM/hexane 3:97 v/v) to afford 
starting material 4.2, DHB-ethyl ester 6.8 (Rf = 0.68; MeOH/DCM 1:24 v/v) and 
diethylamino-adduct 6.7 (Rf = 0.36; MeOH/DCM 1:24 v/v), with a total yield after 










































Figure 6.1. TLC of the reaction of STLs with Et2NH and structures of the 
products 
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6.3.2.1 Structure of (5α,6β,7α,10β,11β)-13-diethylamino-3-oxoeudesma-
1(2),4(15)-dien-12-olide (6.7) 
 
LC-ESI-MS analysis of the fraction B (Figure 6.1) containing mostly the 
diethylamino-DHB adduct (tR = 9.45 min; Method T3.2-1) showed a molecular 
peak (UV λmax = 241.6 nm) at m/z 318.0 [M + H]+ in a positive mode, which is 
consistent with the molecular formula C19H27NO3 and the calculated molecular 
mass of 317.1990. The details of the method are described in the experimental 
Section 3.1.1.4 (Chapter 3). The 1H NMR and 13C NMR data are summarised in 
Table 6.3.  
 
A total of 17 carbon signals were observed in the 13C NMR spectrum. The 
multiplicity of carbon resonances were derived from DEPT spectra. Following the 
same argument as for diethylamino-parthenolide, it could be concluded that the 
addition of the diethylamine proceeded a C-13 of the STL, as anticipated.  
 
Furthermore, the upfield shift of the H-7 resonance by 0.6 in the 1H NMR spectrum 
is ascribed to the allylic disposition of this proton, and it is characteristic for the C-
13-regioselective addition. The absolute alignment of protons H-2 and Ha-15 was 
not affected by the change in hybridisation of the C-11 and C-13 carbons, since 
the 5J coupling of 0.7-0.8 Hz as it in the parent STL, between the aforementioned 
protons, was also evident in the product. The doublet of doublets for the germinal 
Hb-15 appeared as a triplet due to a similar size of coupling constants 1JHb-15 and 
4JαH-5 of 1.5 Hz. In turn, the proton H-5 at the AB ring junction appeared as a set of 
double triplets, and not as the triplet of doublets, since the coupling of 1.5 Hz had 
collapsed due to the resolution restriction of the instrument. The stereochemistry 
at the newly formed stereogenic centre C-11 followed from the size of coupling 
constant (J = 10.3 Hz) between αH-7 and H-11, which is characteristic of the 


















1 CH 160.7 6.97 (d) J2 = 9.8 
2 CH 127.5 5.95 (dd) J1 = 9.8; J15a = 0.8 
3 C 188.2 -  
4 C 143.5 -  
5 CH 53.3 2.96 (dt) J15a = 2.4; J6 = 10.9 
6 CH 79.2 4.40 (t) J5 = 10.9 
7 CH 51.5 1.98 (m)  
8 CH2 24.3 Ha 2.05 (m)  
Hb 2.25 (m) 
 
9 CH2 37.2 Ha 1.75 (m) 
Hb1.85 (m) 
 
10 C 40.4 -  
11 CH 45.1 2.68 (ddd) J7 = 10.3; J13a = 8.2; J13b = 
3.9 
12 C 178.1 - - 
13 CH2 53.8 Ha 2.48 (dd) 
Hb 2.83 (dd) 
J13b = 12.9; J11 = 8.2 
J11 = 3.9; J13a = 12.9 
14 CH3 12.3 1.05 (s)  
15 CH2 120.5 Ha 5.51 (ddd) 
Hb 6.04 (dd) 
J2 = 0.8; J15b = 1.6; J5 = 2.4  
J15a = 1.6; J5 = 1.5 
NCH2CH3 CH2  47.9 Ha 2.4 (m);  
Hb 2.67 (m) 
J = 14.0; J = 7.0 
NCH2CH3 CH3 19.9 1.04 (t) J = 7.0 
 
A total of 17 carbon signals were observed in the 13C NMR spectrum. The 
multiplicity of carbon resonances were derived from DEPT spectra. Following the 
same argument as for diethylamino-parthenolide, it could be concluded that the 
addition of the diethylamine proceeded a C-13 of the STL, as anticipated. 
Furthermore, the upfield shift of the H-7 resonance by 0.6 in the 1H NMR spectrum 
is ascribed to the allylic disposition of this proton, and it is characteristic for the C-
13-regioselective addition. The absolute alignment of protons H-2 and Ha-15 was 





the 5J coupling of 0.7-0.8 Hz as it in the parent STL, between the aforementioned 
protons, was also evident in the product. The doublet of doublets for the germinal 
Hb-15 appeared as a triplet due to a similar size of coupling constants 1JHb-15 and 
4JαH-5 of 1.5 Hz. In turn, the proton H-5 at the AB ring junction appeared as a set of 
double triplets, and not as the triplet of doublets, since the coupling of 1.5 Hz had 
collapsed due to the resolution restriction of the instrument. 
 
The stereochemistry at the newly formed stereogenic centre C-11 followed from 
the size of coupling constant (J = 10.3 Hz) between αH-7 and H-11, which is 
characteristic of the pseudo-axial position of βH-11 in trans-lactones.150 In the 
case of αH-11, the size of coupling constant H-11 - H-7 would be in the region of 
6.4-8 Hz. This is also consistent with the previously deduced spatial orientation of 
the natural amino adducts of eudesmanolides 5.30 and 5.31 with L-proline side 
chain, where the thermodynamically favoured addition product with βH-11 is 
formed.139 
 
6.3.2.2 Structure of ethyl (6α)-hydroxy-3-oxoeudesma-1(2),4(15),11(13)-trien-12-
oate (6.8) 
The structure of the minor product 6.8 was determined from 1H NMR analysis, 
which is summarised in the experimental part (Chapter 3). The resonances of all 
olefinic protons remained unchanged as compared to the parent STL. The position 
of a resonance corresponding to the allylic proton H-7 was also unaffected. Two 
additional resonances with characteristic splitting patterns, the quartet at δH 4.2 
and the triplet at δH 1.3, which integrated for 2- and 3-protons respectively, were 
assigned to an ethyl group as part of an ester function of the ring-opened lactone 
carbonyl. The oxymethine proton H-6 also shifted by 0.4 ppm downfield. This is 
due to a minor conformational change of the cyclohexane ring, which is a result of 
the released ring strain caused by the opening of the lactone. The data were 
consistent with the published 1H NMR data for methyl (6α)-hydroxy-3-
oxoeudesma-1(2),4(15),11(13)-trien-12-oate (or methyl ester of DHB).155 
 
                                            





6.3.3 Michael adducts of compound 5.17 
The reaction was performed on the µM scale, and resulted in a mixture of the two 
major products (Figure 6.1) and some unreacted starting material as was detected 
by TLC analysis (Rf = 0.92; MeOH/DCM 1:24 v/v). The reaction products were 
purified using silica gel column chromatography (MeOH/DCM/hexane 3:97 v/v) to 
afford starting STL (5.17), the STL-ethyl ester 6.10 (Rf = 0.68; MeOH/DCM 1:24 
v/v) and diethylamino-adduct 6.9 (Rf = 0.36; MeOH/DCM 1:24 v/v), with a total 
yield of the DEA adduct of 29%. 
 
6.3.3.1 Structure of (6β,7α,10β,11β)-13-diethyamino-3-oxoeudesma-1(2),4(5),-
dien-12-olide (6.9) 
The positive ESI-MS of the fraction B (Figure 6.1) showed one major product (tR = 
9.52 min; Method T3.2-1; m/z 318 [M + H]+), in the positive mode. This was 
consistent with the molecular formula for the adduct C19H27NO3 and the calculated 
mass of 317.1990. The details of the method are described in the experimental 
Section 3.1.1.4 (Chapter 3). The 1H and 13C NMR data are summarised in Table 
6.4. 
 
A total of 19 carbon signals was observed in the 13C NMR spectrum. Two low-
intensity signals at δC 0.1 and δC 29.9 were assigned to a common NMR solvent 
impurity, which was also observed in the spectra of compounds 5.31 and 6.8. The 
multiplicity of the remaining 17 carbon resonances were derived from DEPT 
analysis. The addition of the diethylamine took place at position C-13 of the STL 
as two of the previous products 6.6 and 6.7. This was evident from the 
disappearance of the resonance of the olefinic carbon C-13 at δC 119.8 from the 
13C NMR spectrum with corresponding signals of its geminal protons in the 1H-
NMR spectrum at δH 5.5 and δH 6.19, which appeared in the olifatic region of the 
spectra. The observed upfield resonance shift of 0.6 ppm, which is due to the 
allylic disposition of the H-7 proton, is characteristic of C-11 - C-13 addition. Due to 
restricted rotation in the N-C bonds, the -NCH2CH3 protons appeared as a 












δC  δH (multiplicity) J (Hz) 
1 CH 155.1 6.64 (d) J = 9.8 
2 CH 126.7 6.21 (d) J = 9.8 
3 C 186.5 -  
4 C 151.3 -  
5 C 128.9 -  
6 CH 81.7 4.73 (dd) J15 = 1.2; J7 = 11.3 
7 CH 51.9 1.95 (m)  
8 CH2 24.3 Ha 1.66 (m); Hb 2.25 (m)  
9 CH2 38.4 Ha 1.48 (m); Hb 1.82 (m)  
10 C 41.4 -  
11 CH 44.8 2.53 (dd) 
 
J = 4.3; J = 8.6; J = 
~10.1* 
12 C 176.7 -  
13 CH2 52.9 Ha 2.59 (dd) 
Hb 2.89 (dd) 
J13b = 13.3; J11 = 4.3 J11 
= 8.6; J13a = 13.3 
14 CH3 11.1 1.25 (s) - 
15 CH3 25.3 2.09 (d) J6 = 1.2 
-NCH2CH3 T 47.2 Ha 2.4 (dd) 
Hb 2.54 (dd) 
J =7.0; J = 13.7 
J17 =7.0; J = 13.7 
-NCH2CH3 Q 11.8 0.96 (q) J = 7.0 
* The multiplicity and coupling constants estimated due to overlapping with another resonance. 
 
The stereochemistry at the newly formed stereogenic centre C-11 could not be 
deduced from the size of the coupling constant between αH-7 and H-11 due to the 
overlapping of the H-11 proton with the diastereotopic –CH2 protons of the ethyl 
group on the amine. Based on the similarity of the chemical shifts and some key 
coupling constants to those of compound 6.7, it is reasonable to assume that the 
proton H-11 assumes a β-spatial orientation. This hypothesis is consistent with the 
previously deduced spatial orientation of H-11 in the Saussureamines (Section 
5.4.3), which are natural amino adducts of eudesmanolides, where the 





6.3.3.2 Structure of (6α)-hydroxy-3-oxoeudesma-1(2),4(5),11(13)-trien-12-oate 
(6.10) 
The structure of the minor product 6.10 was determined from 1H and 13C NMR 
analysis, which is summarised in Table 6.5. The resonances of all the olefinic 
protons remained unchanged from the parent STL. The position of a resonance 
corresponding to allylic proton H-7 was also unaffected by the opening of the 
lactone ring. The release of the steric strain of the lactone ring junction did not 
have an effect on the chemical shift of the oxymethine proton H-6, which appeared 
at δH 4.77, but affected the size of the coupling constant by 0.4 Hz. Two additional 
resonances with characteristic splitting pattern, the quartet at δH 4.21 and the 
triplet at δH 1.3, which integrated for 2- and 3-protons, respectively, were assigned 
to the ethyl group connected to the STL through an ester function at C-12.  
 
Table 6.5.  1H and 13C NMR data for compound 6.10 in CDCl3 
Atom 
number 
δC δH (multiplicity) J (Hz) 
1 156.1 6.63 (d) J = 9.9 
2 126.0 6.22 (d) J = 9.9 
3 187.5 - - 
4 130.1 - - 
5 157.7 - - 
6 74.9 4.77 (d) J15 = 1.2; J7 = 10.9 
7 50.9 2.68 (td) J8 = 3.9; J6 = 10.9; J8 = 12.9 
8 26.2 Ha 1.78 (m); Hb 2.05 (m)  
9 38.1 Ha 1.66 (m); Hb 2.12 (m)  
10 42.3 - - 
11 141.5 - - 
12 167.9 - - 
13 126.6 Hb 5.77 (s); Ha 6.25 (d) J = 0.8 
14 11.4 1.3 (s) - 
15 23.9 2.21 (d) J = 1.2 
O-CH2-
CH3 
61.4 4.21 (q) J = 7.0 
O-CH2-
CH3 






Two low-intensity carbon signals at δC 0.1 and 29.9 were assigned to the common 
NMR solvent impurity. 
 
6.4 Attempted preparation of Michael adducts of STLs in an aprotic 
solvent 
In order to minimise the formation of the by-product, a reaction of compound 5.17 
in the aprotic solvent dioxane for over 48 hours was attempted, but proved 
unsuccessful. Only starting STL was found in the reaction mixture (by TLC). 
 
6.5 Biological screening of Michael adducts of STLs 
The diethylamino derivatives (DEA) prepared in this study were evaluated for their 
growth inhibitory properties on cultured cancer cells. The IC50/GI50 values were 
compared to those of their parent STLs. 
 
6.5.1 In vitro anticancer activity 
The DEA derivatives were tested against a preliminary 3-cancer cell line panel at 
the CSIR. All the compounds were tested across a concentration range of 6.25 – 
100 ppm as described in the experimental Section 3.2.4 (Chapter 3). The effect of 
the test compounds on growth inhibition of CHO cells was also evaluated. The 
results are summarised in Table 6.6. 
 
To summarise the results from Table 6.6, with the exception of the parthenolide: 
DEA-parthenolide pair, a general trend was observed. Whereas for the DHB: DEA 
derivative the toxicity towards mammalian cells has not changed with 
derivatisation, the desired decrease in cytotoxicity was observed for the DEA 
derivative of compound 5.17. For the parthenolide: parthenolide DEA pair, both the 
activity against cancer cells and the cytotoxicity values towards mammalian cells 






Table 6.6.  In vitro activity against a 3-cancer cell line panel and CHO 
3-cell line cancer screen 
(CSIR), µM Structure Code 


































(6.6) 1.11 2.35 3.58 0.75 
 
6.5.2 In vitro antimalarial screening 
All compounds were tested in duplicate against P. falciparum CQS (D10) and CRS 
(K1), with CQ used as a reference compound in all experiments. The results of the 
cytotoxicity were measured as 50% inhibitory concentration obtained from the 
dose response curves (fitting analysis Graph Pad Prism v4 software). The SI index 
was calculated as the ratio of the IC50 values of the toxicity towards mammalian 






As is evident from Table 6.7, there is no general activity or cytotoxicity trend 
between the three pairs of STL and DEA-STL.  
 
Table 6.7.  In vitro antiplasmodial activity against P. falciparum 
IC50 (µg/mL)  
Structure Code 
































(6.6) 4.27 6.95 0.75 0.2 
Chloroquine CQ 0.012 
0.122 (K1)  
0.152 (Dd2) 
   
SI (selectivity index) = cytotoxicity CHO IC50/antiplasmodial  IC50 
D10 =  P. falciparum – chloroquine-sensitive strain 
KI = P. falciparum – chloroquine-resistant strain 
CHO = Chinese hamster ovarian cells 
 
In the case of DHB and its DEA derivative, a 4-fold drop in activity was observed 
against the D10 strain with a subsequent drop in SI value, with no change in 





derivative exhibited a 3-fold lower activity, whilst the cytotoxicity value improved by 
14-fold, with subsequent improvement in SI (3.2). The least active compound, 
parthenolide [IC50(D10) = 1.97 µg/mL], showed the smallest drop in activity (2-
fold), whilst its cytotoxicity value increased with a 5-fold drop in SI. 
 
6.6 Discussion  
Three Michael-type secondary amino adducts of the selected STLs were prepared 
and characterised. The addition of secondary amines was regioselective and 
stereospecific to afford adducts with an α-orientated amino side chain. Attempts to 
minimise the lactolysis by using aprotic solvents in the reaction media proved to be 
unsuccessful.  
 
Furthermore, all diethylamino derivatives and their parent STLs were screened for 
in vitro activity against a 3-cancer cell line panel and against P. falciparum as 
described in the previous chapters. The activity and cytotoxicity of the derivatives 
did not follow any general trend. The activity of all derivatives in the two test 
models used remained in the micromolar range. These results, however, cannot 
be extrapolated to in vivo. Several other Michael adducts of 
dehydrobrachylaenolide (4.2) should be prepared to find the ultimate side chain, 






Chapter 7: Summary and Concluding Remarks 
7.1 General 
The South African medicinal plant Dicoma anomala subsp. gerrardii, the extract of 
which had previously been proved to possess selective in vitro anticancer activity 
against a 3-cell line panel (GI50 = 12.5 µg/mL), was subject of this investigation. To 
our knowledge, this subspecies was not previously documented in the 
ethnobotanical literature. Several compounds, such as flavonoids, terpenoids and 
phytosterols, which were reported to occur in other Dicoma species, could be 
responsible for or contribute to the activity of the root extract. Because of the 
phytochemical variability amongst various members of the genus, the isolation of 
the compounds responsible for the activity through bioassay-guided fractionation 
was performed.  
 
7.2 Confirmation of the taxonomic identity of the ethnobotanical sample 
Since the original botanical specimen was only partially identified, the correct 
taxonomy had to be established prior to the recollection efforts. Based on the 
re-evaluation of the original botanical specimen, and by comparing the stated habit 
with the description of various subspecies in the recent revision of the genus, it 
was possible, with great certainty, to subclassify the plant as D. anomala subsp. 
gerrardii.  
 
7.3 Bulk recollection and processing 
The bulk recollection effort was then directed by the availability of the plant, which 
was harvested from a large population in the North West province, RSA. An 
extraction method was optimised for the small scale of the plant material and the 
selection of solvent was guided by its bioactivity. Five crude extracts were 
produced with solvents of different polarity, which were tested for in vitro 
anticancer activity. Ethyl acetate was found to afford an extract with superior 






7.4 Bioassay-guided isolation of active compounds  
Bioassay-guided fractionation of the ethyl acetate extract of the rhizomes of 
D. anomala subsp. gerrardii led to the isolation of two bioactive compounds: 
a sesquiterpene lactone and a dimeric sesquiterpene lactone. The structures were 
solved on the basis of MS, HR-MS, UV/VIS and NMR analysis (1H-NMR, 
13C-NMR, DEPT135, 1H↔1H COSY, 1H↔13C HMQC and HMBC) to afford two 
known compounds, (4.2; GI50 = 0.67 µg/mL) and (4.3; GI50 = 0.75 µg/mL). The 
compound 4.2 was identical to the previously isolated dehydrobrachylaenolide 
(DHB) (2.42) and its structure was further confirmed by comparing the assigned 
spectroscopic values with the published data. The DHB (4.2) was previously 
reported to possess antibacterial properties against the Bacillus subtilis gram-
positive bacterium and an inhibitory activity regarding the induction of the 
intracellular adhesion molecule-1 (ICAM-1). The dimer 4.3 is a known compound 
which is patented for its antiplasmodial properties; however the NMR data and the 
structure assignment for this compound have not been published previously.  
 
7.5 Structures and stereochemistry of the active compounds 
Relative stereochemistry of compound 4.2 was established on the basis of 1H↔1H 
coupling constants, where hydrogens at C-5, C-6 and C-7 were assumed in the 
anti-periplanar positions (J5,6~J6,7~10.8 Hz). This finding was further confirmed by 
determination of the crystal structure. The previously postulated absolute 
configuration of dehydrobrachylaenolide (4.2) was confirmed on the basis of the 
value of the measured optical rotation ([α]24D+68°; c 0.50, CHCl3), which was 
compared with that of synthetic dehydrobrachylaenolide ([α]24D+67.9°; c 0.16, 
CHCl3). Therefore the configuration of the stereogenic centres in DHB isolated 
from D. anomala subsp. gerrardii is as follows:  10S, 5R, 6S, 7S.  
 
The relative and absolute configuration of the sesquiterpene dimer 4.3 could not 
be assigned with certainty. The relative orientation of the protons was deduced to 
be as follows: H-1/H-5 cis and H-4’/H-5’, H-5/H-6’ and H-4’/H5’ all trans. This 
followed from the sizes of the coupling constants, which were then compared with 
the values reported for guaianolide-type sesquiterpenes. Both lactone moieties are 





could not be confirmed by X-ray due to the difficulties with obtaining suitable 
crystals.  
 
However, it should be possible to determine the absolute stereochemistry by 
employing electronic circular dichroism (ECD) or vibrational circular dichroism 
(VCD) techniques. For ECD technique a simple correlation between the sign of the 
Cotton effect (CE) and the stereochemistry of the chromophores can be deduced 
from the data.156 With the VCD technique, the absolute configuration of the 
guaiane-type sesquiterpene lactones and the predominant solution-state 
conformation can be determined by comparing the experimental and calculated 
VCD spectral data.157 Further experiments need to be conducted to determine the 
absolute stereochemistry of compound 4.3 using one or both of the 
abovementioned techniques. 
 
7.6 Bioactivity of the compounds vs activity of the crude extract 
The activity of the crude extract of D. anomala subsp. gerrardii could probably be 
attributed to the isolated compounds. The presence of other compounds with 
similar bioactivity profiles could not be ruled out. However, since the activity of the 
fractions containing dehydrobrachylaenolide (4.2) and the dimer 4.3 was superior 
amongst the resulting fractions, the overall effect observed for the crude extract in 
vitro could be due to the synergistic action of the various components. 
 
7.7 Chemotaxonomic remarks 
For chemotaxonomic and ethnobotanical purposes, a comparative HPLC study of 
another subspecies of Dicoma was embarked on to establish whether the 
chemistry of the two taxonomically recognised subspecies really differs. The 
results showed that the HPLC profiles were vastly different, and the presence of 
dehydrobrachylaenolide (4.2) and of the sesquiterpene dimer in the DCM-soluble 
fraction of the root extract of D. anomala subsp. anomala (collected in Gauteng) 
could not be confirmed. One publication reports that the dimer 4.3 was isolated 
                                            
156 Stöcklin W., Waddelland T. G., Geissman T. A. (1970). Tetrahedron, 26, 2397–2409. 
157 Michalskia O., Kisielb W., Michalskab K., Setnickac V., Urbanovad M. (2007). Journal of 





from an unspecified subspecies of D. anomala harvested from the Free State and 
Lesotho.28 In order to establish a correlation between the chemistry and the 
proposed classification, further investigations into subspecies and regional forms 
of D. anomala are required. Moreover, it is noteworthy that two vernacular names, 
i.e. Kloenya (Sotho) and Nyongwane (Zulu), were provided by the traditional 
healer for the plant with the specified habitat and life form (erect). A further 
ethnobotanical study should be considered to establish whether the use of 
vernacular names is specific to the plant or to its medicinal properties.  
 
7.8 Identification of sustainable sources of compound 4.2 
There are several possibilities for the bulk production of the reasonably pure 
dehydrobrachylaenolide (4.2). The most obvious resource is the plants 
themselves, which could be harvested from the wild in a sustainable manner (high-
impact harvesting). However, there are several reports pointing to the already 
existing threat of overutilisation of D. anomala in the RSA and Namibia. This is 
because of the widespread use of D. anomala in primary healthcare and because 
this species is propagated only by seed and is highly site-specific and sensitive. 
High-impact harvesting of rhizomes could wipe out the plant populations 
altogether.158 The establishment of cultivation programmes could be an alternative 
to wild harvesting. Plant material of specific genetic make-up could be cultivated 
through tissue culture technique, and was successfully developed at the CSIR for 
D. anomala subsp. gerrardii (results are not reported in this dissertation). 
 
Other plant species were investigated as potential sources of DHB. The roots of 
the invasive tree Brachylaena transvaalensis could serve an alternative, but are 
hardly an attractive source due to their very low content of the compound.  
 
Another route dehydrobrachylaenolide is semisynthesis. A simple one-step 
oxidation of the conjugated unsaturated alcohol 2.43, which was found in 
abundance in the aerial parts of D. capensis can be successfully achieved by 
using MnO2. Cultivation or wild harvesting of D. capensis is also a possibility. 
                                            





Finally, there are several reported methods for the synthesis of DHB from 
commercially available α-santonin. Most of these, however, suffer from low yields 
and irreproducibility.53 However, the attempted synthesis of compound 4.2, using 
some of the reported methods, by Dr E. Mmutlane of the Discovery Chemistry 
group of the CSIR resulted in a thermodynamically favoured reaction product 
compound 5.17. The optimisation of reaction conditions to achieve kinetically 
controlled and thus desired product should be investigated. 
 
7.9 Antimalarial activity of dehydrobrachylaenolide (4.2) 
In addition, the isolated compounds, dehydrobrachylaenolide (4.2) and the dimer 
4.3, were tested for in vitro inhibitory activity against P. falciparum. Based on the 
considerable antiplasmodial activity [IC50(D10) = 0.38 µg/mL; IC50(K1) = 0.06 
µg/mL] and the selectivity index (70), dehydrobrachylaenolide (4.2) was advanced 
into the in vivo murine malaria model. A substantial survival rate of the animals 
treated subcutaneously with dehydrobrachylaenolide (4.2) was achieved (60% of 
the animals in the treated group lived 9 days longer than the control group), but 
the extreme levels of parasitaemia experienced could not be rationalised (60%). 
 
One of the possible explanations for these in vivo data is that 
dehydrobrachylaenolide (4.2) may, in addition to its direct effect on the parasite 
observed in vitro, affect other pathways, leading to offset of the death in spite of 
the lethal parasitaemia levels. One of the clues was found in relation to the 
reported inhibitory activity of the induction of surface intracellular adhesion 
molecule-1 (ICAM-1) in the in vitro model of human endothelial cells. The 
expression of excess ICAM-1 (or “up-regulation”) on the surface of the endothelial 
cells of a blood vessel plays an important role in the progress of a wide range of 
inflammatory and immune reactions,158 and is implied in certain stages of 
progression of tumorigenesis and cerebral malaria. It was previously established 
that there is an increased expression of ICAM-1 on the brain endothelial surface at 
the ring and trophozoite blood stages of the parasite cycle in the host. Since 
ICAM-1 is one of the major receptors for the sequestration of infected erythrocytes 
in the brain endothelium, it is reasonable to hypothesise that 





to the brain endothelium by inhibiting the expression of ICAM-1, thus offsetting the 
necrosis and death. 
 
Furthermore, it was found that the nuclear factor-κB (NF-κB) pathway mediates 
the induction of ICAM-1 at the trophozoite stage. The transcription factor NF-κB is 
a DNA-binding complex regulator related to cellular inflammation, immune 
responses and carcinogenesis. In general, NF-κB promotes the transcription of 
pro-inflammatory genes such as ICAM-1, enzymes such as inducible nitric oxide 
synthase (iNOS) and cycloxygenase-2 (COX-2), cytokines and chemokines.159 
Various components of NF-κB-activating signalling pathways are frequent targets 
for antiinflammatory, anticancer and antimalarial agents such as STLs.89,160 For 
instance, STLs are the only compounds for which a selective alkylation of p65/NF-
κB has been proved to date.161,162 Some results show that compounds with α-
methylene-γ-lactone moiety control the signalling pathway upstream of the nuclear 
translocation of NF-κB.163 The structural make-up of dehydrobrachylaenolide (4.2) 
has all of the elements known to be required for the potential inhibition of NF-κB-
related components. It would be of great value to test dehydrobrachylaenolide 
(4.2) for the inhibitory activity of NF-κB DNA-binding activity, which can lead to the 
deactivation of NF-κB.  
 
The possibility is suggested here that dehydrobrachylaenolide (4.2) has affinity for 
multiple targets; a dose-response study should be conducted since efficacy 
towards multiple drug targets may require a higher dose for in vivo study. In the 
light of the specific mechanism involved, several in vivo models were reviewed. It 
was found that in the current model with P. bergei-infected C57BL/b mice, the 
sequestration of parasitised red blood cells could not be observed.90 However, the 
observed effects of DHB (4.2) in vivo could be partially due to the reduced 
adhesion of monocytes to brain endothelium (as a result of the inhibition of the 
                                            
159 Juurlink B. H. J. (2001). Canadian Journal of Physiology and Pharmacology, 79, 266–282. 
160 Huang W. -C., Chan S. -T., Yang T. -L., Tzeng C. -C., Chen C. -C. (2004). Carcinogenesis, 25, 
1925–1934. 
161 Garcia-Pineres A. J., Lindenmeyer M. T., Merfort I. (2004). Life Sciences, 75, 841–856. 
162 Lyß G. Knorre A., Schmidt T. J., Pahl H. L., Merfort I. (1998). The Journal of Biological 
Chemistry, 273, 33508-33516. 
163 Yuuya S., Hagiwara H., Suzuki T., Ando M., Yamada A., Suda K., Nagai K. (1999). Journal of 





expression of ICAM-1), which subsequently may lead to a reduction of 
perivascular infiltration of mononuclear cells (observed in P. bergei-infected mice) 
and to the prolonged survival of the mice. The fact that on day 9 parasitaemia 
reached 60% at 100% survival could imply that the drug had a higher affinity 
towards inhibiting the induction of ICAM-1 than towards a parasite-related target. 
The importance of this possibility warranted seeking a model in which the effect of 
the drug on the adhesion and sequestration of P. falciparum-infected erythrocytes 
could be observed.  
 
A model with P. bergei, in which young (BALB57XC57BL/b)F1 hybrid mice 
develop typical neurological symptoms (7 to 8 days post infection) in association 
with the sequestration of parasitised red blood cells, was identified.164 The 




These results assumed certain specificity of the reaction of STLs with biological 
thyols. The addition of N-acetyl-L-cysteine to compound 5.17 proceeded 
stereospecifically to afford an adduct with an α-orientated side-chain. This finding 
is in good agreement with the previously reported orientation of the side-chain in 
synthetic and – most importantly – natural Michael adducts of STLs.140 
 
The stereochemistry at C-11 was not determined for the cysteine or glutathione 
adducts due to the overcrowding of the 1H NMR spectra. The attempt to minimise 
the formation of the by-product by using less polar solvents proved unsuccessful. 
The by-product should be isolated and evaluated for efficacy in the in vitro models 
prior to the dose-response studies in vivo. 
 
Several synthetic analogues were evaluated for bioactivity in an attempt to 
establish a correlation between the number of alkylating elements in 
dehydrobrachylaenolide (4.2) and the bioactivity, in both in vitro models (cancer 
                                            






and malaria). Removal of any potentially alkylating elements resulted in 
significantly decreased bioactivity. These results were in good agreement with the 
previously suggested relationship in STLs.55,91-94 The exocyclic double bond C-4 - 
C-15 did not participate in any Michael addition reaction, but probably potentiated 
the reactivity of the C-1 - C-2 alkylating effect, resulting in a 10-fold drop in 
bioactivity when compared with its isomer 5.17 with an endocyclic double bond C-
4 - C-5. However, the overall requirement for the bioactivity of eudesmanolides 
cannot be stated with certainty. 
 
7.11 Preparation of pro-dugs 
If the in vivo efficacy of the compound proves to be convincing, there are a few 
possibilities for modifying the compound for oral administration with estimated oral 
bioavailability up to 70%. A study of the preparation of the so-called “pro-drugs” of 
dehydrobrachylaenolide (4.2) and its close isomer compound 5.17 showed that 
there was no general trend in the changes in the bioactivity-cytotoxicity ratio 
amongst the three drug – pro-drug pairs. However, a general drop in bioactivity 
and cytotoxicity was noted in both the in vitro bioassays (cancer and malaria). 
Further investigations of the kinetics and rate constants of the reverse reaction at 
physiological pH using 1H NMR analysis will be required in order to design a 
further in vivo study with the synthesised pro-drugs, which will be used for to select 
the best side-chain and for further evaluation of efficacy. 
 
Additional studies into the mode of action of dehydrobrachylaenolide (4.2) against 
falciparum malaria have been initiated to elucidate the primary pathways and the 
target(s) underlying the antimalarial efficacy of dehydrobrachylaenolide (4.2) 
through systems biology approaches, by combining primarily proteomics and 
transcriptomics technologies (not reported in this dissertation). The preliminary 
results gave early indications that treatment with dehydrobrachylaenolide (4.2) 
resulted in significant changes in the proteome of P. falciparum in the ring stage of 















Appendix 1: NMR spectra of selected compounds 





















Plate 1.  13C NMR spectrum (400 MHz, CDCl3) of compound 4.2 
(assignments on p. 54) 
 
Plate 2.  1H NMR spectrum (400 MHz, CDCl3) of compound 4.2 (assignments 














Plate 3. 13C NMR spectrum (400 MHz, CDCl3) of compound 4.3 
(assignments on p. 61) 
 
Plate 4. 1H NMR spectrum (400 MHz, CDCl3) of compound 4.3 










Plate 5. 13C NMR spectrum (400 MHz, CDCl3) of compound 5.17 (assignments 
on p. 96) 
 
Plate 6. 1H NMR spectrum (400 MHz, CDCl3) of compound 5.17 (assignments 























Plate 7. 13C NMR spectrum (400 MHz, D2O) of compounds 5.28a and 5.28b 
(assignments on p. 101) 
 
Plate 8. 1H NMR spectrum (400 MHz, D2O) of compounds 5.28a and 5.28b 





















Plate 9. 1H NMR spectrum (400 MHz, D2O) of compound 5.29 (assignments 


























Plate 10. 1H NMR spectrum (400 MHz, D2O) of compound 5.33 (assignments 






























Plate 11. 13C NMR spectrum (400 MHz, D2O) of compound 5.27 (assignments 
on p. 98) 
 
Plate 12. 1H NMR spectrum (400 MHz, D2O) of compound 5.27 (assignments 












Plate 13. 13C NMR spectrum (400 MHz, CDCl3) of compound 5.36 
(assignments on p. 112) 
 
Plate 14. 1H NMR spectrum (400 MHz, CDCl3) of compound 5.36 














Plate 15. 13C NMR spectrum (400 MHz, aceton-d6) of compound 6.6 
(assignments on p. 127) 
 
Plate 16. 1H NMR spectrum (400 MHz, aceton-d6) of compound 6.6 




















Plate 17. 13C NMR spectrum (400 MHz, aceton-d6) of compound 6.7 
(assignments on p. 129) 
 
Plate 18. 1H NMR spectrum (400 MHz, aceton-d6) of compound 6.7 













Plate 19: 1H NMR spectrum (400 MHz, CDCl3) of compound 6.8 (assignments 




















Plate 20. 13C NMR spectrum (400 MHz, CDCl3) of compound 6.9 (assignments 
on p. 132) 
 
Plate 21. 1H NMR spectrum (400 MHz, CDCl3) of compound 6.9 (assignments 












Plate 22. 13C NMR spectrum (400 MHz, CDCl3) of compound 6.10 
(assignments on p.134) 
 
Plate 23. 1H NMR spectrum (400 MHz, CDCl3) of compound 6.10 

















Appendix 2: X-Ray crystallographic data for compound 















Table A2.1.  Crystal data, data collection and structure refinement 
parameters for compound 4.2 
Empirical formula  C15H16O3 
Formula weight  244.28 
Temperature  293(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
a = 9.5648(6) Å   α = 90º 
b = 11.1631(6) Å β = 90º Unit cell dimensions 





Z'  0 
Density (calculated) 1.315 mg/m
3
 
Absorption coefficient 0.091 mm-1 
F(000) 520 
Crystal size 0.3 x 0.45 x 0.45 mm
3
 
Crystal colour  Colourless 
Crystal description  Block 
Theta range for data collection 3.97 to 31.87º 
Index ranges -13<=h<=13, -15<=k<=16, -16<=l<=17 
Reflections collected 12 604 
Independent reflections 2 294 [R(int) = 0.0160] 
Completeness to theta = 25.00º 95%  
Absorption correction 
Multi-scan165 (semi-empirical from 
equivalents) 
Max. and min. transmission 0.909 and 0.963 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2 294 / 0 / 163 
                                            








Final R indices [I>2sigma(I)] R1 = 0.0328, wR2 = 0.0947 
R indices (all data) R1 = 0.0397, wR2 = 0.0913 
Extinction coefficient 0.091 
Highest peak 
0.31 at 0.0571  0.5786  0.4054  [  0.70 
A from C5 ] 
Deepest hole 
-0.21 at  0.0260  0.6593  0.5553  [  1.21 






Table A2.2.  Atomic coordinates and equivalent isotropic displacement 
parameters (Ueq) for non-hydrogen atoms of compound 4.2 
Atom label X Y Z U(eq) 
O(1) 0.15159(13) 0.91471(10) -0.44767(9) 0.0385(3) 
O2 0.12459(10) 0.79267(7) -0.00141(7) 0.0245(2) 
O3 0.14756(12) 0.68047(9) 0.15844(9) 0.0372(3) 
C1 -0.08111(15) 1.08813(12) -0.27617(12) 0.0279(3) 
C2 -0.02875(16) 1.03277(13) -0.36888(11) 0.0304(3) 
C3 0.09192(15) 0.95122(12) -0.36063(11) 0.0274(3) 
C4 0.13820(14) 0.91816(11) -0.24094(11) 0.0237(2) 
C5 0.02974(13) 0.93776(10) -0.14800(10) 0.0197(2) 
C6 0.07435(13) 0.91479(10) -0.02492(10) 0.0197(2) 
C7 -0.04877(12) 0.92856(11) 0.05839(10) 0.0210(2) 
C8 -0.10043(14) 1.05781(12) 0.05999(11) 0.0246(3) 
C9 -0.14347(13) 1.08979(11) -0.06503(11) 0.0245(2) 
C10 -0.02589(13) 1.06955(10) -0.15444(10) 0.0213(2) 
C11 0.01008(14) 0.86585(11) 0.16233(11) 0.0234(2) 
C12 0.10064(14) 0.76895(11) 0.11286(11) 0.0263(3) 
C13 -0.00061(16) 0.88888(13) 0.27472(11) 0.0303(3) 
C14 0.09241(14) 1.16252(11) -0.13671(12) 0.0270(3) 








Table A2.3.  Bond lengths for compound 4.2 
Bond Bond distance [Å] Bond Bond distance [Å] 
C(4)-C(15) 1.332(2) C(14)-H(14B) 0.9600 
C(4)-C(3) 1.4982(18) C(14)-H(14C) 0.9600 
C(4)-C(5) 1.5090(16) C(6)-C(5) 1.5067(16) 
O(2)-C(12) 1.3659(15) C(6)-H(6) 0.9800 
O(2)-C(6) 1.4708(14) C(3)-O(1) 1.2260(16) 
C(7)-C(11) 1.4997(17) C(3)-C(2) 1.473(2) 
C(7)-C(8) 1.5253(18) C(11)-C(13) 1.3278(18) 
C(7)-C(6) 1.5287(16) C(11)-C(12) 1.4991(18) 
C(7)-H(7) 0.9800 C(1)-C(2) 1.334(2) 
C(8)-C(9) 1.5439(18) C(1)-C(10) 1.5167(17) 
C(8)-H(8A) 0.9700 C(1)-H(1) 0.9300 
C(8)-H(8B) 0.9700 C(5)-C(10) 1.5662(15) 
C(9)-C(10) 1.5437(17) C(5)-H(5) 0.9800 
C(9)-H(9A) 0.9700 C(15)-H(15A) 0.9300 
C(9)-H(9B) 0.9700 C(15)-H(15B) 0.9300 
O(3)-C(12) 1.2059(16) C(13)-H(13A) 0.9300 
C(14)-C(10) 1.5490(17) C(13)-H(13B) 0.9300 






Table A2.4.  Bond angles [º] for compound 4.2 
Atom site label Bond angle [º] Atom site label Bond angle [º] 
C(15)-C(4)-C(3) 119.26(12) C(2)-C(1)-H(1) 118.3 
C(15)-C(4)-C(5) 125.99(12) C(10)-C(1)-H(1) 118.3 
C(3)-C(4)-C(5) 114.71(11) C(6)-C(5)-C(4) 116.89(10) 
C(12)-O(2)-C(6) 107.66(9) C(6)-C(5)-C(10) 107.51(9) 
C(11)-C(7)-C(8) 123.60(10) C(4)-C(5)-C(10) 109.63(9) 
C(11)-C(7)-C(6) 99.69(10) C(6)-C(5)-H(5) 107.5 
C(8)-C(7)-C(6) 110.63(10) C(4)-C(5)-H(5) 107.5 
C(11)-C(7)-H(7) 107.3 C(10)-C(5)-H(5) 107.5 
C(8)-C(7)-H(7) 107.3 C(1)-C(10)-C(9) 110.29(10) 
C(6)-C(7)-H(7) 107.3 C(1)-C(10)-C(14) 106.58(10) 
C(7)-C(8)-C(9) 107.08(10) C(9)-C(10)-C(14) 110.22(10) 
C(7)-C(8)-H(8A) 110.3 C(1)-C(10)-C(5) 106.91(10) 
C(9)-C(8)-H(8A) 110.3 C(9)-C(10)-C(5) 110.69(9) 
C(7)-C(8)-H(8B) 110.3 C(14)-C(10)-C(5) 112.02(9) 
C(9)-C(8)-H(8B) 110.3 C(4)-C(15)-H(15A) 120.0 
H(8A)-C(8)-H(8B) 108.6 C(4)-C(15)-H(15B) 120.0 
C(10)-C(9)-C(8) 113.46(10) H(15A)-C(15)-H(15B) 120.0 
C(10)-C(9)-H(9A) 108.9 C(11)-C(13)-H(13A) 120.0 
C(8)-C(9)-H(9A) 108.9 C(11)-C(13)-H(13B) 120.0 
C(10)-C(9)-H(9B) 108.9 H(13A)-C(13)-H(13B) 120.0 
C(8)-C(9)-H(9B) 108.9 O(3)-C(12)-O(2) 121.23(12) 
H(9A)-C(9)-H(9B) 107.7 O(3)-C(12)-C(11) 129.75(13) 
C(10)-C(14)-H(14A) 109.5 O(2)-C(12)-C(11) 109.00(10) 
C(10)-C(14)-H(14B) 109.5 C(1)-C(2)-C(3) 121.90(12) 
H(14A)-C(14)-H(14B) 109.5 C(1)-C(2)-H(2) 119.1 
C(10)-C(14)-H(14C) 109.5 C(3)-C(2)-H(2) 119.1 
H(14A)-C(14)-H(14C) 109.5 C(12)-C(11)-C(7) 104.38(10) 





O(2)-C(6)-C(5) 115.13(9)   
O(2)-C(6)-C(7) 103.21(9)   
C(5)-C(6)-C(7) 111.05(10)   
O(2)-C(6)-H(6) 109.1   
C(5)-C(6)-H(6) 109.1   
C(7)-C(6)-H(6) 109.1   
O(1)-C(3)-C(2) 121.14(13)   
O(1)-C(3)-C(4) 122.53(13)   
C(2)-C(3)-C(4) 116.32(11)   
C(13)-C(11)-C(12) 123.86(13)   





Table A2.5.  Anisotropic displacement parameters for compound 4.2 
Atom 
label 
U11 U22 U33 U23 U13 U12 
O(1) 0.0493(6) 0.0366(6) 0.0297(5) -0.0008(4) 0.0165(5) -0.0062(5) 
O(2) 0.0309(5) 0.0174(4) 0.0253(4) 0.0023(3) 0.0029(4) 0.0031(3) 
O(3) 0.0499(7) 0.0262(5) 0.0356(5) 0.0081(4) 0.0000(5) 0.0061(5) 
C(1) 0.0288(6) 0.0252(6) 0.0297(6) 0.0036(5) -0.0043(5) 0.0015(5) 
C(2) 0.0358(7) 0.0301(6) 0.0253(6) 0.0048(5) -0.0011(5) -0.0048(5) 
C(3) 0.0330(6) 0.0233(6) 0.0259(5) 0.0017(5) 0.0076(5) -0.0079(5) 
C(4) 0.0291(6) 0.0164(5) 0.0257(5) 0.0005(4) 0.0069(5) -0.0021(5) 
C(5) 0.0202(5) 0.0171(5) 0.0217(5) -0.0002(4) 0.0021(4) -0.0007(4) 
C(6) 0.0195(5) 0.0148(5) 0.0248(5) -0.0001(4) 0.0012(4) 0.0006(4) 
C(7) 0.0202(5) 0.0206(5) 0.0221(5) -0.0030(4) 0.0013(4) -0.0010(4) 
C(8) 0.0239(6) 0.0254(6) 0.0244(5) -0.0048(5) 0.0003(5) 0.0037(5) 
C(9) 0.0200(5) 0.0245(6) 0.0289(6) -0.0027(4) -0.0014(5) 0.0036(5) 
C(10) 0.0212(5) 0.0186(5) 0.0241(5) 0.0000(4) -0.0022(4) 0.0011(4) 
C(11) 0.0233(6) 0.0207(5) 0.0261(5) 0.0001(4) 0.0015(5) -0.0040(4) 
C(12) 0.0303(6) 0.0219(6) 0.0266(6) 0.0019(4) -0.0002(5) -0.0028(5) 
C(13) 0.0314(6) 0.0337(7) 0.0257(6) 0.0006(5) 0.0028(6) -0.0050(6) 
C(14) 0.0277(6) 0.0168(5) 0.0366(6) 0.0014(5) -0.0027(5) -0.0020(5) 







Table A2.6.  Hydrogen coordinates and isotropic displacement parameters 
for compound (4.2) 
Atom label X Y Z U(eq) 
H(1) -0.1553 1.1409 -0.2867 0.033 
H(2) -0.0696 1.0460 -0.4408 0.036 
H(5) -0.0491 0.8844 -0.1647 0.024 
H(6) 0.1475 0.9722 -0.0037 0.024 
H(7) -0.1253 0.8789 0.0286 0.025 
H(8A) -0.0268 1.1109 0.0864 0.029 
H(8B) -0.1798 1.0657 0.1117 0.029 
H(9A) -0.1717 1.1732 -0.0675 0.029 
H(9B) -0.2238 1.0416 -0.0866 0.029 
H(13A) 0.0499 0.8436 0.3278 0.036 
H(13B) -0.0586 0.9503 0.3004 0.036 
H(14A) 0.1306 1.1540 -0.0603 0.041 
H(14B) 0.0553 1.2419 -0.1458 0.041 
H(14C) 0.1646 1.1493 -0.1930 0.041 
H(15A) 0.3292 0.8728 -0.2868 0.039 





Table A2.6.  Torsion angles for compound 4.2 
Atom site label Torsion angles 
[º] 
Atom site label Torsion angles  
[º] 
C(11)-C(7)C(8)-C(9) -176.53(11) C(2)-C(1)-C(10)-C(14) -88.95(15) 
C(6)-C(7)-C(8)-C(9) -58.75(13) C(2)-C(1)-C(10)-C(5) 31.01(17) 
C(7)-C(8)-C(9)-C(10) 55.27(14) C(8)-C(9)-C(10)-C(1) -173.06(11) 
C(12)-O(2)-C(6)-C(5) 153.05(11) C(8)-C(9)-C(10)-C(14) 69.52(13) 
C(12)-O(2)-C(6)-C(7) 31.88(12) C(8)-C(9)-C(10)-C(5) -54.96(13) 
C(11)-C(7)-C(6)-O(2) -39.39(11) C(6)-C(5)-C(10)-C(1) 175.55(10) 
C(8)-C(7)-C(6)-O(2) -171.01(9) C(4)-C(5)-C(10)-C(1) -56.42(12) 
C(11)-C(7)-C(6)-C(5) -163.29(9) C(6)-C(5)-C(10)-C(9) 55.39(12) 
C(8)-C(7)-C(6)-C(5) 65.10(12) C(4)-C(5)-C(10)-C(9) -176.57(10) 
C(15)-C(4)-C(3)-O(1) -20.6(2) C(6)-C(5)-C(10)-C(14) -68.06(12) 
C(5)-C(4)-C(3)-O(1) 161.68(12) C(4)-C(5)-C(10)-C(14) 59.98(12) 
C(15)-C(4)-C(3)-C(2) 158.27(13) C(6)-O(2)-C(12)-O(3) 170.70(12) 
C(5)-C(4)-C(3)-C(2) -19.48(16) C(6)-O(2)-C(12)-C(11) -10.45(13) 
C(8)-C(7)-C(11)-C(13) -19.4(2) C(13)-C(11)-C(12)-O(3) -21.0(2) 
C(6)-C(7)-C(11)-C(13) -142.26(15) C(7)-C(11)-C(12)-O(3) 163.19(14) 
C(8)-C(7)-C(11)-C(12) 155.99(11) C(13)-C(11)-C(12)-O(2) 160.33(12) 
C(6)-C(7)-C(11)-C(12) 33.14(12) C(7)-C(11)-C(12)-O(2) -15.53(13) 
O(2)-C(6)-C(5)-C(4) 58.69(14) C(10)-C(1)-C(2)-C(3) 2.2(2) 
C(7)-C(6)-C(5)-C(4) 175.49(10) O(1)-C(3)-C(2)-C(1) 169.28(13) 
O(2)-C(6)-C(5)-C(10) -177.59(9) C(4)-C(3)-C(2)-C(1) -9.6(2) 
C(7)-C(6)-C(5)-C(10) -60.79(12)   
C(15)-C(4)-C(5)-C(6) -2.05(18)   
C(3)-C(4)-C(5)-C(6) 175.53(10)   
C(15)-C(4)-C(5)-C(10) -124.67(13)   
C(3)-C(4)-C(5)-C(10) 52.90(13)   
C(2)-C(1)-C(10)-C(9) 151.41(13)   
 
Symmetry transformations used to generate equivalent atoms:  
1.    x,y,z (identity) order1, type 1 
2.    ½-x, -y, ½+z (screw axis 2-fold), order 2, type 2 
3.    –x, ½+y, ½-z (screw axis 2-fold), order 2, type 2 
















Appendix 3: Selected dose response curves for in vitro 

























































Figure A3-1. Dose-response curves of compound 4.2 (MM-II-15F2) against P. 
falciparum (D10) 
P.falciparum  K1: MM-II-15F2






































Figure A3-2. Dose-response curves for compound 4.2 (MM-II-15F2) against P. 
falciparum (K1) 
 
